AASLD Program (pp. 27A–77A)

HEPATOLOGY, Vol. 38, No. 4, Suppl. 1, 2003 AASLD PROGRAM 27A

Fridav. October 24 Session I1

8:OO am - 3:30 pm Hyiies Convention Center, Ballroom A,B,C Advances in Adult Living Donor Liver Transplantation (LDLT) Course Directors: J. Michael Millis, M D

James F. Trotter, M D Charles Miller, M D

Goals and Obiectives: 6.0 CME

Review the criteria and evaluation process for donors and recipients. Understand the basic technical aspects of the surgery. Describe the post-operative outcomes and complications in donors and recipients. Gain insight into the impact of MELD on live donor liver transplantation. Discuss the role of LDLT in hepatitis C, hepatocellular carcinoma and re-transplantation.

Adult-to-adult right hepatic lobe LDLT has rapidly emerged as a treatment option for selected patients with end-stage liver disease. Approximately lop) of all liver transplantations performed in the United States utilize a living donor. This course is designed to inform physicians about the current topics in this rapidly changing field. From the medical standpoint, the process of donor and recipient selection will be discussed, including radiologic imaging techniques, financial aspects and the psychosocial assessment of donors. The technical aspects of the surgery will be described along with the postoperative complications in donors and recipients. Three current controversial issues in LDLT will be explored: hepatocellular carcinoma, hepatitis C, regulation of the procedure and use of live donors for retransplantation. The etlucal considerations and objections to LDLT will be reviewed, as well as the future role of LDLT in liver transplantation.

Session I

Chairs:

8:00 - 8:05 am

8:05 - 8:25 ain

8125 - 8:45 U ~ T I

8:45 - 9:OO

9:OO - 9:20 am

9:20 - 9:40 am 9:40 - l0:00 am

J. Michael Millis, M D and James F. Trotter, M D Introduction J. Michael Millis, M D Selection and Medical Assessment of the Adult Living Liver Donor James F. Trotter, M D Psychosocial Assessment of the Adult Living Liver Donor Roshan Shrestha, MD Financial Impact of Adult Living Donation Robert S. Brouin, M D , MPH Techniques Utilized in Assessing the Adult Living Donor Liver David J. Brandhageiz, M D Discussion Break

Chairs:

1O:OO - 10:20 a m

10:20 - 10:40 am

10:40 - 11 :OO am

11:OO - 11:20 am

11:20-11:40am

W40 am - Noon Noon- 1:30 pm

Session I11

Federico G. Villamil, M D and Charles Miller, M D Surgical Techniques Used in Adult LDLT Jacques Belghifi, M D Role of Hepatic Regeneration in LDLT Kim M . Olthofl, M D Donor and Recipient Outcomes in Adult LDLT Abhi Humar, M D Early and Late Complications in the Right Lobe Adult Living Donor Elizabeth Pomfret, MD, PhD Early and Late Complications in the Recipient of an Adult Living Donor Ckristoph E. Broelsch, M D , PhD Discussion Meet-the-Professor Luncheons See page 28 for details.

Chairs:

1 :30 - 1 :50 pnr

150 - 2:lO pin

2:10 - 2:30 pm

2:30 - 2:45 p ~ i ?

2:45 - 3 9 0 pm

3:00 - 3:15 pm

3:15 - 3:30 pin

Michael F. Sorrell, M D and Russell H . Wiesizer, M D Impact of MELD on Recipient Selection for Adult Living Liver Donation Richard B. Freeman, M D Role of Adult Living Liver Donation in Patients with Hepatocellular Cancer john P. Roberts, M D Role of Adult Living Liver Donation in Patients with Hepatitis C: Con Gregory T. Everson, M D Role of Adult Living Liver Donation for Retransplantation: Pro Amadeo Marcos, M D Adult LDLT: An Opposing View Byers W. Shaw, Jr., M D Regulation and Oversight of Adult LDLT Charles Miller, M D Future Applications of Adult LDLT in the United States Ronald W. Busuf f i l , MD, PhD

28A AASLD PROGRAM HEPATOLOGY, October 2003

Friday, October 24 Noon - 1:30 pm Please refer to your luncheon ticketfor the nzecting room location. Meet-the-Professor Luncheons

Goals and Objectives:

The goal of the Meet-the-Professor Luncheons is to provide the attendees with an opportunity to explore in more detail a wide variety of topics in transplant hepatology in a small group setting. Topic moderators are experts in their particular specialty area for a given session.

1.5 CME Credits

101.

102.

103.

104.

105.

106.

107.

108.

109.

MELD and Adult LDLT Richard B Freemnn, M D and Russell H Wiesner, M D

LDLT for Hepatitis C Giegory T Everson, M D and Hirgo R Rosen, M D

LDLT for Hepatocellular Cancer Goran Klintmalm, MD, PhD and John P Roberts, M D

Complications in the Adult Living Liver Donor E l m l i e t h Ponzfret, M D and &a/ Kani, M D

Financial Aspects of Adult Living Donation Robert S Brown, MD, M P H and John R Lake, M D

Surgical Aspects of Adult LDLT / n ~ q i r c s Belglziti, M D and Christoph E Broelsrh, MD, PhD

Assessment of the Adult Living Donor ] a i m s F Trotter, M D and Daziid

Immunosuppression in Living Donor Recipient ]oh17

Psychosocial Aspects of Living Donor Transplant ]nines Sorrell, M D and Shed0 ]ozilsey, M D

Brandhagen, M D

Fung, MD, PhD anrf Roshan Shrcsthsa, M D

Transplant Course and Meet-the-Professor Luncheons Facultv Disclosure

All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Jacques Belghiti David J. Brandhagen Christoph Broelsch Robert S. Brown Ronald W. Busuttil Richard B. Freeman John J. Fung Abhi Humar Sheila Jowsey Igal Kam

Goran Klintmalm Amadeo Marcos Charles Miller J. Michael Millis Kim Olthoff John P. Roberts Hugo R. Rosen Roshan Shrestha James Sorrell Russell Wiesner

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does not include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Gregory T. Everson Gran tlResearch Support: Roche, Schering, Amgen, InterMune,

CoiisultantlAdvisor: Roche, Novo Nordisk Speakers’ Bureau: Roche, Schering, Ortko Biotech

Ortho Biotech

John R. Lake GrantlResearcli Slipport: Constr /tan tlAdoisor:

Elizabeth Pomfret GrantlRrsearch Szipport: Roche Pharmaceuticals, Pujisazcla Co,zsultarit/Advisor: Roche Speakers‘ Bureau: Roche

James F. Trotter Speakers’ Bureau: Wyeth, Schering, Roche

Did not provide disclosure at time of printing Eyers W. Shaw

The AASLDIILTS Transplant Course, S!jllabus a n d Meet-the- Professor Lirnclieons are supported by an unrestricted edzicationnl grant froin F U ~ Z M

HEPATOLOGY, Vol. 38, No. 4, Suppl. 1,2003 AASLD PROGRAM 29A

Friday, October 24

Noon - 3:OO pm Hynes Convention Center, Room 302 Liver and Biliary Tract Development: New Genes, New Clinical Insights Course Directors: Saul] . Karpen, M D , PhD

Estella M . Alonso. M D

Goals and Objectives: Understand the involvement of newly discovered genes in the pathogenesis of biliary tract disease. Learn the role of disease modifier genes in inherited liver disease in children and adults. Explore new potential diagnostic and therapeutic targets in biliary tract disease.

In recent years, there has been substantial new information on the development of the liver and biliary tract that has direct application to the care of children with a wide variety of liver diseases. This symposium will highlight several of these findings and place them in a clinical context for the education of both pediatric and adult hepatologists.

3 CME Credits

Noon - 12:05 pm

12:05 - 1225 pm

1225 - 12:45 pm

12:45 - 1:05 pm

1:05 - 1:15 pm

1:15 - 1:25 pm

1:25 - 1:40 pm 1:40 - 2:OO pm

2:OO - 220 pm

220 - 240 pm

2:40 - 250 pm

2:50 - 3:OO pm

Overview/Aims Saul J. Karpen, M D , PhD Anatomical Overview of Liver and Bile Duct Embryology and Development James M. Craruford, M D , PhD Deciphering the Molecular Signaling Code for Early Liver Organogenesis Kenneth S. Zaret, PhD Genetic Determinants of Congenital Hepatic Fibrosis: Newly Discovered Genes Involved in ARPKD Peter C. Harris, PhD Case 1: ARPKD-Associated Liver Disease- Natural History and Treatment Options Estella M . Alonso, M D Roundtable Discussion: Question and Answer Session Break Role of Keratins in Liver Disease: From Bench to Bedside M. Bishr Oinay , MD, PhD Clinical Findings in Biliary Atresia- Clues to Potential Etiologies Ronald J. Sokol, M D Laterality Genes and Biliary Atresia- The Heart is Connected to the Liver John Belmont, MD, PhD Case 2: Biliary Atresia with a "Twist" Estella M . Alonso, M D Roundtable Discussion: Question and Answer Session

Pediatric Symposium Faculty Disclosure

All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off-labelinvestigative use of medicine(s), medical devices, or procedure(s).

Estella M. Alonso John W. Belmont James M. Crawford Peter C. Harris Saul J. Karpen M. Bishr Omary Ronald J. Sokol Kenneth S. Zaret


Friday, October 24

Noon - 4 00 pm Slirratoii G m i d Bollrooin The Role of Endoscopy in Liver Disease and Liver Transplantation Coiii SP Directors Todd H Baron, M D

Deriiirs M \msrn, M D


At the conclusion of this course, participants should be able to:

Summarize the role of endoscopy in the management of esophagogastric varices. Recognize the role of ERCP in the management of primary sclerosing cholangitis. Decide when to utilize ERCP for managing post-liver transplant biliary complications.

This new half-day course is designed for hepatologists, practicing gastroenterologists, trainees in gastroenterology, and medical practitioners involved in gastrointestinal endoscopy who are interested in expanding their knowledge of the role of endoscopy in liver disease and liver transplantation. This interactive state-of-the-art review includes eight presentations by nationally known experts in the field of endoscopy as well as question and answer sessions.

Noon - 12:lO pm

12:lO - 1230 pm

12:30 - 1250 pm

1250 - 1 3 0 pm

1:lO - 1:30 pm

1:30 - 1:50 pm

1:50 - 215 pm 215 - 230 pm 2:30 - 250 pm

2:50 - 3:lO pm

3:lO - 3:30 pm

3:30 - 4:OO pm 4:OO pm

Introduction and Welcome Todd H Biiroii, M D n ~ i d Driiizi\ M le r iwz , M D Sedation and Preparation for Endoscopy in the Patient with Advanced Liver Disease Ma, t n i L Fieeninn, M D Screening for Varices in Patients with Advanced Liver Disease Znii M Ginliiek, M D Prophylactic Endoscopic Therapy of Esophageal Varices DciiIrf5 hI ]twbeii, M D Endoscopic Therapy for Bleeding Esophageal Varices ]o l l i i P Cdlo, M D Gastric Varices: Is there a Role for Endoscopic Therapy in the U.S.? loliii S G o 8 M D Question & Answer Break The Role of EUS in Evaluation of Portal HTN DouCyIm C) Fo~gel, M D The Role of ERCP in Therapy of Primary Sclerosing Cholangitis Dirt Pcteiwi M D The Role of ERCP in Post-Liver Transplant Biliary Tract Complications K ~ d d H Br7f'@IZ, MD Question & Answer Course Wrap-up Adjourn

Endoscopy Course Faculty Disclosure

All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off-label /investigative use of medicine(s), medical devices, or procedure(s).

Todd H. Baron John P. Cello Douglas 0. Faigel Martin L. Freeman John S. Goff Ian M. Gralnek

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Bret Petersen Consultnizt/Adz,isor: Boston Scien fific

Did not provide disclosure at time of printing. Dennis M. Jensen


Fridav, October 24

4:OO - 8:05 pm Hynes Convention Center, Veterans Memorial Auditorium Liver Disease in the 21st Century: Clinico-Pathologic Correlates Course Directors: Bruce R. Bacon, M D

Zachary D. Goodman, MD, PhD Elizabeth M . Brunt, M D

Goals and Objectives: 11.5 CME

Provide state-of-the art reviews in several areas of clinical hepatology to include mechanisms of disease, histopathologic features, and clinical management. A broad spectrum of liver diseases and processes will be discussed, including fibrogenesis, iron- and copper-related liver diseases, nonalcoholic fatty liver disease, viral hepatitis and hepatocellular carcinoma, developmental liver diseases, immune-mediated diseases, vascular diseases, and drug-induced hepatotoxicity. Include discussions between experts in the field of controversial areas in liver disease, including therapies for fibrosis, role of liver biopsy in nonalcoholic fatty liver disease and hepatitis C, and treatment strategies for overlap syndromes. Recognize the significant role that liver biopsy plays in the clinical care of patients with liver disease, provide an authoritative clinical overview of liver biopsy in 2003 as well as a clinico-pathologic case presentation by two leading experts in liver disease.

This Postgraduate Course is aimed at providing an update of a wide spectrum of clinically significant liver diseases. Current understanding of both mechanisms of pathogenesis and treatment strategies will be discussed. The remarkable scientific advances in all fields of hepatology have resulted in major advances in clinical care of patients with liver disease. The collaborative role of the liver pathologist in clinical care and investigational research has remained one of the cornerstones to understanding various forms of injury as well as progression to fibrosis, end-stage liver disease, and hepatocellular carcinoma. In recognition of this, each area of discussion will include in-depth discussions of the pathologic features of the particular disease process. In addition, areas of management controversy will be discussed by authorities in a debate format.

The two-day AASLD Postgraduate Course will be divided into several theme-related sessions. Each of the following sessions will include discussions of pathology and mechanisms of pathogenesis:

Hepatic fibrosis Injury to the liver from iron and copper Nonalcoholic fatty liver disease with a focus on pathology, mechanisms of disease, and controversies related to liver biopsy Prognostic sigruhcance of steatosis in hepatitis C and the effect on treatment Issues in viral hepatitis focusing on complications of viral infection, including current understanding of dysplasia, clinical decisions related to screening for hepatocellular carcinoma, and the role of liver biopsy in clinical management of allograft patients and in treatment of viral hepatitis B and C Pathology of developmental disorders and the significance of these to clinicians caring for adult patients Immune-mediated liver diseases will be described histologi- cally, clinical spectrum and complications of cholestatic liver disease will be addressed, and treatment controversies in overlap syndromes debated Vascular liver disease from pathologic and radiologic points of view, as well as clinical overview of management Pathology, diagnosis and mechanisms of drug-induced hepatotoxicity Overview of the role of liver biopsy in liver disease in 2003 Formal clinico-pathological correlation (CPC) by experts in liver disease

Postgraduate Course C D Rorn supported by an unrestricted educational grantfrom Axcan Pharma.

The Postgraduate Course program will be captured on CD Rom. You can order this excellent educational tool on Friday and Saturday during the course outside the Veteran’s Memorial Auditorium. You may also order this CD at the AASLD booth during registration hours, or at the Axcan Pharma booth, #209, during exhibit hours. Please note, the CD Rom will not be mailed until the Spring of 2004.


Fridav. October 24

4:OO - 4:05 pm Welcome Bruce R. Bi~coir, MD

Fibrosis/Fibrogenesis

Chnirs:

4:05 - 4:25 pm

425 - 4:45 pm

4:45 - 5:15 pm

4:43 ~ 4:55 pni

4:55 - 5:05 prli

r . r J .OS - 5:25 17ri i

Scott L Friedmnn, MD nrid Dn.jid A. Brenner, M D Pathologic Evaluation of Fibrosis Znchnry D Gooiirnnrz, M D , PhD Mechanisms of Fibrogenesis D Moiitpiier;y BisseII, M D Controversies in Fibrosis: Strategies Currently Available to Treat Fibrosis We Are Getting Closer Do11 C r \ ( ~ t k ~ i / , M D We Have a Long Way to Go Ti,riot/iy R Morgari, M D Rebuttals

Metals and the Liver

c1inrr 5 Li7ZUf fe W POZCJCll, MD, PIiD LZl7d

Mltlincl L Schrlsky, M D Pathology of Metal-Induced Liver Disease loc / K Crrcnwii MD Mechanisms of Liver Injury and Fibrosis Due to Iron and Copper Airtoridlo Pi~tr i1 i ig t41 , MD, PhD Non-HFE-Linked Iron Overload PiJlii C Adi71775, MD

5:15 - 5:35 pm

5:35 - 5:55 pm

5:55 - 6:15 pm

6:15 - 6:35 pm Break

Fatty Liver Disease

Chnl I'S;

635 - 6:55 pm

6:55 - 7:15 pm

215 - 8:05 pm Controilersy 1 7:15 - 7:25 J J f 1 1

7:25 - 7:35 pin

Coiitroziersy 2

7:35 - 7:45 p i

7:45 - 755 pnz

7:55 - 8:05 r ~ l i

Aru~r J. Snnyn l , MD i l l i d

Annu Mnc Dichl, M D Pathologic Spectrum of Fatty Liver Disease Elizribeth M. Brunt, MD Mechanisms of Fatty Liver Disease Geoffrey C. Farre// , MD Controversies in NAFLD Sfentosis a n d Hepotitis c Prognostic Significance Arthitr J. McCii/loiqh, M D Response to Therapy ]ohn G. McHutchisoii, MD Cl?nirn/ Utility of h e r Biopsy in NAFLD: The Pros niid Cons Pros Brent A. Tctri, M D Cons Stephen H. C n l d 7 d . M D Rebuttals


Saturday, October 25

8:OO - 5:OO pm Hynes Coizzwztion Center, Veterans Memorial Auditorium Liver Disease in the 21 s t Century: Clinico-Pathologic Correlates Course Directors: Briice R. Bacon, M D

Zachary D. Goodman, M D , PhD Elizabeth M . Brunt, M D

Viral Hepatitis

11:30 am - Noon Controversy: Treatment of Autoimmune Hepatitis and Overlap Syndromes

Chances E. Jenny Heathcute, M D

Albert J. Czaja, M D

Meet-the-Professor Luncheons See page 34for details.

11:30 - 11:40 am Treatment Forever-Don’t Take Any

21:40 - 11:50 am Treatment Withdrawal-Dare to Relapse

11:50 a m -Noon Rebuttals Noon - 1:30 pm

Chairs:

SO0 - 8:20 am

8:20 - 8:40 am

8:40 - 9:00 am

9:OO - 9:30 am

9:00 - 9:lO am

9:30 - 9:20 am

9:20 - 9:30 am

Adrian M . Di Bisceglie, M D and Norali Terrault, M D , MPH Viral Hepatitis as a Pre-Malignant Disease: Dysplastic Lesions Tariia Roskains, MD, PIzD Screening for Hepatocellular Cancer in Chronic Viral Hepatitis Morris Sherman, M D , PhD Role of Liver Biopsy in Post-Transplant Hepatitis C Stefan G. Huhscher, M D Controversies in Viral Hepatitis: Is Liver Biopsy Always Necessary Before Treating Chronic Hepatitis B or C? Yes Mitchell L. Skiffman, M D No Emmet B. Keeffe, M D Rebuttals

Development

Chairs:

9:30 - 9:50 am

Ronald J . Sokol, M D and Eve A. Roberts, M D Pathology of Developmental Anomalies of the Liver Milton 1. Finegold, M D What Every Hepatologist Should Know About Pediatric Liver Disease William E Balistreri, M D

9:50 - 1 O : l O am

1 O : l O - 1030 am Break

Immune-Mediated Liver Diseases

Chairs:

10:30 - 10:50 am

10:50 - 1 1 : l O am

1 1 : l O - 11:30 am

Michael P. Manns, M D and Andrew C. Mason, M D Spectrum of Pathology A . Briaiz West, M D Primary Biliary Cirrhosis: Clinical Spectrum and Mechanisms of Disease Keith D. Lindor, M D Primary Sclerosing Cholangitis and Cholangiocarcinoma Kirsteiz Boberg, M D , PhD

Vascular Diseases of the Liver

Chairs: lan Wanless, M D and

1:30 - 1:50 pm

1:50 - 2:lO pm

Juan Rodis, M D Pathology of Vascular Diseases of the Liver James M . Craziford, MD, PhD Imaging of Vascular Liver Disease and Portal Hypertension Steven Meranze, M D Diagnosis-Putting It All Together Thomas D. Boyer, M D

230 - 230 pm

Drug Hepatotoxicity

Chairs:

2:30 - 2:50 pm

Eugene R. Schifi M D and Paul B. Watkins, M D Pathologic Spectrum of Hepatotoxic Reactions Kamal G. Ishak, MD, PhD Pathogenesis and Diagnosis of Drug Toxicity Neil Kaplowitz, M D Acute Liver Failure-Role of Drugs William M . Lee, M D

2:50 - 3:lO pm

3:lO - 3:30 pm

3:30 - 4:OO pm Break

Role of Liver Biopsy in 2003

Moderator: Bruce R. Bacon, M D 400 - 4:20 pm Controversies in Liver Biopsy

Lawrence S. Friedman. M D

Clinico-Pathological Correlation-CPC

Moilera tor: 4:20 - 4:50 pm

Bruce R. Bacon, M D CPC ”Case”

Adrian M . Di Bisceglie, M D

Jay H . Lefkowitch, M D

4:20 - 4:40 pm Clinician

4:40 - 4:50 pm Pathologist

Course Wrau-uu

4 5 0 - 5:OO pm Course Wrap-up Willis C . Mnddrey, MD



Rgf’v fo your l u ~ ~ ~ h e o i i ticket for meeting room location.

Goals and Objectives:

The goal of the Meet-the-Professor Luncheons is to provide the attendees with an opportunity to explore in more detail a wide variety of topics in hepatology in a small group setting. Topic moderators are experts in their particular specialty area for a given session.

NOOII - 1:30 PIII

1.5 CME Credits

201.

202.

203.

204.

205.

206.

207.

208.

209.

210.

211.

212.

213.

214.

Diagnostic Approaches to Hepatocellular Cancer Morii5 Slzeiinan, MD, PhD arid S7oan N Thung, M D

Liver Biopsy in Patients with Unexplained Abnormal Liver Enzymes Priirl Angtilo, M D and Alistan D Burt, M D

Liver Biopsy in Suspected NAFLD/NASH Nnthnn M Bass, IUD, PhD and Dazud K/fJJier, M D

Chronic Hepatitis C Guidelines for Therapy Gary L Dnzw, M D and Michael W Fried, M D

Liver Biopsy or Serum Markers for Staging Chronic Hepatitis C john R Craig, M D , PhD and Nezam H Afdhal, M D

Liver Biopsy in Cholestatic Liver Disease and Overlap Syndromes ]amcs Neuberger, IUD and Albert

Evaluation of Hepatic Nodules: Pathologist or Radiologist or Both Inn R Wanless, M D and Stephanie Wilson, M D

Diagnosis and Treatment of Hemochromatosis Lnrcwe W Porwll, M D , PhD aiid Anthony S Tazdl, M D

Diagnosis and Treatment of Wilson’s Disease MlChfld L Sthi lsk~/ M D arid Peter Fererici, M D

Diagnosis and Management of Vascular Disorders: VOD and BCS

Czap, M D

Michml Hender WI, M D and Laurie D DeLeve, M D , PhD

Use of Ursodeoxycholic Acid in PBC and Other Cholestatic Liver Diseases Keith D Lindor, M D and Stephanos j Hadziyannis, M D

Treatment of Metabolic Bone Disease in Patients with Chronic Liver Disease Ieffrrty S Crippirz M D mid Vijayan Balari, M D

Complementary and Alternative Medicine in the Treatment of Chronic Liver Disease Gcoffrcy C Fnrrell M D nnd Dour5 B Strader, M D

Genetic Polymorphisms in ALD/NAFLD Chi istophcr P Day, M D , PhD ~ i i d

R ~ J J / / I ~ R Mrr I irnnii M D

215.

216.

217.

218.

219.

220.

221.

222.

223.

224.

225.

226.

227.

228.

229.

230.

231.

232.

233.

234.

Antifibrotic Therapy Scott L. Frzednzan, M D and Daz)id A. Brenirer, M D

Pediatric Cholestatic Syndromes Ronald j . Sokol, M D and Eve A. Roberts, M D

Metabolic Liver Diseases Joseph R. Blooiner, M D and Herbert L. Bonkovsky, M D

Hepatitis C in Children Joel E. Lazliiie, M D , PhD and [ e m P Mollestoii, M D

Hepatitis C and HIV Co-Infection Kenneth E. Sherman, M D , PhD and Douglas T. Dieterich, M D

Hepatitis C in Renal Disease, Pre- and Post-Kidney Transplant Patients Bruce A. LUSOJI, M D , PkD and Michael A. Heiieghan, M D

Hepatitis C and Pregnancy Caroline A. Riely, M D and Grace L. Su, M D

Hepatitis C in African Americans Jacqtielyn E Fleckenstein, M D aizd Lemiox J e f i m , M D

Hepatitis B: New Therapies Robert P Perrillo, M D and A77~7a S. E Lok, M D

Hepatitis C New Therapies john G. McHutchisoii, M D arid Adrian M. Di Bisceglie, M D

NAFLD/NASH: Emerging Treatments Brent A . Tetri, M D aiid Arthur 1. McCuliougk, M D

Alcoholic Liver Disease: Emerging Treatments Estebari Mezey, M D and Claus 1. Fimmel. M D

Treatment of Chronic Hepatitis C: Weight-Based Dosing Ira M. Jacobson, M D and K. Rajender Relid!/, M D

Pruritus in Chronic Liver Disease Nora K Bergasa, M D and Mnvlyn j . Mnyo, M D

Population Screening for Hemochromatosis Paul C. Adams, M D and IohJl K . Olynyk, M D , PhD

Drug-Induced Liver Disease: Rezulin, Duract, Trovan, and Others Paul B. Wutkins, M D and William M . Let., M D

Polycystic Liver Disease: Diagnosis and Management Gregory T. Everson, M D and Roshaii Skvestha, MD Diagnosis and Treatment of Cholangiocarcinoma Stezlen M . Strasberg, M D arid William R. jarnagin, M D

Hepatitis C Special Considerations, Alcohol, Drug Abuse, Depression Howard Moizsour, M D aiid Alexander P. Monto, M D

Liver Biopsy in Patients Taking Lipid Lowering Agents (Statins) with Abnormal Liver Tests Marion G. Peters, M D a i d Stephen H . Cnldzcdl, M D

Please see pages 35 - 36for all Postpradirnte Coursrfai-dty disclosiws


Postgraduate and Meet-the-Professor Presentations Disclosures All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off-label/ investigative use of medicine(s), medical devices, or procedure(s).

Paul C. Adams Paul Angulo Nathan M. Bass Herbert L. Bonkovsky Thomas D. Boyer Alastair D. Burt John R. Craig Jeffrey S. Crippin Albert J. Czaja Laurie D. DeLeve Gregory T. Everson Jacquelyn F. Fleckenstein Scott L. Friedman Joel K. Greenson Stephanos J. Hadziyannis E. Jenny Heathcote

William R. Jarnagin Lennox Jeffers David Kleiner Joel E. Lavine Jay H. Lefkowitch Steven Meranze Alexander P. Monto James Neuberger John K. Olynyk Eve A. Roberts Tania Roskams Michael Schilsky Doris B. Strader Steven M. Strasberg Swan N. Thung Brian A. West

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and did not disclose whether or not there will be a discussion of any unapproved, off- label, or investigational uses of a product:

Vijayan Balan William F. Balistreri D. Montgomery Bissell Kirsten Boberg David A. Brenner Elizabeth M. Brunt James M. Crawford Christopher P. Day Geoffrey C. Farrell Peter Ferenci Claus J. Fimmel Milton J. Finegold Lawrence S. Friedman Zachary D. Goodman J. Michael Henderson

Michael A. Heneghan Stefan G. Hubscher Kamal G. Ishak Emmet B. Keefe Marlyn J. Mayo Timothy R. Morgan Marion C. Peters Antonello Pietrangelo Laurie W. Powell Caroline A. Riely Morris Sherman Mitchell L. Shiffman Grace L. Su Anthony S. Tavill Ian R. Wanless

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does not include discussion of off-label/ investigative use of medicine(s), medical devices, or procedure(s).

Nezam H. Afdhal Grant/Research Support: Prometheus Coiisultaiit/Advisor: Pronietheus

Gary L. Davis GrantlResearch Support: SciClone, HGS, Roche

Dieterich, Douglas T. Grant/Research Support: Scheriq, Roche, Gilead Corzsultant/Aduisor: Schering, Roche, Gilead Speakers’ Bureau: Schering, Roche, Gilead

Neil Kaplowitz Cotzsultatit/Advisor: Purdue Pharn~aceuticals, GlaxoSmifhHine,

Speakers‘ Bureau: Axcan Scandipharm Pfizer, Bristol MJyers Squibb, Actelien

William M. Lee GrantlResearch Support: Roche, Schering, Bristol Myers Squibb,

ConszrltantlAdvisor: Gilead, Eli Lilly, Astra Zeneca Glaxo, ZnterMune, SciClorie

Willis C. Maddrey Cotistrltnnt/Advisor: Schering, IDUN, SciClone, Eli Lilly, Pfizer,

GlnxoStnithKline

John G. McHutchison GratrtlResenrch Support: Akros Pharma lnc, Amgen lnc, Bayer

Phnrmnceuticals, Bio-Medicines, Inc, Bristol-Myers Squibb Cottq~any, Cytel Corporation, Fujisawa, Genprobe, Gilead Sciences, [DUN, lsis Pharmaceuticals, Ortho Diagnostic Systems, Prometheus Laboratories, Ribozyme Pharmaceuticals, Roche Pharrnaceu ticals, Schering-Plough Corporation, SciClone, Triangle Phnriiraceuticals, Vertex Pharinaceuticals

Centocor lnc, GlaxoSinithKline, In terMune Pharmaceuticals lnc, lsis Pharmaceuticals lnc, Natioiial Genetics Institute, Nouartis Pharmaceuticals lnc, Pfizer Pharmaceuticals, Prometheus Laboratories, Ribozyme Pharmaceuticals lnc, Schering-Plough Corporation

Speakers’ Bureau: lnterMune Pharmaceuticals, Roche Pharmaceuticals, Schering-Plough Corporation

Corisultatit/Advisor: Amgen Inc, Anadys Pharmaceuticals lnc,

Raphael B. Merriman Consul tant/Advisov: Celera Diagnostics

Esteban Mezey GrantiResearch Support: NlH

Rajender Reddy Gran t/Research: Roche, Schering-Plough, 1nterMune ConsultantiAduisor: Roche, InterMune, Gilead Speakers‘ Bureau: Roche, Gilead, ZtzterMune

Roshan Shrestha Gran tlResearch: Fujisama, Roche, Schering Sveakers’ Bureau: Ascan Pharma

AASLD PROGRAM HEPATOLOGY, October 2003 36A

Ronald J. Sokol Speakers‘ Bureau: Axcan Pharma

Paul B. Watkins ConsultantlAdvisor: Pjizer (maker of RezulineTrougu)

Stephanie Wilson GrantlResearch Support: Bristol Myers Squibb

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does include discussion of off-label/investigative use of medicine(s), medical devices, or procedure(s).

Nora V. Bergasa GrantlResearch Support: Axcan Speakers’ Bureau: Axcan

Steven H. Caldwell GrantlResearch Support: Bioengineering Inc- Needle Prototype Other: Bioengineering Inc-Needle Prototype, Pfizer

Adrian M. Di Bisceglie GrantlResearch Support: Schering-Plough, Roche, Gileud Sciences,

Consul tan t1Advisor: Roche, Gikad Sciences, ldenix, SciClone

Speakers’ Bureau: Schering-Plough Other: DSMB member

In terMune

Pharmaceuticals, MDS Nordion, InterMune, Chiron, Novartis

Michael W. Fried GrantlResearch Support: H o f i a n LaRoche, Schering, Ortho Biotech Speakers‘ Bureau: H o f i a n LaRoche, Schering, Ortho Biotech

Ira M. Jacobson GrantlResearch Support: Schering, RPI , lntermune, lsis Consultant/ Advisor: Schering, Akros Speakers’ Bureau: Schering, Gilead

Keith D. Lindor Grant1 Research Support: Axcan

Anna S.F. Lok GrantlResearch Support: Roche, Schering, GluxoSmithKline,

Bristol Myers Squibb, Gilead, Innogenetics ConsultantlAdvisor: ldenix, GlaxoSmithKline, Gilead, XTL Other: Member DSMB -Chiron and Achillon

Bruce A. Luxon GrantlResearch Support: Schering ConsultantlAdvisor: Schering Speakers’ Bureau: Schering

Jean P. Molleston GrantlResearch Support: Schering, Glaxo

Robert P. Perrillo Gran t1Research Support: Gilead Sciences, Schering-Plough, GSK,

ConsultantlAdvisor: Gilead Sciences, GSK Roche Pharmaceuticals.

Don C. Rockey GrantlResearch Support: In terMune, Prometheus, Sucampo,

GluxoSmithKline

Kenneth E. Sherman GrantlResearch Support: Schering, Roche, 1nterMune Consultant. Advisor: SciClone Speakers’ Bureau: Schering, Roche, SciClone

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Joseph R. Bloomer Arthw J. McCullough



8:OO am - 4:45 pm Sheraton Grand Ballroom Evaluating and Treating Hepatocellular Carcinoma (HCC) and Metastatic Liver Tumors: What‘s Hot and What’s Debatable in 2003? Course Director: C. Wright Pinson, M D , M B A

Goals and Obiectives: 8.5 CME Become familiar with newer CT modalities such as in combination with PET, 3D reconstruction, and volume calculations. Understand uses of MRC and CTC compared to ERCP and PTC. Be aware of the remaining uses for nuclear imaging studies. Understand some reasons for improving results after resection for colorectal metastasis and the implications for other types of metastasis. Know what adjuvant treatments are indicated under which circumstance. Become familiar with selective internal radiation therapy and isolated hepatic perfusion as methods of treatment. Develop a basis for screening and follow-up practices for hepatic tumors. Be familiar with the potential new and more useful HCC staging system from the report of the joint AJCC/AHPBA 2002 Consensus Conference. Know the current indications and outcomes of various treatment methods for HCC.

Thus year’s Surgical Forum will focus on evaluating and treating liver tumors, a commonly faced serious matter for all hepatologists and hepatobiliary surgeons. The information in the literature changes quickly and a summarizing program, highlighting the areas of definite advance and the weaker areas still in controversy will be useful, interesting and entertaining for those who attend. The three sessions of this one-day course will contain informative lectures and lively, fun debates focusing on:

I. Update on Hepatic Imaging for the Hepatologist and Liver Surgeon

11. The Latest in Staging and Treatment of Hepatocellular Cancer

111. What’s New in the Treatment of Liver Metastasis?

These topics were specifically chosen to emphasize different topics from the other courses at The Liver Meeting.

Session I: Update on Hepatic Imaging for the Hepatologist and Liver Surgeon

Chair: Theodore Pappas, M D 800 - 820 am Ultrasound-State-of-the-Art 2003

Stephanie Wilson, M D 8:20 - 8:40 am Is There Any Role Left for Nuclear

Imaging Studies? Kevin Donokoe, M D Newer CT Modalitites Ckusilp Charnsangavej, M D

Lawrence Schzuartz, M D When, If Ever, Should A Lesion Be Biopsied? David Linehan, M D Case Presentations and Discussion Moderators: Bryan Clary, M D and Richard Sckulick, M D

8:40 - 910 am

9:lO - 9:30 am MRI/MRCP

9:30 - 9:50 am

950 - 1 O : l O am

10:lO - 1030 am Break

Session I 1 The Latest in Staging and Treatment of Hepatocellular Cancer

Chair: 10:30 - 1050 am

1050 - 11:15 am

11:15 - 11:30 am

11:30 - 1k55 am

Ravi Ckari, M D New Staging of Hepatocellular Cancer: Report of the Joint AJCC/AHPBA 2002 Consensus Conference 1. Michael Henderson, MD Debate Surgical Resection for HCC is Best, Especially for Lesions c 5 cm in -= Child C Patients Jacques Belghiti, MD

Image Directed Ablative Options (RF, Cryo, PEIT) Should be Used Preferentially Whenever Possible Michael A. Ckoti, M D Adjuvant Protocols to Reduce Recurrence Kenneth K. Tanabe, M D Debate TACE is the Best Option for the Palliative Management of HCC jordi Bruix, M D

There Are Better Options Than TACE in the Palliative Management of HCC Brian Caw, MD, PhD

vs.

vs.

Supported in part by unrestricted educational grants from TissueLink Medical and Wako Diagnostics.

11:55 am - 12:15 pm Discussion 1295 - 1:30 pm Lunch

38A AASLD PROGRAM HEI’ATOLOGY, October 2003

Session 111: What’s New in The Treatment of Liver Metastasis?

Chrrir: 1:30 - 1 5 0 pm

230 - 255 pm

255 - 320 pm

3:20 - 3:35 pm

3:35 - 4:OO pm

4:OO - 4:15 pm

4:15 - 445 pm

4:45 - 5:OO pm

W Scott Helton, MD Why Are the Results for Resection of CoIorectal Metastasis Improving? Selection, Staging, Portal Embolization, Ischemic Protection, Better Surgeons, Large Volume Centers or What? Yunrari Fong, MD Resection is Now Indicated for What Other Types of Metastasis? ]oe Esynt, M D Debate: Is Laparoscopic Liver Resection More than a Gimmick? P I o Drive Geller, MD Coii A h W Hcnzniing, MD Debate: With the New Drug Regimens Available, Should We Use Neoadjuvant Chemotherapy Prior to Resection of Colorectal Metastasis? Pro Mitch Posner, MD Coif Wzlluzm R lariiignn, MD Debate: Palliation with Ablation. Go For It! Alnn Sipwstein, MD

Just Because it Is Easier, Doesn’t Mean it’s Indicated! Steve11 M Strasberg, MD Isolated Hepatic Perfusion- What‘s the Data? Dougla~ Fraker, MD Debate: Selective Internal Radiation Therapy (SIRT) is a Promising New Therapy for Liver Metastasis (and HCC) P i o Riclznrd Stubb5, MD Coii A h Pnr ~ k h , M D

Screening and Follow-Up Recommendations for Colorectal Metastsis Di7illd In~lr~i t r , MD

vs.

Discussion

AHPBA Business Meeting (Members Only)

Surgical Forum Facultv Disclosure

All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent confLict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Jacques Belghiti Jordi Bruix Chusilp Charnsangavej Michael A. Choti Bryan Clary Kevin J. Donohoe Joseph Espat Yuman Fong

Alan Hemming J. Michael Henderson David Ianniti William R. Jarnigan David Linehan Alex Parikh Mitchell Posner Steven Strasberg

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation may include discussion of off-label /investigative use of medicine(s), medical devices, or procedure(s).

Kenneth K. Tanebe

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does not include discussion of off-label/investigative use of medicine(s), medical devices, or procedure(s1.

David Geller Caristdtnn tlrldvisor: TissireLiirk

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Richard Stubbs S;7mkers’ Brirenii: Sirten- Meiiicnl Products

Stephanie Wilson G rn I i t/Resravch S 1 i pport: B ris to1 Myen S q 11 ibh 11 r id PIi il ips

Did not provide disclosure at time of printing.

Brian I. Carr Ravi Chari Douglas Fraker

Lawrence Schwartz Richard Schulick Alan Siperstein

Poster Session 1 Exhibit Hall Opening and Reception

530 - 8:OOpm Hynes Convention, Exhibit Hall C Refer to page 78 for Poster Presentations

5:30 - 800pm Hynes Convention Center, Exhibtt Hall D


Sunday, October 26 6:30 - 7:50am Hines Conzmfioii Ceiiter, Room 210 Networking Breakfast for Women in Hepatology

breakfast meeting to discuss important issues, including attracting more women to GI and liver training, and improving understanding of liver diseases that predominantly effect women. Interested participants will form the basis of a

AASLD representatives on the Gastroenterology Women’s CoaIition invite women physicians, surgeons, hepatologists,

committee or committees to address these and other interesting issues. Be sure to register, but note the meeting is complimentary.

fellows, and residents to participate in a complimentary This crleiit is supported by Firjisaicw.

Sundav. October 26 Basic Research Workshops

7:OO - 750 am Pltme refir to p r r E M W ticketfor meefing room location.

An excellent way to start your day at The Liver Meeting is to attend an Early Morning Workshop. These small group sessions provide the participants an opportunity to interact with two experts in a specialized area of liver disease or investigation. Registration is on a first-come, first-serve basis, so remember to register early. In order to register, complete the designated section of the registration form on page 28 indicating your first, second and third choices by the number listed next to the title. The registration fee is per workshop, per day.

Goals and Obiectives: 1 CME Credit Each (3 maximum)

The Early Morning Workshops consist of two categories: Basic Research and Clinical Management.

Basic Rmarcl i Workshops Bring together investigators in a specific area of research to discuss their ongoing work. Focus of discussions is on new work and not a review of previous studies. Intended for the active investigator and not for the practicing clinician. Allow ample time for questions from the audience.

Cliriicnl Mnnngement Workshops Discuss difficult management issues utilizing acknowledged experts in the area. Provide an overview of the current state of the art in each area. Intended for the clinician who is seeking the most updated information on a difficult area of management. Allow ample time for questions from the audience.

301.

302.

303.

304.

305.

306.

307.

308.

Signaling Mechanisms in Liver Michael H. Nuthanson, M D , PlrD and Mohaniined S . Anwer, PhD, D M V H

Liver Regeneration Nelson Fniisto, M D nnd R C ~ P T C ~ ~ A . Tnirb, M D

Mechanisms of Drug-Induced Liver Injury Paul B. Wutkins, M D nnd Hartinrrt W. Incsdikc, PfiD

Molecular Mechanisms of Bile Formation Mic/~ncl H. Trnwier, M D ni i i f Rirliord M . Grecri, M D

Molecular Virology of Hepatitis C T. jake Liang, MD and Stanley M . Lrinori, M D

Newer Immunosuppressive Drugs john M . Vierling, M D and Midiarl A. Hcr iq l ia r i , M D

Drug Transport Proteins in the Liver Pcter L.M. jarisen, M D , PliD nilif Dietrich KL>ppler, M D

Pathogenesis of Alcoholic Liver Disease D a r d W. Crabb, M D arid €strban M r q , M D

Clinical Management Workshops

309.

310.

311.

312.

313.

314.

315.

Treatment of Hepatitis C Following Liver Transplant Gary L. Davis, M D nnd Eresn L . Wriyht, M D

Management of Hepatopulmonary Syndrome Mirlinel B. F n l h i , M D arrrf Mirhncl j . Kroirka, M D

Treatment of Hepatocellular Carcinoma jordi Bruix, M D mid Adrinii M . Di Bisci:ylie, M D

Living Donor Transplantation-Risks and Benefits leati C. Ernoiid, M D and Gregory T. E i w w n , M D

NASH (Clinical Aspects) Arthitr j . McCrrlloirgl1, M D anif Aririr 1. Sanyul, M D

Pharmacological Therapy of Portal Hypertension Iuan R ~ J ~ c s , M D m i i f Dori C. Rockiy, M D

Pathogenesis of Autoimmune Hepatitis Michael Z? Mariris, M D arid Marion C . Pt,tcw, M D

4OA AASLD PROGRAM HEPATOLOGY, October 2003

Earlv Morning Workshou Facultv Disclosure


1 Iic~ tollcwing in\.itcd speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off- label /investigative use of niedicine(s), medical devices, or procedure(s).

Gianfranco Alpini Mohammed S. Anwer Vicente Arroyo William F. Balistreri Bruce R. Bacon Nathan M. Bass D. Montgomery Bissell James L. Boyer Thomas D. Boyer Jordi Bruix Laura Bull Martin C. Carey David W. Crabb Mark J. Czaja Laurie D. DeLeve Jean C. Emond Gregory T. Everson Michael B. Fallon Geoffrey C. Farrell Nelson Fausto G~iadal~ipe Gxcia-Tsao Cregoy J , Gores Richard M. Green Roberto J. Groszniann Hartmut W. Jaeschke Ptstc'r L.M. Janseii

Saul J. Karpeii Emmet B. Keefe Dietrich Keppler Andrew Klein Kris V. Kowdley Michael J. Krowka John J. Lemasters Gene D. Lesage T. Jake Liang Jacquelyn J. Maher Ian G. McFarlane Mark A. McNiven Giorgina Mieli-Vergani Michael H. Nathanson Dominique Pessayre Marion G. Peters Don C. Rockey Juan Rodes Bruce A. Runyon Stewart Sell Vijay Shah Neil D. Theise Michael H. Trauner Paul B. Watkins Allan W. Wolkoff

Thc following invited speakers have indicated they have no rclationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does include discussion ot off-label / investigative use ot medicine(s), medical devices, or procedure(s).

Albert J C L ~ J ~ Lcorgc McDonald Brent A Tetri

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does not include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Jorge A. Bezerra Grant/Research Support: NIH, Procter and Gamble

Robert L. Carithers Grarit/Rcsearcli Support: Scheriiiy-Plough, GIaxo bVellconie, 3M

Phnrinocmtical, Noilartis, Chirori, G i l d , Amgrn, Rorhc Co~fsf~/tarrf/A~~r~isor.: Noivzrfr.s, 3M l ' h ~ ~ r n t ~ ~ ~ ~ t ~ ~ ~ t i c d t ; , Sc/rt~riii~-Plofr~~/r,

Speakers' Bureau: Scheriwg-Plough, Merck, Novurt is, Roche, Chiron, Anlp'n, R o c k , Glaxo Widlcorne

Aicaii Phariiia

John Chiang Coiisirltan tlAdvisor: Aventis Pharma

David E. Cohen Graiit/Research Support: Forest Laboratoyies Coiisultaii flAdziisor: Forest Luboratories

Gary L. Davis GrantlResearch Support: SciClone, AGS, Roclie

Anna Mae Diehl GmntlResearch Support: NIH Consultun t/Advisor: Takeda Metabasis Speakers' Burenii: Axcan Scandipharni Employee: johns Hopkins Uniuersity

Douglas T. Dieterich Granf/Rescarch Support: Roche, Scheriiig, Gilead Coiisultaiif/Ad7,isor: Roche, Scliering, Gilead Speakers' Bureau: Roche, Scheriiig, Gilmci'

Michael W. Fried GrnntlResearch Support: Hoffrnaii LaRoche, Schering-Plough, Glaxo CoizsultnnflAdoisor~ Ad hoc to Hofiiinri LaRoche Speakers' Bureau Roche

Scott L. Friedman Corisirltniit/Aduisor: Wyeth Ayerst, Privnetheus, A/[illeiiiiiirni,

Huniaii Genonie Sciciices, Geiizyiiir, Cdern Dii~~qnostics

E. Jenny Heathcote GrantIResearch Support: Ascan Phnrtiiil

CoiisultaiitlAduisor: Axcuii Plinrniii Speakers' Bureau: Axcan Pharnin

Stanley M. Lemon Graii t1Resenrck Support: Scherrny-Plorigli Rcsunrch Jiistrfiite,

Scher~i i~-Plo~rgh, Abhott Labs, Isrs Phnrnmrri~tiwl.;

Craig McClain GrnntlResearch Support: AstraZeneca, Merck, Pfizcr, WJleth Ayerst,

Ross Laboratories, Nestle, SnzifhKlineGlaxo, D U N , Elan Pharninceri ticals, Biogeiz, Sclicrirz~~-Plough, Roclw

HEPATOLOGY, Vol. 38, No. 4, Suppl. 1,2003 A A S L D PROGRAM 41A

John G. McHutchison Grail tIResearch Support: Akros Pharma Ziic, Amgen Znc, Bayer

Pharmaceuticals, Bio-Medicines, Inc, Bristol-Myers Sqiribb Cottipan!/, Cytel Corporation, Fujisawa, Genprobe, Gilead Sciences, IDUN, Isis Pharmaceuticals, Ortho Diagnostic Systems, Prometheus Laboratories, Ribozyme Pharmaceuticals, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone, Triangle Pharmaceuticals, Vertex Pharmaceuticals

CoizsultantlAdvisor: Amgen Znc, Anadys Pharmaceuticals lnc, Centocor lnc, GlaxoSmithKline, InterMune Phartnaceu ticals lnc, lsis Pharmaceuticals Znc, National Genetics Institute, Novartis Pharmaceuticals Znc, Prometheus Laboratories, Ribozyme Pharmacetrticals Znc, Schering-Plough Corpora tioii

Speakers‘ Bureau: 1nterMune Pharmaceuticals, Roche Pharmaceuticals, Schering-Plough Corporation

Brian J. McMahon Gran t/Research Support: GlaxoSmithKline, Prometheus

Esteban Mezey GrantIResearch Support: NZH

Richard K. Sterling GrantlResearch Support: Schering-Plough, Roche, Ortho Speakers’ Bureau: Schering-Plough

Teresa L. Wright Grant/Research Support: Hoffriian La Roche, Schering-Plough,

Gilead Sciences, Celera Diagnostics, SciClone Pharmaceuticals, Ortho Biotech, Ribapharm, ZnterinMune

Speakers’ Bureau: Roche Consultant: Chiron Corporation, Rigel Pharmaceuticals Advisory Board: GlaxoSmithKline, Gilead Sciences, Hoffman La

Roche, ZnterMune, Ortho Biotech, Roche Biosciences, Amgen, Centocor, Novartis, Pfizer

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

Adrian M. Di Bisceglie Gran tlResearch Support: Scherzng-Plough, Roche, Gilead Sciences,

ConsultantlAdvisor: Roche, Gilead Sciences, ldenix, SciClone

Speakers‘ Bureau: Schering-Plough Other: Schering-Plough Member, DSMB

In terMu ne

Pharniaceuticals, MDS Nordion, InterMune, Chiron, Novartis

Michael Heneghan GrantlResearch Support: Schering-Plough

Maureen Jonas GrantlResenrch Support: Schering-P/ough

Keith D. Lindor Grail tlResearch Support: Axcaiz, Roche, Fujisawa

Anna S.F. Lok GrantlResearch Support: BMS, GSK, Gilead, Roche, Schering Consirltni~t/Advisor: BMS, GSK, Gilead, Achillon, Chiron,

Zdenix, XTL

Michael P. Manns GranflResearch Support: Falk Foundation, Novartis

Arun J. Sanyal Consultan tlAdvisor: Protnetheus

Eugene R. Schiff GrantIRcsearch Support: Abbott, Amgen Inc, Bayer Pharmaceuticals,

Bristol-Myers Squibb Company, Gilead Sciences, GlaxoSmithKline, Zdenix, Ortho-Biotech, Ortho-Clinical Diagnostic Systems, Prometheus, Roche Moleculars, Roche Phavrtiaceu ticals, Schering-Plough Corporation, SciClone Pharmaceu ticals, Wako Chemicals U S A

CotisulfantlAduisor: Abbott, Bayer Pharmaceuticals, Bristol-Myers Squibb Company, Gilead Sciences, GlaxoSmithKline, ldenix, IDUN, Maxim, National Genetics Institute, Novartis, Ortho- Biotech, Ortho-Clinical Diagnostic Systems, Prometheus, Roche Moleculars, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharnzaceuticals, Wyeth

Squibb Company, Gilead Sciences, GlaxoSmithKline, Idenix, Ortho-Biotech, Ortho-Clinical Diagnostic Systems, Schering-Plough Corporation

Speakers’ Bureau: Abbott, Bayer Plzarmaceuticals, Bristol-Myers

Kathleen B. Schwarz Grail tlResearch Support: Roche

Mitchell L. Shiffman GrantlResearch Support: Schering-Plough, Roche CoiisultaiitlAdvisor: Roche Speakers‘ Bureau: Schering-Plough, Roche

Benjamin L. Shneider Speakers’ Bureau: Axcan Scandipharm

David L. Thomas CorislcltniitiAdvisor: Roche Pliarniaceuticals

Did not provide disclosure at time of printing. Didier Lebrec Charles E. Rogler Rebecca A. Taub


Sundav. October 26

8 00 am - Noon Hyrir,s Coizzwztmi Center, Bal2unoiir B Apoptosis: Signaling From Multiple Cellular Membranes and Organelles Coirrsr Drrcctnrs Gregoi y ] Gorcl.;, M D

Mark ] Cznp, MD


Provide information on the fundamental cellular processes / mechanisms responsible for cell death. Link cellular mechanisms to treatment strategies to inlubit apoptosis in liver injury. Link cellular mechanisms to treatment strategies for induction of apoptosis in hepatobiliary neoplasis.

The workshop will comprise a half-day scientific overview on the intracellular mechanisms of cell death. The process of cell death is critical to the pathophysiology of a variety of hepatic diseases including viral hepatitis, carcinogenesis, and liver injury from drugs, toxins, or ischemia / reperfusion. Recent investigations have demonstrated that apoptosis plays a critical role in the liver cell death that underlies these diseases. Over the past few wars there has been an explosion of information on the cellular mechanisms of apoptosis. This research workshop will take an organelle approach to an understanding of recent advances in the field. In particular, the cellular pathways of apoptosis triggered by events involving the cell membrane, endoplasmic reticulum, mitochondria, nucleus and lysosome will be emphasized. The objective of the workshop is to provide the attendees with new insights into the current mechanistic concepts of apoptosis and possible interventions to prevent this form of cell death.

Session I: Membrane Signaling: Plasma, Mitochondrial and Endoplasmic Reticulum Signaling Pathways

ChI?lIs Gregory Gorc,i, M D and

8:OO - 8:05 am Introduction 8:05 - 8:35 am

8:35 - 9:05 am

D a ~ d A Rieriiiri, M D

Death Receptor Signaling Mnrku.; Petcr, M D Endoplasmic Reticulum Pathway of Apoptosis ]uriying Yunii, M D Panel Discussion Mitochondria and Apoptosis Robertn Gottlieb, M D Cross-Talk Between Death Receptors and Mitochondrial Pathways of Apoptosis Xino-Ming Ym, M D Panel Discussion and Break

9:05 - 9:20 am 9:20 - 9:50 am

9:50 - 1020 am

1020 - 10:40 am

Session 11: Organelle Dysfunction and Apoptosis: Nucleus and Lvsosomes

Chairs:

10:40 - 11:lO am

Johri J. Lemastcrs, M D , PhD and Mark J. Czajii, M D DNA Damage Initiated Pathways of Apoptosis Yuri Lnzebnik, PhD

11:lO - 11:40 am Lysosomal Pathway of Apoptosis Gregory ]. Gores, M D

11:40 am - Noon Panel Discussion and Concluding Comments

Basic Research Workshop Faculty Disclosure

All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-labcl or investigative use or application of a product or device that may occur during the educational presentation.

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of oft-label / investigative use of medicine(s), medical devices, or procedure(s):

Yuri Lazebnik Markus Peter Xiao-Ming Yin Junying Yuan

The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s):

Roberta Gottlieb

The following invited speakers have indicated they have the following financial relationships and the content of the presentation does not include discussion of off-label /investigative use of medicine(s), medical devices, or procedure(s):

Gregory J. Gores Spenkers’ B u r m i : Celero


Sundav, October 26 8:OO am - 3:OO pm Sheraton Coiistitutioii Bal~rooni Hepatology Associates Course Course Directors: Carla M . Viscomi, RN, BSN

Mary E l k n Geragkty, BSN, RN, C G R N

Goals and Objectives: Describe the impact of alcohol, nutrition, and supplements on the liver. Discuss treatment issues for Hemochromatosis and HCC.

This one-day course is specifically designed for the hepatology associate (nurse, physician assistant, research, transplant coordinator, or other hepatology health professional) interested in expanding his or her knowledge base for the treatment of patients with liver disease. This course will elaborate on HCC, HCV, HW, nutrition, and CAM/Herbal supplement and their clinico-pathologic correlates.

5.5 CME; 5.8 Nursing Contact Hours

800 - 8:lO am Opening Remarks: About the Associates Course Carla M . Viscomi, R N , BSN and Mary Ellen Geraglity, BSN, R N , CGRN

Dietary Issues in Liver Disease

8:lO - 9:OO am CAM TherapiedHerbal Supplements: Risks and Benefits Jolynne Myers, C S , M S N , MSEd, A N P Alcohol and Hepatitis C Eugene R. Self#, M D

9:OO - 1O:OO am

1O:OO -10:15 am Break

Iron and Liver Disease

10:15 - 1045 am Diagnosis and Treatment of Hemochromatosis Paul C. Adams, M D

Hepatitis C: Special Populations

10:45 - 11:30 am

11:30 am - Noon

Noon - 1:30 pm Lunch 1:30 - 1:45 pm

Hepatitis C in Correctional Facilities Elizabeth N . Britton, M S N Treatment Issues in HIV/HCV Co-Infection Karen Muller, FNP-C, M S

Business Meeting

Complications of Liver Disease

1:45 - 2:15 pm

2:15 - 2:45 pm

HCC Screening and Treatment losepli A. Azond, M D Portal Hypertension: Screening and Treatment Noriiinfi D. Grace, M D Summary and Closing Remarks 245 - 3:OO pm

Nurses must have paid tuition fee and completed, signed and turned in an attendance/evaluation form, prior to leaving the Hepatology Associates Course in order to receive a certificate of completion/ attendance. Forms turned in after the conference will not be accepted.

Participants not fulfilling these requirements will not receive a certificate. Certificates will be mailed after the course.

Hepatology Associates Course Faculty Disclosure


The following speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of their presenatation does not include discussion of off-label/ investigative use of medicine(s), medical devices or procedure( s):

Paul C. Adams Joseph A. Awad Norman D. Grace

The following speakers provided the following disclosure information:

Elizabeth N. Britton GrontlResearch Support: Scheriizg, Roche Sptvkcrs' Bureau: Schering, Roche, Ortho Biotech Conterit ofpresentation does include discussion ofoff-

Inbrlliizvestigativc use of Inedicinds), medical devices or JJrOCeLfllJ'ds)

Karen Muller G r m t/Ricsmrch Support: Roche Pharmaceuticals Spenkers' Bureau: Roche Phnrinaceu ticals Corrteut of presentation does include discussion ofof-

Inbellirzoestigative use of Inedicinds), niedical devices or proccdurds)

Jolynne Myers Speakers' Bureau: Roche Coiiterit ofpresentation does Hot include discussion ofoff-

Inbcl/irivesti~ative use of rrzedicinds), nzedical devices or p rocedu re(s)

Eugene R. Schiff Grnrit/Rlm?rch Support: Scheriiig CorisiiltnntlAdvisor: Schering Content ofpresenfation does riot inclrrdc rfisczrssiori ( fo j f -

Inhel/inzrestigatioe use of medici!fefs), nledica/ deuices or puocedirrds)

Supported b!y ai l unrestricted educatioiial grantfrom Schering Hepatitis Innovations.

AASLD PROGRAM HEPATOLOGY, October 2003 4.14

Poster Session 2 Exhibit Hall

Sunday, October 26

8:OOam - 5:OOpm Hynes Coirzmtion Center, Exhibit Hall C See page %for Poster Presentations

Sunday, October 26 9:30am - 3:00pm Hynes Convention Center Exhibit Hall D

Sundav. October 26

#1 THE CLINICAL COURSE OF ULCERATIVE COLITIS AFTER ORTHOTOPIC LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS Alexandia J Seddon, Gwo-Tzer Ho, Western General Hoqpital, Edinburgh, UK, Geoige Therapondo\, Peter C Hayes, Royal Infiiniai y 01 Ediiiburgh, Edinbuigh, UK, Jack Satstangi, Western Geiieial Hospital, Ediiiburgh, UK

8:lSam $2 LIVER TRANSPLANTATION FOR FAMILIAL AMYLOID POLYNEUROPATHY DOES NOT PREVENT DISEASE PROGRESSION IN A MAJORITY OF PATIENTS Roman E Pel ri David Brandhagen, Steven Zeldenrust, Charles B Roscn, John J Poterurha, Morie A Gertz, Giegory J Gores, Mayo Clinic, Rochestel, MN

8:30am ~~

:3 THE IMPACT OF EXPANSION OF CONVENTIONAL TUMOR CRITERIA AND PRE-OPERATIVE LOCO-REGIONAL TREATMENTS ON SURVIVAL FOLLOWING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: RESULTS FROM TWO CENTERS Francis Y Yao, University ot California San Francisco, San Fi a i ic iwo, CA, Milan Kinhhabwala, New York Presbyterian Ho5pital We\\ York, NY, ]exme LaBeige, Nathan M Bass, Robert

Kerlan, John P Roberts, University of California Sail Francisco, San Francisco, CA

8:45am 114 THE SELECTION OF CALCINEURIN INHIBITOR AFFECTS THE RATE OF RECURRENCE OF PRIMARY BILIARY CIRRHOSIS (PBC) James Neubeiger, Bridget K Gunson, Queen EIiL'ibeth Hospital, Birmingham, UK, Stefan G Hubscher, University of Birmingham Medical School, Birminghain, UK, Peter Nightingale, Q~ieeii Elizabeth Hospital, Birmingham, UK

9:OOam

25 CLASSIFICATION OF OPERATIVE COMPLICATIONS IN LIVE LIVER DONORS Chri\topher R Shackleton, Steven D Colqudioun, Nicholas Nissen, John M Vierling, Paul Martin, Fred Poordad, Tram Tran, Andrea Peterson, Shannon Hogan, Cedars-Sinai Medical Centei, UCLA 5chool of Medicine, Los Angeles, CA

9:l Sam $ 6 DEFINITIONS AND OUTCOMES OF TRANSPLANTS USING EXPANDED CRITERIA DONOR LIVERS Sandy Feiig, University of California San Francisco, Sail Francisco, CA; Jennifer L Bragg-Gresham, Dawn M Dykstra, SRTR/URREA, Ann Arbor, MI; Jeffrey D Punch, Meelie DebRoy, University of Michigan, Arui Arbor, MI; Stuart M Greenstein, Albert Einstein College of Medicine, Bronx, NY; Robert M Merion, University of Michigan, Ann Arbor, MI


Sunday, October 26 9:30 - 1000 am Transplant Surgery ”Now That We Are Here, Where Are We Going?” Speaker: Frederick Ryckman, M D Moderator: J. Michael Millis, M D

Faculty Disclosure informa tion: All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest

related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

Frederick Ryckman provided the following disclosure

No relationship to disclose Content ojpresentatioiz does not include disctission ofoff-labell

investigative use ofniedicine(s), medical devices or procedureM

Break 1000 - 1030 am

Sunday, October 26 10:30am - 12:OOpm Veterans Memorial Auditorium Moderators: T l M O T H Y PRUETT and H A R I S . CONJEEVARAM

10:30am # 7 EFFICACY AND TOLERABILITY OF PREEMPTIVE INTERFERON (IFN) VERSUS IFN PLUS RIBAVIRIN (RBV) TREATMENT IN HEPATITIS C VIRUS (HCV) INFECTED LIVER TRANSPLANT RECIPIENTS Norah A Terrault, Mandana Khalili, Stephanie Straley, Kathy Bollinger, Nathan Bass, John P Roberts, Nancy A Ascher, University of California San Francisco, San Francisco, CA

10:45am #8 PATIENT AND GRAFT SURVIVAL AFTER ADULT LIVING DONOR LIVER TRANSPLANTATION COMPARED TO CADAVERIC LIVER TRANSPLANTATION IN PATIENTS WITH CHRONIC HEPATITIS C AN ANALYSIS OF THE UNITED NETWORK FOR ORGAN SHARING DATABASE Mark W Russo, Joseph A Galanko, Kimberly Beavers, Michael W Fried, Steven L Zacks, Roshan Shrestha, University of North Carolina, Chapel Hill, NC

11 :OOam #9 INCREASED RISK OF CHOLESTATIC HEPATITIS C IN RECIPIENTS OF GRAFTS FROM LIVING VERSUS CADAVERIC LIVER DONORS Paul J Gaglio, Snkar Malireddy, Brian A Levitt, Dianne Lapointe- Rudow, Jay Lefkowitch, Milan Kinkhabwala, Mark W Russo, Jean C Emond, Robert S Brown Jr, Columbia University College of Physicians and Surgeons, New York, NY

11rlSam

# 10 RESISTANCE SURVEILLANCE OF LIVER TRANSPLANTA- TION PATIENTS WITH LAMIVUDINE-RESISTANT HEPATITIS B VIRUS (HBV) AFTER 96 WEEKS OF ADEFOVIR DIPIVOXIL TREATMENT Christopher E Westland, Gilead Sciences, Inc., Foster City, CA; Jean-Pierre Villeneuve, HGpital Saint-Luc, Centre Hospitalier de l’Universit6 de Montreal, Montreal, PQ, Canada; Norah A Terrault, UCSF, San Francisco, CA; Fabien Zoulim, INSERM, Lyon, France; Carol L Brosgart, Michael Wulfsohn, Michael D Miller, Shelly Xiong, Gilead Sciences, Inc., Foster City, CA

11 :30am # 11 ADEFOVIR DIPIVOXIL 10 MG (ADV) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN PATIENTS PRE-LIVER TRANSPLANTATION WITH LAMIVUDINE-RESISTANT PATIENTS Eugene Schiff, University of Miami, Miami, FL; Ching-Lung Lai, Queen Mary Hospital, Hong Kong, Hong Kong; Stefanos Hadziyannis, Henry Dunant Hospital, Athens, Greece; Peter Neuhaus, Charite, Campus Virchow-Klinikum, Berlin, Germany; Norah Terrault, University of California San Francisco, San Francisco, CA; Pietro Lampertico, Universith degli Studi Milano e IRCCS, Ospedale Maggiore, Milano, Italy; Hans Tillmann, Hannover Medical School, Hannover, Germany; Samuel Didier, Paul Brousse Hospital, Villejuif, France; Nicole Lama, Craig James, Graeme Currie, Carol L Brosgart, Gilead Sciences, Inc., Foster City, CA

1 1 :45am # 12 PROGRESSION AND TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION IN

Michael E de Vera, Bijan Eghtesad, Ashokkumar Jain, John J Fung, University of Pittsburgh, Pittsburgh, PA

PATIENTS CO-INFECTED WITH HIV

4h A AASLD PROGRAM HEPATOLOCY, October 2003

Sunday, October 26 Faculty Disclosure

Noon - 12:30pm Hans Popper Basic Science “Hepatitis C Virus: A 15-year Perspective” Spcnkrr: Charles M. Rice, PhD Moderator: k 1 W L . Wright, M D


Charles Rice provided the follwing disclosure information: Major stock shareholder: Apath, UC Content of presentation does not include discussion ofof-la-lnbeli

inuestigatizle use of niedicinefs), rrzedicals devices or procedurefs)

Sunday, October 26 1 00 - 4 30 p n ~ Hyiies Conuci~tioii Ceriter, Room 304/306 Hepatotoxicity in Alpha-1 Antitrypsin Deficiency: Molecular Pathogenesis and Therapeutic Approaches Clrmr i Eicytvte R Schgfi M D

Wdliani F Balistrcii, M D Mark A Zcrn, M D


Understand the pathophysiology of alpha-1 antitrypsin deficiency. Review current concepts concerning protein trafficking in liver cells. Learn about new therapeutic modalities applicable to a varietv of liver diseases.

There is, in general, a lack of understanding of alpha-1 antitrypsin deficiency on the part of most hepatologists. This course will provide an overview of the disease process focusing on the pathophysiology and treatment options, thus enhancing the education of most hepatologists. It will also provide a forum for an in-depth discussion of the disease by experts from a number of different research perspectives, thus fostering new collaborative interactions and novel research initiatives. This approach not only provides for an in-depth analysis of this unique inherited disease, but also yields insight into cutting-edge research approaches applicable to all types of liver disease.

The registration fee for this symposium is included in the Annual Meeting registration fee. Please indicate your intent to attend this event on the Registration Form on page 28 to assist in ensuring adequate seating.

1:00 - 1:15 pm Introduction

1:15 - 1:40 pm Rrtrce Trapnell, M D Molecular and Cellular Biology of Quality Control in the Biosynthesis of Alpha-1 Antitrypsin Richard Sifers, PhD Modifying Genes in Hepatic Fibrosis Dn71id A. Brenizer, MD

1:40 - 2:05 pm

205 - 230 pm

230 - 255 pm

2:55 - 3:20 pm

320 - 3:45 pm

3:45 - 4:lO pm

410 - 4:30 pm

Autophagy of the Endoplasmic Reticulum in Response to Alpha-1 Antitrypsin Z jeffuey Teckmari, M D The ”Overstuffed” Endoplasmic Reticulum Response to Alpha-1 Antitrypsin Accumulation Peter Arvnii, M D , PI7D Heterozygote Disadvantage in Alpha-1 Antitrypsin Z Carriers Eugeiie R. Sclzifi MD Gene Therapy Approaches for the Treatment of Liver Disease in Alpha-1 Antitrypsin Deficiency Terence Flotte, M D Hepatocyte Transplantation for the Treatment of Liver Failure in Alpha-1 Antitrypsin Deficiency Mark A. Zerii, M D General Discussion

Alpha-1 Antitrypsin Symposium Faculty Disclosure


The following invited speakers have indicated they have no relationships with commercial entities that might be perceived as having a connection with their presentation and the content of the presentation does not include discussion of off-label / investigative use of medicine(s), medical devices, or procedure(s).

David A. Brenner Jeffrey Teckman Terence Flotte Bruce Trapnell Eugene R. Schiff Richard N. Sifers

Mark A Zem

Did not provide disclosure at time of printing: Peter Arvan

Supported by an educational gran t from Alpha-l Foundation


Sunday, October 26

3:00 - 4:3O pm Hynes Convention Center Veterans Memorial Auditorium Moderators: Laurie D. DeLeve, MD, PhD

Michael B . Fallon, M D


Identify factors that influence candidacy for therapy of Hepatitis C. Define appropriate therapy for gastro-esophageal varices. Review optimal management of patients following liver transplantation.

This session should be of particular interest to the practicing hepatologist. Attendees will hear about the latest developments on topics summarized by leading authorities in their specialty area. Presentations will be made in symposium format with a question period following each talk.

3:OO - 3:30 pm

3:30 - 4 0 0 pm

400 - 430 pm

HCV-Who Should Be Treated? lra M . lacobson, M D Management of Varices Giiadalupe Garcia-Tsao, M D Management of the Post-Transplant Patient John R. Lake, M D

General Hepatology Update Faculty Disclosure


Speakers have provided the following disclosure information:

Guadalupe Garcia-Tsao No relationship to disclose Content ofpresentation does not inclnde discussion of of-label/

inaesfigative use of medicin&), medical devices or procedtrre(s)

Ira M. Jacobson GrantlResearch Support: InterMune, ISIS, RPl, Prometheus, Schering Coizsultant/Aduisor: Akros, Amgen, C m tocor, Schering, Prometheus,

Speakers' Bureau: Gilead, Schering Content ofpresentation does include discussion of of-labell

Ortho, In terMune

investigative use of medicine(s), medical devices or procedurek)

John R. Lake

Fujisaiua GrantlResearch Support: Schering, Roche, Wyeth-Amgest, Novartis,

Consultan t/Advisor: Fujisazoa Content of presentation does not include discussion ofof-label/

inzmtigative use of medicinek), medical devices or procedurds)


Parallel Session 1: Autoimmune and Infectious Liver

and Biliary Tract Injury

Sunday, October 26 3:OO pm - 4:30pm Hynes Conaention Center Room 312 Moderators: WAIAHAT Z . MEHAL and M . ERIC GERSHWZN

3:OOpm 8 13 BILE DUCT INJURY IN RESPONSE TO EXPRESSION OF ANTIGEN ON THE SURFACE OF BILIARY EPITHELIUM Yuki Young, James Buxbaum, Ciera Khuu, UCSF, San Francisco, CA; Benjamin Shneider, Mount Sinai School of Medicine, New York, NY; Paul M Allen, Washington University School of Medicine, St. Louis, MO; Marion G Peters, UCSF, San Francisco, CA

3:15pm # 14 DEVELOPMENT OF AN ANIMAL MODEL FOR

TOLERANCE IN THE CYP2D6 HUMANIZED MOUSE BY VIRAL INFECTION Urs Christen, Antje Rhode, La Jolla Institute for Allergy and Immunology, San Diego, CA; Eric F Johnson, The Scripps Research Institute, La Jolla, CA; Michael P Manns, Hannover Medical School, Hannover, Germany; Matthas G von Herrath, La Jolla Institute for Allergy and Immunology, San Diego, CA

3:30pm x 15 TOLEROGENIC ANTIGEN PRESENTATION IN THE LIVER

AUTOIMMUNE HEPATITIS: BREAKING OF SELF-

ANTIGEN PRESENTING HEPATOCYTES RE-DIFFERENTIATE DENDRITIC CELL-PRIMED PRO-INFLAMMATORY THl CD4 T CELLS TO ANTI-INFLAMMATORY TH2 CELLS Christiane Wiegard, Johannes Herkel, Peter R Galle, Edgar Schmitt, Ansgar W Lohse, Johannes Gutenberg University, Mainz, Germany

3 : 4 5 ~ m ~

# 16

HEPATITIS BY INHIBITION OF NKT LYMPHOCYTES: A NEW IMMUNEMODULATORY TOOL Maya Margalit, Ruslana Alper, Nilla Hemed, Victoria Doviner, Yoav Sherman, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Barbara E Thalenfeld, Dean L Engelhardt, Elazar Rabbani, Enzo Biochem Inc., Framingdale, NY; Yaron Ilan, Hadassah Hebrew University Medical Center, Jerusalem, Israel

400pm

GLUCOCEREBROSIDE TREATMENT AMELIORATES CON-A

415pm # 18 CRYPTOSPORIDIUM PARVUM INVADES HUMAN CHOLANGIOCYTES BY ACTIVATING A CDC42 SIGNALING PATHWAY CAUSING ACTIN REMODELING Xian-Ming Chen, Bing Q Huang, Patrick L Splinter, James D Orth, Mark A McNiven, Nicholas F LaRusso, Mayo Medical School, Clinic and Foundation, Rochester, MN

Parallel Session 2: Hepatocyte Transplantation

Sunday, October 26 3:OOpm - 4:30pm Hynes Coizuention Center Room 309 Moderators: STEPHEN C. STROM and MILAN KZNKHAB W A L A

3:OOpm # 19 HUMAN HEPATOCYTES TRANSPLANTED INTO IMMUNOCOMPETENT RATS ARE SUSCEPTIBLE TO HEPATITIS C VIRAL INFECTION George Y Wu, Cherie M Walton, Denise Olive, Masayoshi Konishi, Catherine H Wu, University of Connecticut Health Center, Farmington, CT

3:15pm # 20 ACCEPTANCE OF IMMUNOGENIC HEPATOCYTE ALLOGRAFTS UNDER COVER OF DONOR SPECIFIC TRANSFUSION AND COSTIMULATORY BLOCKADE WITH

Keri E Lunsford, Donghong Gao, Ginny L Bumgardner, The Ohio State University Medical Center and College of Medicine and Public Health, Columbus, OH

3:30pm # 21 HEPATIC STELLATE CELLS (HSC) ARE PERTURBED BY HEPATOCYTE TRANSPLANTATION IN THE LIVER AND HSC PERTURBATION IMPROVES CELL ENGRAFTMENT Daniel Benten, Vinay Kumaran, Brigid Joseph, Sanjeev Gupta, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY

3:45om

ANTI-CD40L MAB REQUIRES HOST CD8+ T CELLS

x 22 IN VIVO EVALUATION OF SURVIVAL AND FUNCTION OF PORCINE HEPATOCYTES IN RECIPIENT MICE Ryuta Nishitai, Bruce E Knudsen, Timothy B Plummer, Kim A Butters, Kiyoshi Ogata, Cody A Koch, Jeffrey L Platt, Mayo Clinic, Rochester, MN

# 17 400pm FUNCTIONAL IMPAIRMENT OF CD25+CD4+ REGULATORY T ~~

# 23 FIBROBLAST GROWTH FACTORS ENHANCE THE TRANS- DIFFERENTIATION AND PROLIFERATION OF BONE MALLOW CELLS INTO HEPATOCYTES

CELLS CHARACTERIZES AUTOIMMUNE HEPATITIS TYPE 2 Yun Ma, Maria Serena Longhi, Dimitrios P Bogdanos, Giorgina Mieli-Vergani, Diego Vergani, King’s College Hospital, London, UK Tsuyoshi Ishikawa, Shuji Terai, Kouji Aoyama, Kaoru Omori,

Isao Sakaida, Yamaguchi University School of Medicine, Ube- Yamaguchi, Japan; Hiroshi Nishina, University of Tokyo, Tokyo, Japan; Kiwamu Okita, Yamaguchi University School of Medicine, Ube-Yamaguchi, Japan


4:lSpm # 24 PROLONGED SURVIVAL OF PORCINE HEPATOCYTES IN CYNOMOLGUS MONKEYS H Nagata, R Nishitai, C Shirota, J Zhang, University of Nebraska Medical Center, Omaha, NE; C A Koch, Mayo Clinic, Rochester, MN; J Cai, University of Nebraska Medical Center, Omaha, NE; M Awaad, H J Schuurman, Immerge BioTherapeutics, Inc., Charlestown, MA; U Christians, University of Colorado Health Sciences Center, Denver, CO; J L Platt, Mayo Clinic, Rochester, MN; Ira J Fox, University of Nebraska Medical Center, Omaha, NE

Parallel Session 3: Cholangiocyte Biology and Experimental Cholestasis

Sunday, October 26 3:OOpm - 4:30pm Hynes Conuention Center Room 311 Moderators: GENE D. LESAGE and MlCHAEL H. N A T H A N S O N

3:OOpm # 25 FIBROCYSTIN, THE ARPKD PROTEIN, IS LOCALIZED TO CHOLANGIOCYTE CILIA AND IS DISRUPTED IN THE ORTHOLOGOUS RAT MODEL, PCK Tatyana V Masyuk, Bing Q Huang, Anatoliy I Masyuk, Patrick L Splinter, Christopher J Ward, Xiofang Wang, Rachaneekorn Punyashthiti, Peter C Harris, Vicente E Torres, Nicholas F LaRusso, Mayo Medical School, Clinic and Foundation, Rochester, MN

3 : l S ~ m # 26

REGULATION AND FUNCTIONAL IMPAIRMENT OF THE ORGANIC CATION TRANSPORTER 1 (OCT1) IN RAT LIVER Gerald U Denk, Carol J Soroka, Albert Mennone, Yale University School of Medicine, Liver Center, New Haven, CT; Hermann Koepsell, Bayerische Julius-Maximilians-Universitat, Institut f i r Anatomie und Zellbiologie, Wurzburg, Germany; Ulrich Beuers, Ludwig-Maximilians-Universitat, Medizinische Klinik 11, Klinikum Groghadern, Munich, Germany; James L Boyer, Yale University School of Medicine, Liver Center, New Haven, CT

3:30pm # 27

CHOLESTEROL 7a HYDROXYLASE PROMOTER FACTOR (CPF) AND IS HEPATOPROTECTIVE IN OBSTRUCTIVE CHOLESTASIS Alan Bohan, Wen-Sheng Chen, Lee A Denson, Matthew A Held, James L Boyer, Yale University School of Medicine, New Haven, CT

OBSTRUCTIVE CHOLESTASIS RESULTS IN DOWN-

MRP3/MRP3(ABCC3/ABCC3) IS UP-REGULATED BY TNFa VIA

3 : 4 5 ~ m # 28 TAUROCHOLATE FEEDING PREVENTS THE FUNCTIONAL DAMAGE OF INTRAHEPATIC BILE DUCTS INDUCED BY ADRENERGIC DENERVATION IN A PI3K DEPENDENT MANNER Marco Marzioni, The Texas A & M University System HSC COM, Temple, TX; Shannon Glaser, Heather Francis, Silvia Taffetani, Scott and White Hospital, Temple, TX; Luca Marucci, Antonio Benedetti, University of Ancona, Ancona, Italy; Domenico Alvaro, University of Rome La Sapienza, Rome, Italy; Jo Lynne Phinizy, Scott and White Hospital, Temple, TX; Brandy Baumann, Julie Venter, The Texas A & M University System HSC COM, Temple, TX; Yoshiyuki Ueno, Tohoku University School of Medicine, Sendai, Japan; Gianfranco Alpini, The Texas A & M University System HSC COM and Central Texas Veterans HCS, Temple, TX

4 0 0 p m # 29 KUPFFER CELL GENERATED DEATH LIGANDS POTENTIATE CHOLESTATIC LIVER INJURY Ali Canbay, Ariel E Feldstein, Hajime Higuchi, Nate Werneburg, Annette Grambihler, Steve F Bronk, Gregory J Gores, Mayo Clinic, Rochester, MN

4 1 5 p m # 30 REGULATION OF TREFOIL FACTOR FAMILY EXPRESSION IN

MEDIATED GP130 STAT3 SIGNALING UNDER STEADY STATE CONDITIONS AND DURING BILIARY TRACT DISEASES lsao Nozaki, John G Lunz, Tsukasa Ezure, Susan Specht, Noriko Murase, Anthony J Demetris, University of Pittsburgh, Pittsburgh, PA

BILIARY EPITHELIAL CELLS BY INTERLEUKIN-6 (IL-6)-

Parallel Session 4: Hepatitis C: Pathogenesis

Sunday, October 26 3:OOpm - 4:30pm Hynes Convelztion Center Ballroom A Moderators: KYONG-MI CHANG and J A M A DARLING

3:OOpm # 31 HCV EXPRESSION INHIBITS INTERFERON SIGNALING

Wenyu Lin, Yoichi Hiasa, Yoshitaka Kamegaya, Jason Blackard, Carolynne Zander, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Gregory Beck, University of Massachusetts, Boston, MA; Emmett V Schmidt, Raymond T Chung, Massachusetts General Hospital, Harvard Medical School, Boston, MA

IN A CELL-BASED HCV REPLICATION MODEL


3:lSpm l~ 32 AN ANALYSIS OFCTLA4SINGLE NUCLEOTIDE POLYMORPHISMSAND HAPLOTYPES WITH HEPATITIS C VIRUS OUTCOMES Chloe L Thio, Timothy Mosbruger, Jacquie Astemborski, Johns Hopkins School of Medicine, Baltimore, MD; James G Goedert, National Cancer Institute, Rockville, MD; Stephen OBrien, National Cancer Institute, Frederick, MD; David L Thomas, Johns Hopkins School of Medicine, Baltimore, MD

3:30pm

Parallel Session 5: Hepatobiliary Surgery:

Clinical and Experimental

Sunday, October 26 3:OOpm - 4:30pm Hynes Conaention Center Room 320 Moderators: STEPHEN COLQUHOUN and

STEVEN M . STRASRERG

3:OOpm

# 33 MICROARRAY ANALYSIS OF INTRAHEPATIC GENE EXPRESSION IN DIFFERENT PATTERNS OF HCV RECURRENCE POST LIVER TRANSPLANT Amany Zekry, Rohan William, Centenary Institute for Cancer Research and Cell Biology, Sydney, Australia, Geoffrey W McCaughan, Centenary Inshtute for Cancer Reseaich and Cell Biology and the AW Morrow Gastroenterology and Liver Centre, Sydney Au5tialia

3:45pm 3 34 CROSSPRIMING OF HEPATITIS C VIRUS SPECIFIC CD8+ T CELLS IN MICE BY IMMUNIZATION WITH DENDRITIC

Vito Racanelli, National Institutes of Health, Bethesda, MD; Sven Erik Behrens, Fox Chase Cancer Center, Philadelphia, PA; Julio Aliberti, Barbara Reliermann, National Institutes of Health, Bethesda. MD

CELLS TRANSFECTED WITH SELF-REPLICATING RNA

4 0 0 p m :: 35 CHARACTERIZATION OF NOVEL CD4+ T CELL EPITOPES IN ACUTE SELFLIMITED HCV INFECTION Tilmaii Gerlach, I<linikuni GroRhadern, Munich, Germany; Axel Ulsenheimer, Institute for Immunology, Munich, Germany; Norbert Gruener, Klinikum GroGhadern, Munich, Germany; Reinhart Zachoval, Maria-Christina Jung, Medical Department 11, Grosshadern, Munich, Gerinaiiy; Winnfried Schraut, Institute for Immunology, Munich, Germany; Albercht Schirren, Medical Department 11, Grosshadern, Munich, Germany; Martin Wachtler, Michael Backniund, Stadtisches Krankenhaus Schwabing, Munich, Germany; Gerd R Pape, Helmut Diepolder, Klinikum GroRhadern, Munich, Germany

415pm # 36 INDUCTION OF HEPATITIS C VIRUS SPECIFIC T CELLS BY

Anne K Kubitschke, Matthias Bahr, Nuray A s h , Haruiover Medical School, Hannover, Germany; Christoph Sarazzin, University of Saarland, Homburg, Germany; Hans L Tillmann, Tim Greten, Manuela Meyer, Johannes Wiegand, Michael P Manns, Heiner Wedemeyer, Hannover Medical School, Hannover, Germany

NEEDLE STICK INJURY IY THE ABSENCE OF HCV-VIREMIA

# 37 A SINGLE CENTER EXPERIENCE IN THE MANAGEMENT OF 125 IATROGENIC BILE DUCT INJURIES FOLLOWING LAPAROSCOPIC CHOLECYSTECTOMY Vijayaragavan Muralidharan, Michael Silva, Simon R Bramhall, David Mayer, John A C Buckels, Paul McMaster, Darius F Mirza, University Hospital Birmingham, Birmingham, UK

3:lSpm # 38 ACTIVATION OF TUMOR SPECIFIC T LYMPHOCYTES AFTER

METASTASES Thaddaeus Till H Wissniowski Jr, Johannes Haensler, Thomas Bernatik, Detlef Schuppan, E G Hahn, Deike Strobel, Friedrich- Alexander-University Erlangen Nuernberg, Erlangen, Germany

3:30om

RADIO-FREQUENCY ABLATION IN PATIENTS WITH LIVER

# 39 RESECTION PRIOR TO LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA Alexandre Cortes, Franqois Durand, Reza lanmanesh, Eddie K Abdalla, Daiiiele Sommacale, Federica Dondero, Alain Sauvanet, Olivier Farges, Jacques Belghiti, Hospital Beaujon, Clichy, France

3:45pm # 40

HEPATOPROTECTIVE FACTOR WHICH DEFENDS THE

Maria Iiliguez, Eduardo Martinez-Anso, Naiara Beraza, Matilde Bustos, Puri Fortes, Jesus Prieto, Clinica Universitaria and Medical School, University of Navarra, Pamplona, Spain

4 0 0 p m 4 41 ISCHEMIC PRECONDITIONING PROTECTS HEPATOCYTES AGAINST WARM ISCHEMIA/REPERFUSION INJURY VIA OXYGEN RADICALS DERIVED FROM KUPFFER CELLS Kazuaki Tejima, Masahiro Arai, Hitoshi Ikeda, Tomoaki Tomiya, Mikio Yanase, Yukiko Inoue, Kayo Nagashima, Naoko Watanabe, Masao Omata, University of Tokyo, Tokyo, Japan; Keiiji Fujiwara, Saitama Medical School, Saitama, Japan

4:15pm ft 42 A20 CONFERS A PROLIFERATIVE ADVANTAGE T O HEPATOCYTES AND PROMOTES LIVER REGENERATION Christopher R Longo, Virendra I Patel, Maria B Arvelo, Soizic Daniel, Shane T Grey, Christiane Ferran, Beth Israel Deaconess Medical Center, Boston, MA

CARDIOTROPHIN-1 (CT-1) IS A POTENT

LIVER AGAINST ISCHEMIA-REPERFUSION INJURY


Parallel Session 6: Portal Hypertension: Experimental

Sundav, October 26 3:OO pm - 4:30pm Hyizes Convention Center Room 302 Moderators: DON C. ROCKEY and W. WAYNE LAUTT

3:OOprn # 43 LOSS OF CEREBRAL AUTOREGULATION IN RATS AFTER PORTACAVAL ANASTOMOSIS Chuhan Chung, Javier Vaquero, Jeanne Gottstein, Andres T Blei, Lakeside VA Medical Center and Northwestern University, Chicago, IL

3:15pm # 44 A LIVER-SPECIFIC NITRIC OXIDE DONOR IMPROVES THE INTRA-HEPATIC VASCULAR RESPONSE TO INCREASE PORTAL BLOOD FLOW AND METHOXAMINE IN CIRRHOTIC RATS Mauricio Loureiro-Silva, Yale University School of Medicine, VA Medical Center, West Haven, CT; Gregory W Cadelina, VA Medical Center, West Haven, CT; Yasuko Iwakiri, Roberto J Groszmann, Yale University School of Medicine, CT-VA Healthcare System, West Haven, CT

3:30pm # 45 MESENTERIC VASOCONSTRICTION IS RESPONSIBLE FOR THE INITIAL ENOS UPREGULATION IN THE SUPERIOR MESENTERIC ARTERY OF PORTAL HYPERTENSIVE RATS Ming-Hung Tsai, Chang Gung Memorial Hospital, Taipei, Taiwan; Yasuko Iwakiri, Yale University School of Medicine, VA Medical Center, West Haven, CT; Gregory Cadelina, Veterans Administration Medical Center, West Haven, CT; William C Sessa, Yale University School of Medicine, New Haven, CT; Roberto J Groszmann, Yale University School of Medicine, VA Medical Center, West Haven, CT

3:45pm # 46 CAVEOLIN INHIBITS A CONSTITUTIVELY ACTIVATED FORM OF RECOMBINANT ENOS EXPRESSED IN HEPATIC STELLATE CELLS: POSSIBLE MECHANISM FOR DYSFUNCTION OF RECOMBINANT ENOS GENE DELIVERY TO LIVER IN PORTAL HYPERTENSION Suvro Chattejee, Helen Hendrickson, Vijay Shah, Mayo Clinic, Rochester, MN

4 w D m # 47 RHO MODULATES HEPATIC SINUSOIDAL ENDOTHELIAL FENESTRAE VIA REGULATION OF THE ACTIN CYTOSKELETON Hiroaki Yokomori, Kitasato Institute Medical Center, Saitama, Japan; Masaya Oda, Organized Center of Clinical Medicine, Tokyo, Japan; Hiromasa Ishii, Keio University School of Medicine, Tokyo, Japan

415om ~~~ ~~

# 48 UNEQUIVOCAL EVIDENCE FOR A ROLE OF NEUROSTEROIDS WITH POSITIVE ALLOSTERIC

THE PATHOGENESIS OF HEPATIC ENCEPHALOPATHY Samir Ahboucha, Nicolas Chatauret, Paul Desjardins, Gilles Pomier-Layrargues, Roger F Butterworth, CHUM-HBpital Saint- Luc, Montreal, PQ, Canada

MODULATORY PROPERTIES AT THE GABA-A RECEPTOR IN

Parallel Session 7: Hepatocellular Carcinoma: Pathogenesis

Sunday, October 26 4:45pm - 6:15pm Hynes Convention Center Room 309 Moderators: DAVID A. BRENNER and CHARLES E . ROGLER

445om

849 THE MOUSE FORKHEAD BOX M1B TRANSCRIPTION FACTOR IS REQUIRED FOR DEVELOPMENT OF HEPATOCELLULAR CARCINOMAS Robert H Costa, Vladimir V Kalinichenko, Xinhe Wang, Joseph Kuechle, Yoder Yoder, Brian Shin, University of Illinois at Chicago, College of Medicine, Chicago, IL

5:OOpm # 50 DIFFERENTIAL PROCARCINOGENIC POTENTIAL OF LYMPHOCYTE SUBSETS IN IMMUNE PATHOGENESIS OF HEPATOCELLULAR CARCINOMA Yasunari Nakamoto, Takashi Suda, Shuichi Kaneko, Kanazawa University, Kanazawa, Japan

5:lSpm # 51 NOVEL GROWTH SUPPRESSOR TARGETS OF THE KLF6 TUMOR SUPPRESSOR GENE IDENTIFIED BY STRINGENT MICROARRAY ANALYSIS Helen L Reeves, University of Newcastle, Newcastle-upon-Tyne, UK; Michael J P Arthur, University of Southampton, Southampton, UK; Goutham Narla, Amanda Katz, Eldad Hod, Jose Walewski, Frank Eng, Scott L Friedman, Mount Sinai School of Medicine, New York, NY

5:30pm # 52 ONCOGENIC ROLE AND SPECIFICITY OF FRIZZLED RECEPTOR EXPRESSION IN ANIMAL MODELS OF HEPATOCELLULAR CARCINOMA Marc Herrmann, Philippe Merle, Suzanne de la Monte, Liver Research Center, RI Hospital and Brown Medical School, Providence, RI; L Lefrancois, INSERM U271, Hotel Dieu, Lyon, France; Sophia Califano, Liver Research Center, RI Hospital and Brown Medical School, Providence, RI; Christian Trepo, INSERM U271, Hotel Dieu, Lyon, France; Shinji Tanaka, Kyushu University, Fukuoka, Japan; Jack Wands, Liver Research Center, RI Hospital and Brown Medical School, Providence, RI

AASLD PROGRAM HEPATOLOGY, October 2003 i 2 A

5:45pm G 53 THE BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE ACTIVITY REDUCES THE EMERGENCE OF HEPATOCELLULAR CARCINOMA WITHIN CIRRHOTIC RAT LIVER Olivier Rosmorduc, INSERM U402, Paris, France; Eduardo Schiffer, HBpital Cantonal de Geneve, Geneve, Switzerland; Veronique Barbu, INSERM U402, Paris, France; Dominique Wendum, Anatomie Pathologique, HBpital Saint-Antoine, Paris, France; Colette Rey, Helene Robin, INSERM U402, Paris, France; Franqois Clergie, HBpital Cantonal de Geneve, Geneve, Switzerland; Raoul Poupon, Chantal Housset, INSERM U402, Paris, Francc.

6:OOpm P 54 SUPPRESSION OF HEPATOCELLULAR CARCINOMA BY TRANSPLANTATION OF EX-VIVO IMMUNE-MODULATED NKT LYMPHOCYTES IS ASSOCIATED WITH STAT4 EXPRESSION AND A THl IMMUNE RESPONSE Maya Margalit, Oren Shibolet, Athalia Klein, Ruslana Alper, Hadassah Hebrew University Medical Center, Jerusalem, Israel; B a r b x a E Thcilenfeld, Enzo Biochem Inc., Farmingdale, NY; Dean L Engelhardt, Elazar Rabbani, Enzo Biochem Inc., Framingdalc, IVY; Yaron Ilan, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Parallel Session 8: Hepatitis C: Epidemiology and Natural History

Sundav. October 26

4 4 5 ~ m ~ ~

55 GENETIC POLYMORPHISMS IN PROMOTER REGION OF OSTEOPONTIN GENE AS A MARKER TO DETERMINE HEPATITIS ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C Atsushi Matsui, Satoshi Mochida, Masashi Naito, Mie Inao, Sumiko Nagoshi, Third Department of Internal Medicine, Saitama Medical School, Saitama, Japan; Michie Hashimoto, Shunji Mishiro, Toshiba General Hospital, Tokyo, Japan; Kenji Fujiwara, Third Department of Internal Medicine, Saitama Medical School, Saitama, Japan

5:OODm B 56 NATURAL HISTORY OF FIBROSIS IN CHRONIC HEPATITIS C John B Wong, Tufts-New England Medical Center, Boston, MA; Thierry Poynard, Groupe Hospitalier Pitie Salpetriere, Paris, France

5:15pm # 57 HCV EXPOSURE IN HUMANS: STIMULATION OF CELLULAR, BUT NOT HUMORAL IMMUNE RESPONSES IN THE ABSENCE OF DETECTABLE VIREMIA The0 Heller, Yuji Sobao, Eishiro Mizukoshi, Fareed Rahman, National Institutes of Health, Bethesda, MD; Arlene Sheets, Donna Gordon, Averell Sherker, Washington Hospital Center, Washington, DC; Ellen R Kessler, Kathleen S Bean, Lnova Fairfax Hospital, Falls Church, VA; Steven Herrine, Thomas Jefferson University, Philadelphia, PA; James Schmitt, MLou Stevens, Yoon Park, Harvey Alter, Jay H Hoofnagle, Jake Liang, Barbara Rehermann, National Institutes of Health, Bethesda, MD

5 : 3 0 ~ m ft 58 SEXUAL TRANSMISSION OF HEPATITIS C VIRUS IN

PARTNERS STUDY Norah A Terrault, University of California San Francisco, San Francisco, CA; Michael Busch, Edward Murphy, Blood Centers of the Pacific, San Francisco, CA; Maria Tong, Jenya Dvorkm, University of California San Francisco, San Francisco, CA; Miriam J Alter, Centers for Disease Control and Prevention, Altanta, GA

5:45pm # 59 INTRAFAMILIAL TRANSMISSION OF HEPATITIS C VIRUS IN PATIENTS WITH ACUTE HEPATITIS C CORRELATION WITH VIROLOGICAL AND IMMUNOLOGICAL PARAMETERS Sanaa M Kamal, Harvard Institutes of Medicine, Boston, MA; Nakano Tatsarouni, CDC, Atlanta, GA; Jens Rasenack, University of Freiburg, Freiburg, Germany; Qi He, Cami Graham, Harvard Institutes of Medicine, Boston, MA; Alaa Ismail, Ahmed A1 Tawil, Mahmoud Massoud, Ain Shams University Cairo, Egypt; Margaret J Koziel, Harvard Institutes of Medicine, Boston, MA

600pm # 60 HCV PRESENCE IN GENITAL SECRETIONS IN HIV/HCV COINFECTED WOMEN Jorge Rakela, Marek Radkowski, Tomasz Laskus, Jeffrey Wilkinson, Debra Adair, Mayo Clinic, Scottsdale, AZ; Andrea Kovacs, Marek Nowicki, University of Southern California, Los Angeles, CA

HETEROSEXUAL MONOGAMOUS COUPLES-THE HCV

Parallel Session 9: Hepatitis C Treatment: Translational Research

Sunday, October 26 4:45pm - 6:15pm Hynes Convention Center Ballroom A Moderators: CHARLES D. HOWELL and STANLEY M . LEMON

445pm # 61

UPA/SCID MICE WITH GENE THERAPY MECHANISMS Belinda Hsi, University of Alberta, Edmonton, AB, Canada; Eric Hsu, Amgen Institute, Toronto, ON, Canada; Dave Bigam, University of Alberta, Edmonton, AB, Canada; Chris Richardson, Amgen Institute, Toronto, ON, Canada; Lorne Tyrrell, Norman Kneteman, University of Alberta, Edmonton, AB, Canada

INDUCING APOPTOSIS IN HEPATITIS C INFECTED ALB-


5:OOpm # 62 THE USE OF NS5 PROTEIN-TRANSDUCED DENDRITIC CELLS AS A NOVEL APPROACH FOR VACCINATION AGAINST HEPATITIS C VIRUS Noriyoshi Kuzushita, Stephan Gehring, Stephan Gregory, Jack Wands, Liver Research Center, RI Hospital and Brown Medical School, Providence, RI

5:15pm # 63 PEGINTERFERON a-2A (40KD) ENHANCES HCV SPECIFIC T-CELL RESPONSES BY RESTORATION OF ALLOSTIMULA- TORY FUNCTION OF DENDRITIC CELLS IN CHRONIC HEPATITIS C Sanaa M Kamal, Qi He, Harvard Institutes of Medicine, Boston, MA; Jutta Fehr, University of Freiburg, Freiburg, Germany; Alaa M Ismail, Ain Shams University, Cairo, Egypt; Bemd Roessler, University of Freiburg, Freiburg, Germany; Mahmoud A Massoud, Ain Shams University, Cairo, Egypt; Jens Rasenack, University of Freiburg, Freiburg, Germany

5:30~m # 64 EFFECT OF EARLY ANTIVIRAL THERAPY ON THE CELLULAR IMMUNE RESPONSE IN ACUTE HEPATITIS C Fareed Rahman, The0 Heller, Yuji Sobao, Eishiro Mizukoshi, Harvey Alter, National Institutes of Health, Bethesda, MD; Steven Herrine, Thomas Jefferson University, Philadelphia, PA; Jay H Hoofnagle, Jake Liang, Barbara Rehermann, National Institutes of Health, Bethesda, MD

5:45pm # 65 INDUCTION OF HCV-SPECIFIC IMMUNE RESPONSES BY HEPATITIS C VIRUS-LIKE PARTICLES IN NON-HUMAN PRIMATES: IMPLICATIONS FOR PREVENTION AND THERAPY OF HEPATITIS C Sook-Hyang Jeong, Ming Qiao, Michelina Nascimbeni, Barbara Rehermann, National Institutes of Health, Bethesda, MD; Kris Murthy, Southwest Foundation for Biomedical Research, San Antonio, TX; T Jake Liang, National Institutes of Health, Bethesda, MD

6:OOrim # 66 HUMORAL AND CELLULAR IMMUNE RESPONSES TO SUB- EPIDERMAL El-BASED THERAPEUTIC VACCINATION IN HEALTHY VOLUNTEERS AND PATIENTS WITH PAST OR ONGOING HCV INFECTIONS Geert Leroux-Roels, ArsGne-H&lhe Batens, Isabelle Desombere, Ghent University, Ghent, Belgium; Bart Van Den Steen, Christine Vander Stichele, Erik D’Hondt, Geert Maertens, Frank Hulstaert, Innogenetics NV, Ghent, Belgium

Parallel Session 10: Hot Clinical Topics in Hepatology

Sunday, October 26 4:45pm - 6:15pm Veterans Memorial Auditorium Moderators: KENNETH D. FLORA and TAREK HASSANElN

445pm # 67 OCCULT HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PERSISTENTLY ABNORMAL LIVER FUNCTION TESTS OF UNKNOWN ETIOLOGY Inmaculada Castillo, Margarita Pardo, Javier Bartolome, Nuria Ortiz-Movilla, Elena Rodriguez-Inigo, Susana de Lucas, Fundacion Estudio Hepatitis Virales, Madrid, Spain; Clara Salas, Clinica Puerta de Hierro, Madrid, Spain; Jose A Jimenez- Heffernan, Hospital La Zarzuela, Madrid, Spain; Arturo Perez- Mota, Javier Graus, Hospital Virgen de la Torre, Madrid, Spain; Juan Manuel Lopez-Alcorocho, Vicente Carreno, Fundacion Estudio Hepatitis Virales, Madrid, Spain

5:OOpm # 68 INDEPENDENT PROSPECTIVE MULTICENTER VALIDATION

THE PREDICTION OF LIVER FIBROSIS AND ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C P Halfon, Alphabio Laboratory, Marseille, France; M Bourliere, HBpital Saint Joseph, Marseille, France; R Deydier, Alphabio Laboratory, Marseille, France; I Portal, HBpital La Conception, Marseille, France; C Renou, J J Bertrand, HBpital d’Hy&es, HyPres, France; A Tran, A Rosenthal, HBpital de l’Archet, Nice, France; M Rotily ClinSearch, Paris, France; A Sattonet, D Ouzan, Institut Arnault Tzanck, Saint Laurent du Var, France

5:lSpm

OF BIOCHEMICAL MARKERS (FIBROTEST-ACTITEST) FOR

# 69 RAPID DIAGNOSIS OF SPONTANEOUS BACTERIAL PERITONITIS WITH LEUKOCYTE ESTERASE REAGENT

CENTERS Thierry Sapey, Centre Hospitalier General, Chateauroux, France; Edward Mena, University of Southern California, Downey, CA; Denis Kabissa, Eric Fort, Christine Laurin, Samda TchangaY-Kao, Centre Hospitalier General, Chateauroux, France; Michel-Henry Mendler, University of Southern California, Downey, CA

5:30pm # 70

HEPATOTOXICITY IN THE ADULT AIDS CLINICAL TRIALS GROUP (AACTG) Julie C Servoss, Massachusetts General Hospital, Boston, MA; Douglas Kitch, Janet Andersen, Harvard School of Public Health, Boston, MA; Gregory K Robbins, Massachusetts General Hospital, Boston, MA; Ronald B Reisler, University of Maryland School of Medicine, Baltimore, MN; Raymond T Chung, Massachusetts General Hospital, Boston, MA

STRIPS (NEPHUR-TEST@ AND MULTISTIXSG@) IN TWO

PREDICTORS OF ANTIRETROVIRAL-RELATED


5:45vm B 71

COMBINATION WITH RIBAVIRIN IN AFRICAN AMERICAN AND CAUCASIAN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1: RESULTS OF A MULTICENTER STUDY Lennox J Jeffers, Miami VA Medical Center, Miami, FL; William Cassidy, Louisiana State University Health Sciences Center, Baton Rouge, LA; Charles Howell, University of Maryland School of Medicine, Baltimore, MD; K Rajender Reddy, University of Pennsylvania, Philadelphia, PA; Susan Sheridan, Irwin Ho, Sarkis Khouri, George Harb, Roche Laboratories, Inc., Nutley, NJ

600pm

PEGINTERFERON ALFA-2A (40KD) (PEGASYSB) IN

# 72 A NEW DEFINITION IS NEEDED FOR THE NORMAL UPPER LIMIT OF SERUM ALANINE AMINOTRANSFERASE (ALT) Revital Kariv, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Moshe Leshno, Tel Aviv University, Tel Aviv, Israel; Ran Oren, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Anat Beth-Or, Maccabi Health Care Services, Tel Aviv, Israel; Shira Zelber-Sagi, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Ehud Kokia, Dina Noff, Bracha Sheinberg, Maccabi Health Care Services, Tel Aviv, Israel; Zamir Halpern, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Parallel Session 11: NASH: Experimental

Sunday, October 26 4:45pm - 6:15pm H!lnes Coni~errtion Center Room 304, 306 Moderators: ANNA MAE DIEHL and NATHAN M. BASS

445pm 5 73 LEPTIN RECEPTOR-DEFICIENT ZUCKER (FA/FA) RAT RETARDS THE DEVELOPMENT OF PIG SERUM-INDUCED LIVER FIBOSIS WITH KUPFFER CELL DYSFUNCTION Isao Sakaida, Koichi Uchida, Shuji Terai, Kiwamu Okita, Yamaguchi University, Ube-Yamaguchi, Japan

5:OOpm P 74 AMELIORATION OF NON-ALCOHOLIC STEATOHEPATITIS AND GLUCOSE INTOLERANCE IN OB/OB MICE VIA ORAL IMMUNE REGULATION TOWARDS LIVER EXTRACTED PROTEINS IS ASSOCIATED WITH ELEVATED INTRAHEPATIC NKT LYMPHOCYTES AND A TH2 IMMUNE SHIFT Eran Elinav, Orit Pappo, Miriam Sclair-Levy, Moshe Gomori, Oren Shibolet, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Barbara Thalenfeld, Dean Engelhardt, Elazar Rabbani, Enzo Biochem Inc., Farmingdale, NY; Yaron Ilan, Hadassah Hebrew University Medical Center, Jerusalem, Israel

5:lSprn # 75 HEPATIC STEATOSIS ENHANCES FAS EXPRESSION AND LIVER INJURY IN MICE A E Feldstein, A E Canbay, M E Guicciardi, H Higuchi, G J Gores, Mayo Clinic, Rochester, MN

5:30pm 8 76

OVEREXPRESSION Jorn M Schattenberg, Yongjun Wang, Raina M Rigoli, Mark J Czaja, Albert Einstein College of Medicine, Bronx, NY

5:45pm # 77 NOREPINEPHRINE MEDIATES EFFECTS OF LEPTIN DEFICIENCY ON HEPATIC INNATE IMMUNE SYSTEM IN A MOUSE MODEL OF NONALCOHOLIC STEATOHEPATITIS Zhiping Li, Jude A Oben, Sluqi Yang, Huizhi Lin, Anna Mae Diehl, Johns Hopkins University, Baltimore, MD

6:OOpm # 78 THE RELATIONSHIP BETWEEN METABOLIC FUNCTIONS AND LIVER HISTOLOGY IN NONALCOHOLIC STEATOHEPATITIS BEFORE AND AFTER TREATMENT Pouneh S Mofrad, Carol Sargeant, Melissa J Contos, John Clore, Velimir A Luketic, Mitchell A Shiffman, Richard K Sterling, Richard T Stravitz, A m J Sanyal, Virginia Commonwealth University Richmond, VA

HEPATIC INSULIN SIGNALING IS INHIBITED BY CYPLE1-

Parallel Session 12: Organic Anion and Bile Acid Transport:

Lipid Metabolism

Sunday, October 26

4:45pm - 6:15pm Hynes Convention Center Roorri 322 Moderntors: MOHAMMED S . ANWER nizd DAVID E. COHEN

4 4 5 p m # 79 CORTACTIN AND THE CORTACTIN BINDING PROTEIN, HAX-1, REGULATE LEVELS OF THE BILE SALT EXPORT PUMP (BSEP) IN THE APICAL MEMBRANE OF MDCK CELLS Daniel F Ortiz, Amy Swift, James Moseley Shaohua Li, Irwin M Arias, Tufts University School of Medicine, Boston, MA

5:OOpm # 80 DEPHOSPHORYLATION OF S226 IN THE THIRD CYTOPLASMIC LOOP OF RAT NTCP IS INVOLVED IN NTCP TRANSLOCATION TO THE PLASMA MEMBRANE Mohammed S Anwer, Henry Gillin Jr, Tufts University School of Veterinary Medicine, North Grafton, MA; Natarajan Balasubramaniyan, Federick Suchy, Meena Ananthanarayanaii, Mount Sinai Medical Center, New York, NY


5 1 5pm # 81 MRP4 (ABCC4) IS LOCALIZED TO THE BASOLATERAL HEPATOCYTE MEMBRANE AND FUNCTIONS AS A COTRANSPORTER OF REDUCED GLUTATHIONE WITH BILE SALTS Maria Rius, Anne T Nies, Johanna Hummel-Eisenbeiss, Gabriele Jedlitschky, Dietrich Keppler, Deutsches Krebsforschungszentrum, Heidelberg, Germany

5:30pm # 82 THE CHOLESTEROL-7a HYDROXYLASE PROMOTER FACTOR (CPF) UP-REGULATES THE HUMAN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3 (MRP3) AND IS INDUCED BY BILE SALTS IN HEPG2 CELLS Wen-Sheng Chen, Lee A Denson, Alan Bohan, Shi-Ying Cai, Lin Wang, Carol J Soroka, James L Boyer, Yale University School of Medicine, New Haven, CT

5:45pm # 83 THE BLOCKADE OF ESTROGEN ACTION BY FULVESTRANT (ICI 182,780) PREVENTS CHOLESTEROL GALLSTONE FORMATION IN THE MOUSE Helen H Wang, Nezam H Afdhal, David Q Wang, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

6:OOom # 84 DIRECT INTERACTION OF RAT ILEAL NA+DEPENDENT BILE ACID TRANSPORTER WITH A 16 KDA SUBUNIT C OF VACUOLAR H+ATPASE Natarajan Balasubramaniyan, Mount Sinai School of Medicine, New York, NY; Chuan-Ju Liu, New York University, New York, NY; Mohammad Shahid, Frederick J Suchy An-Qiang Sun, Mount Sinai School of Medicine, New York, NY

Parallel Session 13: Complications of Cirrhosis: Pathobiology

Sundav. October 26 4:4Spm - 6:15pm Hyrzes Corzaention Center Room 302 Moderators: CRAIG McCLAIN and ANDRES T. BLEl

445om it 85 PORTAL RESPONSE TO ARTERIAL ADMINISTRATION OF BRADYKININ INTO THE LIVER Luciana Gioli-Pereira, Universidade Federal de S l o Paulo, S l o Paulo, Brazil; Ecio A Nascimento, Adelar Bracht, Universidade Estadual de Maringa, Maringa, Brazil; Edson L Santos, JoZo B Pesquero, Maria A Juliano, Durval R Borges, Maria Kouyoumdjian, Universidade Federal de Slo Paulo, SSo Paulo, Brazil

5:OOpm # 86 ROLE OF TUMOR NECROSIS FACTOR AND NITRIC OXIDE IN PORTAL HYPERTENSION Nicholas J Skill, Nicholas G Theodorakis, Yining N Wang, Matthew M Metz, Eileen M Redmond, James V Sitzmann, University of Rochester Medical Center, Rochester, NY

5:l 5om 1: 87 NEW STEROL REGULATORY ELEMENT DEPENDENT

1 GENE TRANSCRIPTION BY LIPOPROTEIN DEPLETION:

CIRRHOSIS AND PORTAL HYPERTENSION Sheng Cao, Dongzu Jin, Vijay Shah, Mayo Clinic, Rochester, MN

5:30prn # 88 ROLE OF ENDOCANNABINOID SYSTEM IN THE GENESIS OF CIRRHOTIC CARDIOMYOPATHY Seyed A Gaskari, Yang Li, Hongqun Liu, Samuel S Lee, University of Calgary, Calgary, AB, Canada

5:45pm

PATHWAY FOR ACTIVATION OF ENDOTHELIAL CAVEOLIN-

IMPLICATIONS FOR CAVEOLIN-1 UPREGULATION IN

# 89 KUPFFER CELLS ARE A MAJOR SOURCE OF INCREASED PLATELET ACTIVATING FACTOR IN THE CCLCINDUCED CIRRHOTIC RAT LIVER Yongping Yang, Stephan A K Harvey, Chandrashekhar R Gandhi, University of Pittsburgh, Pittsburgh, PA

600pm # 90 ENDOTHELIN-1 IN EXPERIMENTAL HEPATOPULMONARY SYNDROME: EVALUATION IN PREHEPATIC PORTAL HYPERTENSION, BILIARY AND NONBILIARY CIRRHOSIS Bao Luo, Liping Tang, Junlan Zhang, Yiqun Ling, Michael B Fallon, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL

Parallel Session 14: Pediatric Hepatology

Sunday, October 26 4:4Spm - 6:lSpm Hynes Convention Center Room 31 0 Moderntors: IOHN C. BUCUVALAS niid BENIAMIN L. SHNEIDER

445pm # 91 CLINICAL AND HISTOLOGICAL CHARACTERISTICS OF

Ruben E Quiros-Tejeira, Sandy Cope-Yokoyama, Kelly D Brown, Seiji Kitagawa, William J Klish, Milton Finegold, Baylor College of MedicineTexas Children’s Hospital, Houston, TX

CHILDREN WITH OBESITY-ASSOCIATED STEATOHEPATITIS


5:oosm 3 92

8 YEARS Patrick J McKiernan, Birmingham Children’s Hospital, Birmingham, UK; Alastair J Baker, Georgina Mieli-Vergani, King’s College Hospital, London, UK; Deirdre A Kelly, Birmingham Children’s Hospital, Birmingham, UK

5:lSsm

THE BPSU STUDY OF BILIARY ATRESIA-OUTCOME AFTER

t 93 LECTIN-REACTIVE ALPHA-FETOPROTEIN IN PATIENTS WITH TYROSINEMIA TYPE I AND HEPATOCELLULAR CARCINOMA Ulrich Baumann, Birmingham Children’s Hospital, Birmingham, UK; Valeska Duhme, Marcus K H Auth, University of Essen, Essen, Germany; Patrick J McKiernan, Birmingham Children’s Hospital, Birmingham, UK; Elisabeth Holme, Sahlgrenska University Hospital, Gothenburg, Sweden

5:30~m

3 94 THE NATURAL HISTORY OF TRANSFSUION ACQUIRED HEPATITIS C (HCV) IN CHILDHOOD CANCER SURVIVORS: AN UPDATE OF THE ST. JUDE CHILDREN’S RESEARCH HOSPITAL (S JCRH)HCV SEROPOSITIVE (+)COHORT Sharon M Castellino, St. Jude Children’s Research Hospital, Memphis, TN; Caroline A Rely University of Tennessee, Memphis, TN; Shelly Lensing, St. Jude Children’s Research Hospital, Memphis, TN; Mark Levstik, Rene Davila, Jackie Fleckenstein, University of Tennessee, Memphis, TN; Shari Taylor, GI Pathology Partners, Memphis, TN; Melissa Hudson, St. Jude Children’s Research Hospital, Memphis, TN

5:45pm 2 95 HEPATIC PATHOLOGY OF NEONATAL INTRAHEPATIC CHOLESTASIS CAUSED BY CITRIN DEFICIENCY Masayoshi Kage, Kojiro Masamichi, Akihiko Kimura, Kurume University, Kurume, Japan; Keiko Kobayashi, Takeyori Saheki, Kagoshima University, Kagoshima, Japan

6:OOpm 8 96 DE NOVO AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION IN CHILDREN; A SINGLE CENTRE EXPERIENCE Nedim Hadzic, Ramesh Srinivasan, Mohamed Rela, Nigel Heaton, Diego Vergani, Ciorgina Mieli-Vergani, Institute of Liver Studies, Kng‘s College Hospital, London, U K

Parallel Session 15: Primary Biliary Cirrhosis/

Primary Sclerosing Cholangitis

Sunday, October 26 445pm - 6:15pm Hyws Conventiorz Celllei. Room 312 Moderators: KEITH D. LlNDOR and ANDREW C. MASON

4:45pm 2 97 INDUCTION OF PRIMARY BILIARY CIRRHOSIS IN GUINEA PIGS FOLLOWING IMMUNIZATION WITH A CHEMICAL XENOBIOTIC Patrick S C Leung, Shuji Matsumura, Ogyi Park, Judy Van de Water, Chao Quan, Mark J Kurth, Michael H Nantz, University of California Davis, Davis, CA; Aftab A Ansari, Emory University School of Medicine, Atlanta, GA; Ross L Coppel, Monash University, Melbourne, Australia; M Eric Gershwin, University of California Davis, Davis, CA

5:OOpm $I 98 IS PRIMARY BILIARY CIRRHOSIS CAUSED BY MOLECULAR MIMICRY WITH NOVOSPHINGOBIUM AROMATICIVORANS, A UBIQUITOUS XENOBIOTIC METABOLIZING BACTERIUM? Carlo Selmi, University of California Davis, Davis, CA; David L Balkwill, Florida State University, Tallahassee, FL; Pietro Invernizzi, University of Milan, Milan, Italy; Aftab A Ansari, Emory University School of Medicine, Atlanta, GA; Ross L Coppel, Monash University Melbourne, Australia; Mauro Podda, University of Milan, Milan, Italy; Patrick S C Leung, Thomas P Kenny Judy Van de Water, Mark J Kurth, Michael H Nantz, M Eric Gershwin, University of California Davis, Davis, CA

5:lSpm # 99 ANTI-MITOCHONDRIAL IGA ANTIBODY INDUCES APOPTOSIS TO MDCK CELLS BEARING HUMAN POLYMERIC IMMUNOGLOBULIN RECEPTOR: EVIDENCE FOR AMA INDUCED IMMUNOPATHOLOGY Shuji Matsumura, Patrick S C Leung, Judy Van de Water, University of California Davis, Davis, CA; Kazuhide Yamamoto, Yasushi Shiratori, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; Gregory J Gores, Mayo Clinic and Foundation, Rochester, MN; Aftab A Ansari, Emory University School of Medicine, Atlanta, GA; Ross L Coppel, Monash University, Clayton, Australia; M Eric Gershwin, University o f California Davis, Davis, CA


5:30pm # 100 A PROSPECTIVE, RANDOMIZED CONTROLLED PILOT STUDY OF URSODEOXYCHOLIC ACID (UDCA) COMBINED WITH MYCOPHENOLATE MOFETIL (MMF) IN THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS Richard K Sterling, Virginia Commonwealth University Health System, Richmond, VA; Jennifer J Salvatori, Velimir A Luketic, Arun J Sanyal, R Todd Stravitz, Ann S Fulcher, Melissa J Contos, A Scott Mills, Mitchell L Shiffman, Virginia Commonwealth University, Richmond, VA

5:45pm

6:OOpm # 102 USE OF A CONJUGATED PEPTIDE MICROARRAY FOR ULTRA FINE MAPPING OF ANTIMITOCHONDRIAL ANTIBODIES Katsushi Ammo, Patrick S C Leung, Qingchai Xu, Jan Marik, Chao Quan, Mark J Kurth, Michael H Nantz, Kit S Lam, University of California Davis, Davis, CA; Mikio Zeniya, Jikei University School of Medicine, Tokyo, Japan; Aftab A Ansari, Emory University School of Medicine, Atlanta, GA; Ross L Coppel, Monash University, Melbourne, Australia; M Eric Gershwin, University of California Davis, Davis, CA

# 101 CCL25 MEDIATES RECRUITMENT OF CCR9+ GUT HOMING LYMPHOCYTES TO THE LIVER IN PRIMARY SCLEROSING CHOLANGITIS Bertus Eksteen, Allister J Grant, Alice Miles, Patricia F Lalor, Stefan G Hubscher, University of Birmingham, Birmingham, UK; Michael Briskin, Millenium Pharmaceuticals Inc., Cambridge, MA; David H Adams, University of Birmingham, Birmingham, UK

%A AASLD PROGRAM HEPATOLOGY, October 2003

Monday, October 27 7:OO - 7:50 ain Plensc. r+er to your EMW ticket for meeting rooni location.

Basic Research Workshops

401.

402.

403.

404.

405.

406.

407.

Nuclear Receptors and Regulation of Bile and Homeostasis Snul ] Karperr, MD, PhD arid Iohii Chiang, PhD

Pathophysiology of Portal Hypertension Robei to ] Grosznianii, M D and Vqay Shah, M D

Cholangiocyte Cell Biology Genc D Lesage, M D and Giaiifranco Alpini, PhD

Pathogenesis of NASH Annn Mae Diehl, iLlD arid Geoffrey C Fnriell, M D

Microarray Analysis in Liver Disease: Pitfalls and Promise C h n i l e ~ E Rogler, PhD arid Iorge A Bezerra, M D

Hepatic Fibrosis Scott L Fi iedmnn, M D a n d David A Breniier, M D

Apoptosis and Hepatocellular Necrosis Giegoi 11 I Goreq, A4D mid Mark Czala, M D

Clinical Management Workshovs

408.

409.

410.

411.

412.

413.

414.

415.

Diagnosis and Management of Hemochromatosis Kris V Kowdley, M D and Bruce R. Bacon, M D

Therapy of PBC and PSC Keifh D. Lindor, M D and E. Imny Heafhcote, MD Therapy of Hepatitis B Anna S.F. Lok, M D and Eugene R. Schifi MD

Ascites and Spontaneous Bacterial Peritonitis Bruce A. Runyon, M D arid Guadalupe Garcia-Two, MD

Neonatal Cholestasis William F. Balistreri, MD and Giorgina Midi-Vergani, MD, PhD

Hepatitis C in the HIV-Infected Patient David L. Thomas, M D and Douglas T. Dieterich, M D

Treatment of Alcoholic Hepatitis Robert L. Carifhers, IT., MD and Jacquelyrr 1. Maher, M D

Screening for Hepatocellular Carcinoma Eniniet B. Keeffe, M D and Brim J McMahon, M D

Please see pages 40 - 41 for all of the Early Morning Workshop faculty disclosures.

Monday, October 27 8:OOani - 10:OOam Vrternirs Meiiiorral Audrtoriuiii Moilclators. FREDERlCK J. SUCHY a n d ARUN ]. SANYAL

8:OOam

,7 103 MULTICENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL OF NON-SELECTIVE BETA-BLOCKERS IN THE PREVENTION OF THE COMPLICATIONS OF PORTAL HYPERTENSION: FINAL RESULTS AND IDENTIFICATION OF A PREDICTIVE FACTOR I< 1 Gros~nimn, Yale University, VA Medical Center, West Haven, C-r; G Garcia-Tsao, R Makuch, Yale University, New Haven, CT; J Bosch, A Escorsell, J C Garcia-Pagan, University of Barcelona, Barcelona, Spain; N Grace, D S Matloff, Tufts University, Boston, M A ; A Burroughs, D Patch, Royal Free Hospital, London, UK

8:lSam 0 104 TIME COURSE OF FIBROSIS PROGRESSION IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE Leon A Adaim, Jil l Keach, Keith D Lindor, Paul Angulo, Mayo Clinic, Rochwter, MN

830am # 105 CONDITIONAL EXPRESSION OF HEPATITIS C VIRUS GENOME INDUCES INFLAMMATION, STEATOSIS AND HEPATOCELLULAR INJURY IN A TRANSGENIC MOUSE MODEL Toshi Gundji, Elan Manickan, Zongyi Hu, Kiyoshi Mochizuki, Lijun Mi, T Jake Liang, National Institutes of Health, Bethesda, MD

845am # 106 INTERNATIONAL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C AND PERSISTENTLY

(40KD) (PEGASYSB) AND RIBAVIRIN (COPEGUSB) Stefan Zeuzem, Saarland University Hospital, Hornburg/Saar, Germany; Moises Diago, Hospital General de Valencia, Valencia, Spain; Edward Cane, Middlemore Hospital, AucWand, New Zealand; Rajender Reddy, University of Pennsylvania, Philadelphia, PA; Paul Pockros, The Scripps Clinic, La Jolla, CA; Patrizia Farci, Uiuversita di Cagliari, Cagliari, Italy; Norman Gitlin, Emory University, Atlanta, GA; Franqois Lamour, Pilar Lardelli, Roche Diagnostics, Basel, Switzerland; Mitchell Sluffman, VCU Health System, Richmond, VA

NORMAL ALT LEVELS WITH PEGINTERFERON ALFA-PA


900am # 107 CHOLANGIOCYTES CONTAIN PRIMARY CILIA THAT FUNCTION AS SENSORY ORGANELLES: POTENTIAL ROLE IN DUCTAL BILE FORMATION Anatoliy I Masyuk, Tatyana V Masyuk, Patrick L Splinter, Bing Q Huang, Nicholas F LaRusso, Mayo Medical School, Clinic and Foundation, Rochester, MN

915am # 108

SUPPRESSION OF NTCP GENE EXPRESSION Romi Ghose, Duo Li, Tracy L Zimmerman, Li Wang, David Moore, Saul J Karpen, Baylor College of Medicine, Houston, TX

ROLES OF JNK AND SHP IN ENDOTOXIN-MEDIATED

930am Presentation of the Distinguished Achievement Award Presented to: Nicholas F. LaRusso, MD Presented by: Gregory J. Gores, MD

943am Presentation of the Distinguished Service Award Presented to: Paul D. Berk, MD Presented by: Allan W. Wolkoff, MD

956am Presentation of the Student Research Award Presented to: Clayton D. Knox Presented by: Saul J. Karpen, MD, PhD

Poster Session 3 Exhibit Hall

Monday, October 27 8:oOam - 5:OOpm Hynes Convention Center Exhibit Hall C See page 11 7 fw Poster Presentations

Monday, October 27 9:30am - 300pm Hynes Convention Center, Exhibit D

Monday, October 27 1O:OO - 10:30 am Nuclear Receptors in Regulation of Drug Metabolism Speaker: David D. Moore, P h D Moderato?: Frederick 1. Suchy, M D

Faculty Disclosure

All faculty participating in continuing medical education

for the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

David Moore provided the following disclosure: No relationship to disclose Content of presentation does not include discussion of off-label/

investigative use of medicinds), inedicals devices or procedurek) , * . - -

programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify

The Hyman Zimmerman State-of-the-Art Lecture is supported by an educational grantfrom Eli Lilly and Company pledged in support of AASLD’s 50th Anniuersary Campaign.

Break

1030 - 1l:OOam

hOA AASLD PROGRAM HEPATOLOGY, October 2003

~ ~~

Mondav. October 27 1l:OOam - 12:30pm V L ~ E Y ~ S Muinorid Atidi toiiirni Mod~rntors: BRUCE R. BACON atid TERESA L. WRlGHT

1 1 :OOam

r 109 SIGNIFICANT DISPARITY IN MELD SCORES OF LIVER TRANSPLANT RECIPIENTS IN SMALL VS. LARGE ORGAN PROCUREMENT ORGANIZATIONS: IMPACT ON ORGAN ALLOCATION Michael Osgood, James F Trotter, University of Colorado, Denver, CO

11:15am

$110 THE HEPATITIS C VIRUS P7 PROTEIN, A NEW TARGET FOR DRUG DEVELOPMENT, IS CRITICAL FOR INFECTIVITY AND

FUNCTION Akito Sakai, National Institutes of Health, Bethesda, MD; Marisa St. Claire, Bioqual INC, Rockville, MD; Suzanne U Emerson, Robert H Purcell, Jens Bukh, National Institutes of Health, Bethesda, MD

1 1 :30am # 111 HCV-SPECIFIC CELLULAR IMMUNE RESPONSES IN SUBJECTS WHO ARE ANTIHCV-NEGATIVE, HCV RNA-

CONTAINS SEQUENCES WITH GENOTYPE-SPECIFIC

NEGATIVE DESPITE LONGTERM (> 15 YEARS) INJECTION DRUG USE Eishiro Mizukoshi, Christoph Eisenbach, National Institutes of Health, Bethesda, MD; Brian Edlin, University of California and Center for the Study of Hepatitis C, Weill Medical College of Cornell University, San Francisco, CA and New York, NY; Christina Weiler, National Institutes of Health, Bethesda, MD; Mary Carrington, SAIC-Frederick Inc., Frederick, MD; Thomas O'Brien, Barbara Rehermann, National Institutes of Health, Bethrsda, MD

# 112 THE PRIMARY BILIARY CIRRHOSIS (PBC) URSODIOL (UDCA) PLUS METHOTREXATE (MTX) OR ITS PLACEBO

Burton Combes, University of Texas Southwestern Medical Center, Dallas, TX; Scott S Emerson, University of Washington School of Public Health and Community Medicine, Seattle, WA; Nancy L Flye, University of Washington Medical Center, Seattle, WA

1200pm

STUDY (PUMPS)-A MULTICENTER RANDOMIZED TRIAL

fi 113 MICE WITH HEPATOCYTE-SPECIFIC DISRUPTION OF TRANSFORMING GROWTH FACTOR BETA (TGF-P) SIGNALING HAVE ENHANCED MITOGENIC RESPONSE DURING LIVER REGENERATION Eric R Lemmer, Elizabeth A Comer, Shoshiro Oe, Valentina M Factor, National Cancer Institute, Bethesda, MD; Per Levken, Lund University Hospital, Lund, Sweden; Tyjen L Tsai, National Cancer Institute, Bethesda, MD; Jonas Larsson, Stefan Karlsson, Lund University Hospital, Lund, Sweden; Snorri S Thorgeirsson, National Cancer Institute, Bethesda, MD

1215pm

# 114 CATHEPSIN B ACTIVATES CASPASE-2 T O PROMOTE HEPATOCYTE APOPTOSIS UPON TNF-ALPHA TREATMENT M E Guicciardi, S F Bronk, G J Gores, Mayo Clinic, Rochester, MN

Parallel Session 16: Acute Liver Failure

Monday, October 27 3 OOpm - 4 3Opm Hync.5 Convention Ceriter Rooni 302 Modi7ri1fof ROBERT 1 kONTANA a n d HUMBERTO E SORlANO

3:OOpm # 115

PROSTAGLANDINS AND VEGF RESPONSE IN THE REGENERATING LIVER Naiara Beram, Pilar Alzuguren, Jesus Prieto, Matdde Bustos, University of Navarra, Spain, Spain

CONTRIBUTION OF CARDIOTROPHIN-1 IN THE

3:15pm It 116 SERUM PHOSPHATE AS A PREDICTOR OF CLINICAL

FAILURE Timothy J Davem 11, University of California San Francisco, San Francisco, CA; Robert S Brown Jr, Columbia Presbyterian Medical Center, New York, NY; A 0 Shakil, University of Pittsburgh Medical Center, Pittsburgh, PA; kchard T Stravitz, Medical College Virginia, kchmond, VA; Julie Polson, Ezmina Lalani, William M Lee, University of Texas Southwestern Medical Center, Dallas, TX

3:30pm # 117

ACUTE LIVER FAILURE Moiitserrat Mari, Albert Morales, Carmen Garcia-Ruiz, Jose Carlos Fernfindez-Checa, Hospital Clinic, IDIBAPS, CSIC, Barcelona, Spain

OUTCOME IN ACETAMINOPHEN-INDUCED ACUTE LIVER

S-ADENOSYLMETHIONINE PROTECTS MICE AGAINST

HEPATOLOGY, Vol. 38, No. 4, Suppl. 1, 2003 AASLD PROGRAM 61 A

3:45pm # 118

FROM CD95 AND TNF MEDIATED APOPTOTIC LIVER DAMAGE Gisa Tiegs, Markus Biburger, Renate Bang, University of Erlangen-Nuremberg, Erlangen, Germany

400pm # 119

LIVER FAILURE WITH PORTAL VEIN ARTERIALIZATION IN THE RAT Paolo Caraceni, Bruno Nardo, Lorenza Puviani, Marco Domenicali, h a m a r i a Pertosa, Graziella Angiolini, Milena Pariali, Pasquale Chieco, Antonino Cavallari, Mauro Bemardi, University of Bologna, Bologna, Italy

4 15pm # 120 NEUROLOGICAL CHARACTERIZATION OF A NOVEL MOUSE MODEL OF ACUTE LIVER FAILURE Mireille Belanger, Paul Desjardins, Roger F Butterworth, CHUM- HGpital Saint-Luc, Montreal, PQ, Canada

NEUROKININ-1 RECEPTOR ANTAGONISTS PROTECT MICE

SUCCESSFUL TREATMENT OF CCL4-INDUCED ACUTE

Parallel Session 17: Cell Biology and Signal Transduction

Monday, Qctober 27 3:OOpm - 4:30pm Hynes Convention Center Room 310 Moderators: LOPA MlSHRA and MARK A . MCNlVEN

3 : 0 0 ~ m ~ ~~

# 121 ELF IS A KEY ADAPTOR FOR TGF-BETA SIGNALING, LIVER DEVELOPMENT AND HEPATOCELLULAR CANCER Yi Tang, Varalakshmi Katuri, Allan Dillner, Stuart Danovitch, Bibhuti Mishra, Lopa Mishra, Laboratory of GI Developmental Biology, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, DVAMC & Department of Medicine, Georgetown University, Washington, DC

3: 15Dm P 122 SECRETORY VESICLE FORMATION FROM THE TRANS- GOLGI NETWORK IN HEPATOCYTES IS REGULATED BY

Hong Cao, Shaun Weller, James Orth, Jing Chen, Bing Huang, Mayo Clinic, Rochester, MN; Ji-Long Chen, Mark A Stamnes, University of Iowa, Iowa City, IA; Mark A McNiven, Mayo Clinic, Rochester, MN

3:30pm # 123

(JNK) SIGNALING ASSOCIATED WITH LIVER REGENERATION IS MEDIATED VIA THE ACTIVATION OF P2 PURINERGIC RECEPTORS Sundararajah Thevananther, Hongdan Sun, Samir S Awad, Samuel Wyllie, Saul J Karpen, Baylor College of Medicine, Houston, TX

THE F-ACTIN, DYNAMIN-BINDING PROTEIN CORTACTIN

THE RAPID INDUCTION OF C-JUN N-TERMINAL KINASE

3 : 4 5 ~ m ~~~ ~

# 124

MATRIX (ECM) COMPONENT INTERACTIONS REGULATE HEPATOCYTE ENGRAFTMENT IN THE LIVER Vinay Kumaran, Brigid Joseph, Daniel Benten, Sanjeev Gupta, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY

400pm # 125 MITOCHONDRIAL CALCIUM UPTAKE IN HEPATOCYTES IS REGULATED BY MITOCHONDRIAL PHOSPHOLIPASE C Clayton D b o x , Andrey E Belous, Janene M Pierce, Aya Wakata, Ian B Nicoud, Christopher D Anderson, C W Pinson, Ravi S Chari, Vanderbilt University Medical Center, Nashville, TN

415pm

HEPATIC INTEGRIN-DEPENDENT EXTRACELLULAR

# 126 THE STAT SIGNALLING IN HEPATOCYTES IS RESPONSIBLE FOR IL6/GP130 DEPENDENT PROTECTION DURING

Christian Klein Jr, Torsten Wuestefeld, Medical School of Hannover, Hannover, Germany; Mathias Ernst, Royal Melburne Hospital, Melbume, Australia; Frank Tacke, Medical School of Hannover, Hannover, Germany; Peter C Heinrich, Institute for Biochemestrie, Aachen, Germany; Michael P Manns, Christian Trautwein, Medical School of Hannover, Hannover, Germany

CONCANAVALIN A-INDUCED LIVER FAILURE

Parallel Session 18: Gastrointestinal Bleeding from

Portal Hypertension

Monday, October 27 3:OOpm - 4:30pm Hynes Convention Center Room 304, 306 Moderators: SHlV KUMAR SARlN and MICHAEL B. FALLON

3:OO~rn # 127

OF ESOPHAGEAL VARICES IN PATIENTS WITH CIRRHOSIS

CLINICAL TRIAL Carlo Merkel, University of Padua, Padua, Italy; Renato Marin, City Hospital of Dolo, Dolo, Italy; Paolo Angeli, University of Padua, Padua, Italy; Pierluigi Zanella, City Hospital of Thiene, Thiene, Italy; Martina Felder, City Hospital of Bolzano, Bolzano, Italy; Elisabetta Bernardinello, University of Padua, Padua, Italy; Giorgio Cavallarin, City Hospital of Chioggia, Chioggia, Italy; Massimo Bolognesi, University of Padua, Padua, Italy; Carlo Donada, City Hospital of Pordenone, Pordenone, Italy; Pierluigi Torboli, City Hospital of Trento, Trento, Italy; Angelo Gatta, University of Padua, Padua, Italy

BETA-BLOCKERS IN THE PREVENTION OF AGGRAVATION

AND SMALL VARICES: A PLACEBO-CONTROLLED

AASLD PROGRAM HEP.4TOLOGY, October 2003 62A

3:lSprn

$ 128 ENDOSCOPIC BANDING LIGATION VERSUS PROPRANOLOL FOR THE PRIMARY PREVENTION OF VARICFAL BLEEDING IN CIRRHOSIS: A RANDOMIZED CONTROLLED MULTICENTER TRIAL Michael Schepke, Christa Goebel, Dieter Nuernberg, Joerg Willert, Lydia Koch, Tilman Sauerbluch, University of Bonn, Bonn, Germany

3:30prn $129 THE PRESENCE AND SPECTRUM OF VARICES IN THE ABSENCE OF CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS C Arun J Sanyal, Virginia Commonwealth University, Richmond, VA; Robert Fontana, university of Michigan, Ann Arbor, MI; James Everhart, NIDDK, Bethesda, MD; Adrian Di Bisceglie, Sant Louis University, St. Louis, MO; Elizabeth Wright, New England Research Institute, Boston, .MA

3:45~m W 130 PHARMACOLOGICAL REDUCTION OF PORTAL PRESSURE AND LONG TERM RISK OF FIRST VARICEAL BLEEDING IN PATIENTS WITH CIRROSIS Juan Turnes, Juan Carlos Garcia-Pagan, Juan C Abraldes, Alessandra Dell’Era, Manuel Hernandez-Cuerra, Jaime Bosch, Juan Rod&, Hepatic Hemodyiiamic Lab, Liver Unit, IMD Hospital Clinic, Barcelona, Spain

400pm

131 PULMONARY VASCULAR COMPLICATIONS OF LIVER DISEASE: SURVIVAL ANALYSIS OF 140 PATIENTS EVALUATED AT MAY0 CLINIC Karen L Swanson, Russell H Wiesner, Charles B Rosen, Michael J Krowka, Mayo Clinic, Rochmter, MN

415prn 4 132 A 3 MONTHS COURSE OF LONG ACTING REPEATABLE OCTREOTIDE (SANDOSTATIN-LAR) REDUCES PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS. A DOUBLE- BLIND RANDOMIZED CONTROLLED TRIAL La~ireiit Spahr, lean-Louii Froswd, Emihano Giostra, Gilles Mentha, Antoine Hadengue, Geneva University Hospital, Geneva, Su itr~ilartd

Parallel Session 19: Hepatitis C: New Antiviral Developments

Monday, October 27 3 OOpm - 4 3Opm Vctcrnrrs Merilclr rnl Audrfoi r u i l l

Modontors T / A K E LIANG 1711d ]OWN G MCHllTCHlSON

3:OOprn # 133 DEVELOPMENT OF SMALL INTERFERING RNA (SIRNAS) AGAINST FULL-LENGTH HEPATITIS C VIRUS 1A STRAIN Rainesh Prabhu, Padmaja Vital, Erik Flemington, Robert F Garry Frank Kcistian, Srikanta Dash, Tulane University Health Science5 Centei, Net\ Oileans, LA

3:15~rn

W 134 IN VITRO ANTIVIRAL ACTIVITY OF SCH6, A NOVEL INHIBITOR OF THE HEPATITIS C VIRUS NS3 SERINE PROTEASE Karim Abid, University Hospital, Geneva, Switzerland; Rong Liu, Schering-Plough Research Institute, Kenilworth, NJ; Christine Rossi, University Hospital, Geneva, Switzerland; Stephane L Bogen, Bahige M Baroudy, Schering-Plough Research Institute, Kenilworth, NJ; Francesco Negro, University Hospital, Geneva, Switzerland

3:30~m

$135

POLYMERASE INHIBITORS AS POTENTIAL DRUG CANDIDATES FOR TREATMENT OF CHRONIC HEPATITIS C INFECTION Shlonio Dagan, Ehud Ilan, Sigal Aviel, Ofer Nussbaum, Eden Arazi, Ofer Ben-Moslie, Dafna Slama, Iris Tzionas, Yariv Shoshany, XTL Biopharmaceuticals Ltd., Rehovot, Israel; Sang- Wook Lee, Jae-Jin Han, Sang-Jin Park, Geun-Hyung Lee, Eul- yong Park, Joong-Chul Shm, B&C Biopharm, Kyungki-Do, South Korea; Joo-Won Suh, Myong Ji University, Yongin, Gyunggido, South Korea; Jong-Woo Kim, B&C Biopharm, Kyungki-Do, South Korea

3 : 4 5 ~ m

IN-VITRO AND IN-VIVO EVALUATION OF HCV

k 136 ANTIVIRAL EFFECT OF BILN 2061, A NOVEL HCV SERINE PROTEASE INHIBITOR, AFTER ORAL TREATMENT OVER 2

GENOTYPE 1 Markus Reiser, Medizinische Universitatsklinik, Bochum, Germany; Holger Hinrichsen, 1 Medizinische Universitatsklinik K~el, Kiel, Germany; Yves Benhamou, Groupe Hospitalier Pitie- Salpetriere, Paris, France; Roe1 Sentjens, Academisch Medisch Centruni Amsterdam, Amsterdam, Netherlands; Heiner Wedemeyer, Medizinische Hochschule, Hannover, Germany; Luis Calleja, Clinica Puerta de Hierro, Madrid, South Africa; Xavier Forns, Hospital Clinic0 Barcelona, Barcelona, Spain; Jens Croenlein, Boehringer Ingelheim, Biberach, Germany; Chan Yong, Boehringer Ingelheim, Ridgefield, CT; Gerhard Nehmiz, Gerhard Steinmaim, Boehringer Ingelheim, Biberach, Germany

400prn

DAYS IN PATIENTS WITH CHRONIC HEPATITIS C, NON-

# 137

WITH A SUPERIOR SUSTAINED INHIBITORY RESPONSE IN HCV REPLICON CELLS Kai Lin, Cynthia A Gates, Yu-Ping Luong, Robert B Perni, Ann D Kwong, Vertex Pharmaceuticals Inc, Cambridge, MA

4: 15prn #138 INHIBITION OF INTRACELLULAR HEPATITIS C VIRUS

DERIVED SMALL INTERFERING RNA Naoya Sakamoto, Yoko Tanabe, Nobuyuki Enomoto, Shinya Maekawa, Masayuki Kurosaiu, Mina Nakagawa, Tsuyoshi Yamashiro, Cheng-Hsin Chen, Nobuhiko Kanazawa, Takanori Yokota, Mamoru Watanabe, Tokyo Medical and Dental University, Tokyo, Japan

VX-950: A TIGHT-BINDING HCV PROTEASE INHIBITOR

REPLICATION BY ADENOVIRUS DELIVERY OF VECTOR-


Parallel Session 20: Hepatic Fibrogenesis: Experimental Models

Monday, October 27 3:OOpm - 4:30pm Hynes Convention Center Room 312 Moderators: DETLEF SCHUPPAN and SCOTT L. FRIEDMAN

3:OOorn # 139 COMPLEMENT FACTOR 5 (C5) IS A GENETIC DETERMINANT OF LIVER FIBROGENESIS IN MICE AND HUMANS Sonja Hillebrandt, Aachen University (RWTH), Aachen, Germany; Ralf Weiskirchen, Institute of Clinical Chemistry and Pathobiochemistry, Aachen University (RWTH), Aachen, Germany; Hermann E Wasmuth, Alexa Werth, Hildegard Keppeler, Aachen University (RWTH), Aachen, Germany; Claus Hellerbrand, Regensburg University, Regensburg, Germany; Johann Lorenzen, Institute of Pathology, Aachen University (RWTH), Aachen, Germany; Axel M Gressner, Institute of Clinical Chemistry and Pathobiochemistry, Aachen University (RWTH), Aachen, Germany; Siegfried Matern, Frank Lammert, Aachen University (RWTH), Aachen, Germany

3:lSpm # 140 TRANSPLANTATION OF LIV-8 NEGATIVE FRACTION OF BONE MARROW CELLS REVERSES CCL4-INDUCED LIVER FIBROSIS Isao Sakaida Sr, Koji Aoyama, Naoki Yamamoto, Tsuyoshi Ishikawa, Kaoru Omori, Shuji Terai, Yamaguchi University, Ube- Yamaguchi, Japan; Hiroshi Nishina Sr, University of Tokyo, Tokyo, Japan; Kiwamu Okita Sr, Yamaguchi University, Ube- Yamaguchi, Japan

3:30~rn # 141

LIVER INJURY THROUGH ENHANCED ACTIVATION COMBINED WITH INCREASED SUSCEPTIBILITY OF ACTIVATED HSC’S TO KILLING Alaa Melhem, Hadassah University Hospital, Jerusalem, Israel; Carlus E Alvarez, Mount Sinai School of Medicine, New York, NY; Yaron Ilan, Amal Bishara, Hadassah University Hospital, Jerusalem, Israel; Scott L Friedman, Mount Sinai School of Medicine, New York, NY; Rifaat Safadi, Hadassah University Hospital, Jerusalem, Israel

ANTI-FIBROTIC ACTIVITY OF NK CELLS IN EXPERIMENTAL

3:45Dm # 142

ACTIVITY ATTENUATES THE DEVELOPMENT OF EXPERIMENTALLY INDUCED LIVER FIBROSIS Richard A Rippe, Jeff Lindquist, Ramon Bataller, Terry Morris, Michael D Wheeler, David A Brenner, University of North Carolina, Chapel Hill, NC

INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE

400om

# 143

ADENOVIRUS FROM HEPATOCYTES TO ACTIVATED STELLATE CELLS Marieke H Schoemaker, Marianne G Rots, Leonie Beljaars, Arjen Y Ypma, Peter L M Jansen, Hidde J Haisma, Klaas Poelstra, Han Moshage, University of Groningen, Groningen, Netherlands

4 1 5nm

REDIRECTION OF PDGF-RECEPTOR TARGETED

# 144 RECOMBINANT FOLLISTATIN REDUCES HEPATIC FIBROSIS IN AN ANIMAL MODEL OF CIRRHOSIS Shane Patella, David J Phillips, David M de Kretser, William Sievert, Monash University, Melbourne, Australia

Parallel Session 21: Hepatitis C and Liver Transplantation

Monday, October 27 3:OOpm - 4:30pm Hynes Convention Center Ballroom A Moderators: GUY W. NEFF and MYRON E. SCHWARTZ

3:OOpm # 145 ANALYSIS OF UNOS DATA SHOWS THAT THE OUTCOME OF LIVER TRANSPLANTATION IN PATIENTS WITH

2001 IN THE USA Hwan Y Yoo, Indiana University School of Medicine, Indianapolis, IN; Paul J Thuluvath, Johns Hopkins University School of Medicine, Baltimore, MD

3:15prn

HEPATITIS C HAS REMAINED UNCHANGED BETWEEN 1991-

# 146 A MORE SEVERE HEPATITIS C RECURRENCE (HCVR) POST LIVER TRANSPLANTATION (OLT) OBSERVED IN RECENT YEARS MAY BE EXPLAINED BY THE USE OF LOWER-DOSE CORTICOSTEROID (CS) MAINTENANCE PROTOCOLS Carlos G Fasola, George J Netto, Nicholas Onaca, Mark Thomas, Edmund Q Sanchez, Shrina Chinnakotla, Robert M Goldstein, Marlon F Levy, Gary L Davis, Goran B Klintmalm, Baylor University Medical Center, Dallas, TX

3:30pm # 147 SHOULD WE DISCARD OLD DONORS FOR HEPATITIS C CANDIDATES ? THE IMPORTANCE OF DONOR STEATOSIS Marta Ponce, Marina Berenguer, Martin Prieto, Victoria Aguilera, Doming0 Carrasco, Mguel R a y h , Francisco Orbis, Joaquin Berenguer, La Fe Hospital, Valencia, Spain

3:45prn # 148

RIBAVIRIN ON LIVER FIBROSIS FOR RECURRENT

CENTER EXPERIENCE Sandeep Mukherjee, Richard K Gilroy, Joyce Rogge, Lynne Weaver, Timothy M McCashland, Daniel F Schafer, University of Nebraska Medical Center, Omaha, NE

IMPACT OF PEGYLATED INTERFERON ALFA-PB AND

HEPATITIS C IN LIVER TRANSPLANATION-A SINGLE


400pm # 149

TION IN PATIENTS WITH RECURRENT HEPATITIS C Ulf P Neumann, Thomas Berg, Peter Neuhaus, Charit6, Virchow Clinic, Berlin, Germany

4:lSpm # 150 TACROLIMUS LEVELIDOSE RATIO IS SIGNIFICANTLY HIGHER IN HEPATITIS C LIVER TRANSPLANT RECIPIENTS: IMPACT ON COST Julie C Osborne, Michael A Heller, Lisa Forman, Marcelo Kugelmas, Gregory Everson, Thomas Bak, Michael Wachs, Igal Kam, James F Trotter, University of Colorado, Denver, CO

FIBROSIS PROGRESSION AFTER LIVER TRANSPLANTA-

Parallel Session 22: Metabolic Liver Diseases

Monday, October 27 3:OOpm - 4:30pm H p r s Coriilcrititm Cmter Room 311 Moiferators: MARK A. ZERN and KRlS V KOWDLEY

3:OOpm ir 151 LONG TERM CORRECTION OF BILIRUBIN UDP GLUCURONYLTRANSFERASE DEFICIENCY IN RATS BY IN UTERO LENTIVIRAL GENE TRANSFER Jurgen Seppen, Roos van der Rijt, Norbert Looije, Niek P van Til, Wout H Lamers, Ronald P J Oude Elferink, AMC Liver Center, Amsterdam, Netherlands

3:lSpm 152

SV40-DERIVED RIBOZYME CONSTRUCT MEDIATES

TRANSCRIPTS IN A TRANSGENIC MOUSE MODEL Yuyou Duan, Jian Wu, University of California, Davis Medical Center, Sacramento, CA; Iwata Ozaki, Saga Medical College, Saga, Japan; David S Strayer, Thomas Jefferson University, Philadelphia, PA; Mark A Zern, University of California, Davis Medical Center, Sacramento, CA

3:30~m

EFFECTIVE DESTRUCTION OF HUMAN ctl-ANTITRYPSIN

X 153 AMELIORATION OF HISTOPATHOLOGICAL LESIONS OF LIVER AND SPLEEN OF A MOUSE MODEL OF

GLUCURONIDASE GENE TRANSFER USING A

Yujo Kawashita, Namita Roy-Chowdhury, Sung W Lee, Chandan Guha, Albert Einstein College of Medicine, Bronx, NY; David S Strayer, Thomas Jefferson University, Philadelphia, TN; Jayanta Roy-Chowdhury, Albert Einstein College of Medicine, Bronx, NY

MUCOPOLYSACCHARIDOSIS VII AFTER BETA-

REPLICATION-DEFECTIVE SIMIAN VIRUS 40 VECTOR

400om _ _ _ _ _ ~

# 155 PREVALENCE OF SELF-REPORTED SYMPTOMS IN THE HEIRS STUDY DIFFERENCES BY HFE GENOTYPE Paul C Adams, London Health Sciences Centre, London, ON, Canada; David Reboussin, Wake Forest University School of Medicine, Winston-Salem, NC; Ron Acton, University of Alabama at Birmingham, Birmingham, AL; Jim Barton, Southern Iron Disorders Center, Birmingham, AL; Victor Gordeuk, Fitzroy Dawkins, Howard University, Washington, DC; Christine McLaren, Gordon McLaren, College of Medicine, University of California at Irvine, Irvine, CA; Emily Harris, Kaiser Permanente Center for Health Research, Portland, OR; Nancy Press, Oregon Health Sciences University, Portland, OR; Mark Speechley, University of Western Ontario, London, ON, Canada; Bev Mellen, Wake Forest University School of Medicine, Winston- Salem, NC; Elizabeth Thomsen, National Human Genome Research Institute, Bethesda, MD; John Eckfeldt, University of Minnesota, Minneapolis, MN; Phyliss Sholinsky, National Heart, Lung and Blood Institute, Bethesda, MD

4 15Dm # 156

AND INCREASE LIVER INJURY IN A MODEL OF AlAT DEFICIENCY David Rudnick, Jeffrey Teckman, Washington University School of Medicine, St. Louis, MO

NSAIDS INCREASE A-1-ANTITRYPSIN PROTEIN SYNTHESIS

Parallel Session 23: NASH: Natural History

Monday, October 27 3:OOpm - 4:30pm Hyries Convention Center Ballroom B, C Moderators: RAPHAEL B. MERRlMAN aid BRE,YT A. TETRl

3:00pm # 157 EXPANDING KNOWLEDGE ON NATURAL HISTORY OF NONALCOHOLIC STEATOHEPATITIS: A LONGITUDINAL STUDY OF SEQUENTIAL LIVER BIOPSIES Eduardo Fassio, Estela Alvarez, Nora Dominguez, Graciela Landeira, Cristina Longo, Professor A. Posadas Hospital, Buenos Aires, Argentina

3:lSpm # 158 HISTOLOGIC CORRELATION OF PAIRED RIGHT LOBE AND LEFT LOBE LIVER BIOPSIES IN MORBIDLY OBESE INDIVIDUALS WITH SUSPECTED NON ALCOHOLIC FATTY LIVER DISEASE Raphael B Merriman, Linda D Ferrell, Marco C Patti, James W Ostroff, Karen Bagetelos, Bradley E Aouizerat, Nathan M Bass, University of California San Francisco, San Francisco, CA

3:30pm # 159 NATURAL HISTORY AND DETERMINANTS OF DISEASE PROGRESSION IN NON ALCOHOLIC FATTY LIVER D1SEASE:GOOD AND BAD NEWS

Tyne, UK

3:45pm t 154 THE IMPORTANCE OF MOLECULAR DIAGNOSIS FOR WILSON DISEASE Diane W Cox, Lisa M Prat, University of Alberta, Edmonton, AB,

Roberts, The Hospital for Sick Children, Toronto, MB, Canada; Marc Bilodeau, Hapita1 Saint LUC, Montreal, PQ, Canada

Canada; John Walshe, WD Huntington Grey, UK; Eve A Sushma Saksena, University of Newcastle, Newcc>stle-upon.


3:45pm 3:30pm # 160 DESIGN AND VALIDATION OF A HISTOLOGIC SCORING SYSTEM FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) David E Kleiner, NCI, Bethesda, MD; Elizabeth M Brunt, Sant Louis University, St. Louis, MO; Mark L Van Natta, Johns Hopkins University, Baltimore, MD; Cynthia Behling, University of California San Diego, San Diego, CA; Melissa J Contos, Virginia Commonwealth University, Richmond, VA; Oscar W Cummings, Indiana University, Indianapolis, IN; Linda D Ferrell, University of California San Francisco, San Francisco, CA; Yao- Chang Liu, MetroHealth Medical Center, Cleveland, OH; Michael S Torbenson, Johns Hopkins University, Baltimore, MD; Matthew Yeh, University of Washington Medical Center, Seattle, WA; Arthur J McCullough, MetroHealth Medical Center, Cleveland, OH; Arun J Sanyal, Virginia Commonwealth University, Richmond, VA

4 0 0 p m # 161 NONALCOHOLIC STEATOHEPATITIS (NASH) IN PATIENTS WITH MORBID OBESITY IS COMMONLY ASSOCIATED WITH NORMAL LIVER ENZYMES Patricia S Latham, Marie L Borum, Ephraim E Nsien, George Washington School of Medicine, Washington, DC; Joseph D Afram, Center for Obesity Surgery, Washington, DC

415pm # 162

DISORDER IN PATIENTS PRESENTING FOR LAPAROSCOPIC CHOLECY STECTOMY Martin D Weltman, Amitabha Das, Christopher Martin, Jenny Ma Wyatt, Michael Cox, Nepean Hospital, Penrith NSW, Australia

NON-ALCOHOLIC FATTY LIVER DISEASE-A COMMON

Parallel Session 24: Oxidative Stress, Antioxidants

Monday, October 27 3:OOpm - 4:30pm Hynes Convention Center Room 309 Moderators: JACQUELYN J. MAHER and DAVID W. CRABB

3:00pm # 163 HEPATOCYTE RESISTANCE TO OXIDATIVE STRESS IS DEPENDENT ON PKC-MEDIATED DOWN-REGULATION OF JNK/AP-1 Yongjun Wang, Jom M Schattenberg, Raina M Rigoli, Mark J Czaja, Albert Einstein College of Medicine, Bronx, NY

3:15pm # 164 PROTEOMIC ANALYSIS OF LIVER MITOCHONDRIA PROTEINS: EVIDENCE FOR ALTERED PROTEIN THIOL REDOX STATUS AFTER CHRONIC ALCOHOL CONSUMPTION Shannon M Bailey, Aparna Venkatraman, Aimee Landar, Ashley J Davis, Elena Oulasova, University of Alabama at Birmingham, Birmingham, AL; Michael P Murphy, MRC-DUM Human Nutrition Unit, Cambridge, UK; Victor Darley-Usmar, University of Alabama at Birmingham, Birmingham, AL

# 165

PROTEIN EXPRESSION IN REGENERATING MOUSE LIVER Masayoshi Horimoto, Peter Fulop, Zoltan Derdak, Jack Wands, Gyorgy Baffy, Liver Research Center, RI Hospital and Brown Medical School, Providence, RI

3:45pm

UNCOUPLING PROTEIN-2 DEFICIENCY ALTERS CELL CYCLE

# 166 OXIDATIVE STRESS MEDIATES HEPATIC IRON UPTAKE IN VITRO AND IN VIVO Stephan Hegedusch, Julia Mangin, Daniel Rost, Andreas Welker, Kostas Pantopoulos, Wolfgang Stremmel, Sebastian Mueller, University of Heidelberg, Heidelberg, Germany

4:OOpm # 167

INDEPENDENT OF CLINICAL SEVERITY AND OUTCOME IN PATIENTS WITH SEVERE ALCOHOLIC LIVER DISEASE Rajeshwar P Mookerjee, Sukhwinderjit Lidder, Sambit Sen, Stephen J Hodges, Roger Williams, Rajiv Jalan, University College London, London, UK

415pm # 168 HEPATITIS C CORE PROTEIN INCREASES SENSITIVITY OF

PRE-PRIMED NEUTROPHIL OXIDATIVE BURST IS

HEPG2 CELLS TO OXIDANTS AND DOWN-REGULATES HEME OXYGENASE-1 Feng Wen, Maher Y Abdalla, Costica Aloman, Michael Icardi, Michael L McCormick, University of Iowa, Iowa City, IA; Andrea D Branch, Jose Walewski, Mount Sinai School of Medicine, New York, NY; Douglas R LaBrecque, Michael Voigt, Kyle E Brown, Bradley E Britigan, Warren N Schmidt, University of Iowa, Iowa City, IA

Parallel Session 25: Artificial Liver Support

Mondav. October 27 4:45pm - 6:15pm Hynes Convention Center Room 302 Moderators: PHlLlP ROSENTHAL and JOHN O’GRADY

4 4 5 u m # 169

TO ALBUMIN: RELEVANCE IN LIVER DISEASE Christian Steiner, Sambit Sen, Roger Williams, Rajiv Jalan, University College London, London, UK

5:OOpm

KINETICS OF BINDING OF NON-DIALYSABLE SUBSTANCES

# 170 FUNCTIONAL ACTIVITY OF HUMAN HEPATOMA CELLS AND PRIMARY RAT HEPATOCYTES TRANSFECTED WITH ADENOVIRUS-MEDIATED HEPATOCYTE NUCLEAR FACTOR (HNF)-4 GENE Takafumi Naiki, Masahito Nagak, Takahiko Asano, Takayuki Kimata, Atsushi Suetsugu, Shinichi Satake, Tomohiro Kato, Hisataka Moriwaki, Gifu University School of Medicine, Gifu City Japan

h6A AASLD PROGRAM HEPATOLOGY, October 2003

5:15pm P 171 CEREBRAL AMINO ACID AND OXIDATIVE METABOLISM IN PATIENTS WITH HEPATIC ENCEPHALOPATHY DURING TREATMENT WITH THE MOLECULAR ADSORBENTS RECIRCULATING SYSTEM Lars E Schmidt, Flemming Tofteng, Gitte I Strauss, Fin S Larsen, Rigshospitalet, Copenhagen, Denmark

5:30pm # 172 MOLECULAR ADSORBENTS RECIRCULATING SYSTEMS (MARS): A POTENTIAL MODEL FOR REMOVING MIDAZOLAM, FENTANYL AND POSSIBLY OTHER PROTEIN- BOUND DRUGS Sambit Sen, University College London, London, UK; Christopher Rose, Max-Delbruck Center for Molecular Medicine, Berlin, Germany; Lars M Ytreber, Ole-Martin Fuskevaag, University Hospital Northern Norway, Tromsn, Norway; Nathan A Davies, University College London, London, UK; Geir I Nedredal, Revhaug Arthur, University Hospital Northern Norway, Tromser, Norway; Roger Williams, Rajiv Jalan, University College London, London, UK

5:45pm # 173 PATHOPHYSIOLOGICAL BASIS OF EXTRACORPOREAL

LIVER FAILURE DUE TO ALCOHOL Sambit Sen, Nathan A Davies, Rajeshwar P Mookejee, Lisa M Cheshire, Stephen J Hodges, Roger Williams, Rajiv Jalan, University College London, London, UK

6:OOpm # 174 EXPERIENCES WITH MARS THERAPY IN LIVER DISEASE: ANALYSIS OF 385 PATIENTS OF THE INTERNATIONAL MARS REGISTRY Christian Steiner, Achiin Zinggrebe, Andrea Viertler, University of Rostock, Rostock, Germany

ALBUMIN DIALYSIS WITH MARS IN ACUTE-ON-CHRONIC

Parallel Session 26: Cell Death

Monday, October 27 4:45pm - 6:15pm Hyries Cot i iv i i t im Cetifrr Roovi 311 Mo&rators: tIAR7'MUT W. IAESCHKE a n d GRACE L. SU

4:45pm 8 175 APOPTOSIS AND ONCOTIC NECROSIS DURING ACUTE LIVER INJURY AFTER BILE DUCT LIGATION IN MICE Jaspreet S Gujral, University of Arizona, Tucson, AZ; Anwar Farhood, University of Texas Health Science Center, Houston, TX; Hartmut Jaeschke, University of Arizona, Tucson, AZ

5:OOpm 8176

ACTIVATION OF THE SMALL GTP BINDING PROTEIN, RAP1 John McCool, M Sawkat Anwer, Cynthia R L Webster, Tufts University, Grafton, MA

THE ANTI-APOPTOTIC EFFECT OF CAMP INVOLVES

5:15pm # 177

SUPEROXIDE DISMUTASE GENE DELIVERY PREVENTS ACUTE LIVER INJURY IN MICE Jian Wu, Li Liu, Roy Yen, Hai T Le, Mark A Zem, University of California, Davis Medical Center, Sacramento, CA; Michael H Nantz, University of California Davis, Davis, CA; Stefan L Marklund, University of Umea, Umea, Sweden

5 : 3 0 ~ m

POLYCATIONIC LIPOSOME-MEDIATED EXTRACELLULAR

# 178 BILE SALT-INDUCED HEPATOCYTE APOPTOSIS INVOLVES EPIDERMAL GROWTH FACTOR RECEPTOR-DEPENDENT CD9S-TYROSINE PHOSPHORYLATION IN VITRO AND IN VIVO Roland Reinehr, Dirk Graf, Dieter Haussinger, Universitatsklinikum Diisseldorf, Duesseldorf, Germany

5:45om # 179

BY A JNK SIGNALING CASCADE Philip Hilgard, Guido Gerken, University Hospital Essen, Essen, Germany; Mark J Czaja, Richard J Stockert, Albert Einstein College of Medicine, Bronx, NY

6 : 0 0 ~ m

PRO-APOPTOTIC ROLE OF CASEIN KINASE 2 IS MEDIATED

# 180 INHIBITION OF NUCLEAR FACTOR-KB AND PHOSPHATIDYLINOSITOL 3-KINASE/AKT IS ESSENTIAL FOR MASSIVE HEPATOCYTE APOPTOSIS INDUCED BY TUMOR NECROSIS FACTOR a IN MICE Motoalu Imose, Masahito Nagaki, Takafumi Naiki, Yosuke Osawa, Gifu University School of Medicine, Gifu City, Japan; David A Brenner, University of North Carolina, Chapel Hill, NC; Takahiko Asano, Hideki Hayashi, Motohiro Imao, Shinji Takai, Kiminori Kimura, Tomohiro Kato, Hisataka Moriwaki, Gifu University School of Medicine, Gifu City, Japan Travel Award Recipient

Parallel Session 27: Gene Expression and Therapy

Monday, October 27 4:45pm - 6:15pm Hynes Conzwztion Cetzfer Room 310 Moderators: LINDA E. GREENBAUM arid M A R I O CHOlKlER

445Dm ~~

#181 FOXAl AND FOXA2 ARE REQUIRED FOR THE SPECIFICATION OF THE LIVER Joshua R Friedman, Catherine S Lee, Klaus H Kaestner, University of Pennsylvania, Philadelphia, PA


5:OOpm 445pm # 182

HEPATOCELLULAR CARCINOMAS IS ASSOCIATED WITH HYPERMETHYLATION AT SPl BINDING SITES IN THE

Christian Liedtke, Nils-Holger Zschemisch, Anne Cohrs, Medical School of Hannover, Hannover, Germany; Juergen Borlack, Fraunhofer Institute of Toxicology and Experimental Medicine, Hanover, Germany; Michael P Manns, Christian Trautwein, Medical School of Hannover, Hannover, Germany

5: 1 5pm

LACK OF CASPASE-8 EXPRESSION IN MURINE

MURINE CASPASE-8 PROMOTER

# 183 THE INDUCTION OF THE E2F GENES DURING HEPATIC CELL CYCLE PROGRESSION IS DEPENDENT ON CEBPBETA Brian Larris, Jessica Garces, Linda E Greenbaum, University of Pennsylvania, Philadelphia, PA

5:30pm # 184

APOPTOSIS THROUGH MODULATION OF THE GLUCOCORTICOID RECEPTOR IN PRIMARY RAT HEPATOCYTES Susana Sola, Rui E Castro, University of Lisbon, Faculty of Pharmacy, Lisbon, Portugal; Betsy T Kren, Clifford J Steer, University of Minnesota Medical School, Minneapolis, MN; Cecilia M P Rodrigues, University of Lisbon, Faculty of Pharmacy, Lisbon, Portugal Travel Award Recipient

5:45pm

URSODEOXYCHOLIC ACID PREVENTS TGF-P1-INDUCED

# 185 WNT SIGNALING IN EARLY LIVER DEVELOPMENT IN A XENOPUS MODEL Valerie A McLin, Aaron M Zom, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

6:OOpm

# 186 IDENTIFICATION OF NOVEL HNF6 TARGET GENES BY

IMMUNOPRECIPITATION Joshua R Friedman, Phillip P Le, Klaus H Kaestner, University of Pennsylvania, Philadelphia, PA

HIGH-THROUGHPUT CHROMATIN

Parallel Session 28: Hepatitis C: Therapy

Monday, October 27 4:45pm - 6:15pm Veterans Memorial Auditorium Moderators: K . RAJENDER REDDY and DORIS B. STRADER

# 187 EFFICACY AND SAFETY OF 22 WEEKS OF MAINTENANCE

(PEGASYS(tm)) ALONE VERSUS PEGINTERFERON ALFA-PA (40KD) PLUS RIBAVIRIN(COPEGUS(tm)) IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND GENOTYPE 1 WHO

THERAPY WITH PEGINTERFERON ALFA-2A (40KD)

RESPONDED TO A 24-WEEK COURSE OF PEGINTERFERON ALFA-PA (40KD) PLUS RIBAVIRIN : AN OPEN, MULTICENTER, RANDOMIZED TRIAL Jean-Pierre Bronowicki, Hospital Brabois, Nancy, France; Denis &an, Amaud Tzanck Institute, St Laurent du Var, France; Tarik Asselah, Hospital Beaujon, Clichy, France; Heme Desmorat, Clin du Parc, Toulouse, France; Jean-Pierre Zarski, University Hospital, Grenoble, France; Juliette Foucher, Hospital Haut Leveque, Pessac, France; Marc Bourliere, Hospital Saint Joseph, Marseille, France; Christophe Renou, Hospital, Hyeres, France; Albert Tran, Hospital Acad2, Nice, France; Pascal Melin, Hospital, St Dizier, France; Christophe Hezode, Hospital Henn Mondor, Creteil, France; Michele Chevallier, Laboratoire Meyrieux, Lyon, France; Magali Bouvier, Hospital Henri Mondor, Creteil, France; Isabelle Lonjon-Domanec, Roche, Neuilly sur Seine, France; Jean-Michel Pawlotsky, Hospital Henri Mondor, Creteil, France

5:Wpm It 188 INTERACTING RANTES/CCL5 GENE VARIANTS MODIFY THE RESPONSE TO COMBINATION THERAPY WITH

CHRONIC HEPATITIS C Hermann E Wasmuth, Aachen University (RWTH), Aachen, Germany; Tobias Muller, Humboldt University Berlin (Charite), Berlin, Germany; Alexa Werth, Christoph G Dietrich, Andreas Geier, Carsten Gartung, Aachen University (RWTH), Aachen, Germany; Thomas Berg, Humboldt University Berlin (Charite), Berlin, Germany; Siegfried Matern, Frank Lammert, Aachen University (RWTH), Aachen, Germany

5:l Spm

INTERFERON-ALPHA AND RIBAVIRIN IN PATIENTS WITH

lQ 189 TREATMENT OF CHRONIC HEPATITIS C WITH PEGINTERFERON ALFA-ZA (40KD) (PEGASYSB) AND RIBAVIRIN (COPEGUSB): PATIENT AGE HAS A MARKED INFLUENCE ON THE INDIVIDUAL ESTIMATED PROBABILITY OF ACHIEVING A SUSTAINED VIROLOGICAL RESPONSE Graham R Foster, Digestive Disease Research Centre, Barts and The London, London, UK; Michael W Fried, University of North Carolina, Chapel Hill, NC; Stephanos J Hadziyannis, Henry Dunant Hospital, Athens, Greece; Monique Chaneac, Roche Diagnostics, Basel, Switzerland

5:30pm # 190 INTERFERON-STIMULATED GENE EXPRESSION AND VIROLOGICAL RESPONSE DURING PEGINTERFERON ALFA- 2A AND RIBAVIRIN TREATMENT IN AFRICAN AMERICAN AND CAUCASIAN HCV GENOTYPE 1 PATIENTS Charles D Howell, Shengyuan Luo, University of Maryland, Baltimore, MD; William Cassidy, Louisiana State University, Baton Rouge, LA; Lennox Jeffers, Rajender Reddy, University of Miami, Miami, FL; Christine Bruno, Emory University, Atlanta, GA

6XA AASLD PROGRAM HEPATOLOGY, October 2003

5:45prn # 191 RELATIONSHIP BETWEEN EARLY VIRAL KINETICS AND IMMUNE REACTIVITY IN CHRONIC HEPATITIS C

ALFA 2A AND RIBAVIRIN Kwok H Tang, Institute of Hepatology, UCL, London, UK; Eva Herrmann, Department of Medicine, Homburg /Sax, Germany; Nick Tatman, Shilpa Chokshi, Helen Cooksley, Institute of Hepatology, UCL, London, UK; Erwin Sablon, Innogenetics NV, Chent, Belgium; Stefan Zeuzem, Department of Medicine, Homburg/Saar, Germany; Roger Williams, Nikolai V Naoumov, Institute of Hepatology, UCL, London, UK

6:OOprn

(GENOTYPE 1) PATIENTS TREATED WITH PEGINTERFERON-

# 192 EARLY VIRAL KINETICS PREDICTION OF SUSTAINED VIROLOGICAL RESPONSE AFTER 1 OR 4 WEEKS OF PEG- INTERFERON-ALFA-2A AND RIBAVIRIN THERAPY (DITTO- HCV PROJECT) Avidan U Neumann, Esther Hagai, Bar-Ilan University, Ramat- Gan, Israel; Solko W Schalm, University Hospital Rotterdam Dijkzigt, Rotterdam, Netherlands; Michael von Wagner, Saarland University Hospital, Homburg/Saar, Germany; Georgios Germaiudis, Aristotle University of Thessaloniki, Thessaloniki, Greece; Yoav Lurie, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Gabriele Missale, Azienda Ospedaliera di Parma, Parma, Italy; Maria Martell, Hospital General Val1 d’Hebron, Barcelona, Spain; Jan-Maarten Vrolijk, University Hospital Rotterdam Dijkzigt, Rotterdam, Netherlands; Cristophe Hezode, HBpital Henri Mondor-Universite Paris XII, Creteil, France; Gunnar Norkrans, University of Goeteborg, Goeteborg, Sweden; Francesco Negro, Hospital University of Geneve, Geneve, Switzerland; Alexandre Soulier, HBpital Henri Mondor- Univcrsite Paris X11, Creteil, France; Elke Verheij-Hart, University Hospital Rotterdam Dijkzigt, Rotterdam, Netherlands; Giuseppe Colucci, Tegimenta AG, Rotkreuz, Switzerland; Carlo Ferrari, Azienda Ospedaliera di Parma, Parma, Italy; Stefan Zeuzem, Saarland University Hospital, Homburg/Saar, Germany; Jean- Michel Pawlotsky, HApital Henri Mondor-Universite Paris XII, Creteil, France

Parallel Session 29: Hepatic Inflammation

5:OOprn

# 194 GENERATION AND FUNCTIONAL IMPORTANCE OF CXC

DURING ENDOTOXEMIA IN MICE Robert B Dorman, Jaspreet S Gujral, Mary L Bajt, University of Arizona, Tucson, AZ; Anwar Farhood, University of Texas Health Science Center, Houston, TX; Hartmut Jaeschke, University of Arizona, Tucson, AZ

5: 15Pm

CHEMOKINES FOR NEUTROPHIL-INDUCED LIVER IN JURY

# 195 THROMBOXANE A2 (TXA2) RELEASED FROM KUPFFER CELLS IS RESPONSIBLE FOR THE HYPER-RESPONSIVENESS OF HEPATIC PORTAL CIRCULATION T O ENDOTHELIN-1 IN ENDOTOXEMIC RATS Hongzhi Xu, Katarzyna Korneszczuk, Mark G Cleniens, Jian X Zhang, University of North Carolina at Charlotte, Charlotte, NC

5:30pm # 196 INNATE IMMUNE SYSTEM DETERMINES ACETAMINOPHEN (APAP) HEPATOTOXICITY Zhang-Xu Liu, Neil Kaplowitz, Uiuvei\ity of Southern Califorma Research Center for Liver Disease, Los Angeles, CA

5:45prn # 197

TLR4 IN LIVER SENSITIZATION AND INJURY Gyongyi Szabo, Laszlo Romics Jr, Kaien Kodys, Angela Dolganiuc, Pranoti Mandrekar, Douglas Colenbock, Uruvcrsitv of Massachusetts Medical School, Worcester, MA

6:OOpm

DISTINCT ROLES FOR TOLL-LIKE RECEPTOR 2(TLR2) AND

# 198 BILIRUBIN REGULATES INOS EXPRESSION AND NITRIC OXIDE PRODUCTION IN ENDOTOXEMIA Weizheng W Wang, Darcey L H Smith, Stephen D Zucker, University of Cincinnati, Cincinnati, OH

Parallel Session 30: Hepatitis 8: Natural History and Pathogenesis

Mondav. October 27

Monday, October ~. 27

4:45pm - 615pm Hyirr5 Conzmtioir Ccrifci Roririi 309 Moifcmtor S T E P H E N D 7 1 I C K E R nnd MlCHAEL P M A N N S

4:45pm - 6:15pm Hyrirs Coimi i f ion Center Room 304, 306 Moderators: IACK R. WANDS arid ANNA S.F. LOK

4:45pm

4 4 S p m # 193 INTERFERON y SIGNALING PATHWAY PLAYS A KEY ROLE IN CON A INDUCED LIVER INJURY Juergen Siebler, Stefan Wirtz, Martina Protschka, University of Mainz, Mainz, Germany; Laurie H Glimcher, Harvard Medical School, Boston, MA; Manfred Blessing, Peter R Galle, Markus F Neurath, University of Mainz, Mainz, Germany

# 199 EXPERIMENTAL INFECTIVITY STUDIES OFGENETICALLY ENGINEERED MONOCLONAL HEPATITIS B VIRUS (HBV) POLYMERASE GENE MUTANTS IN CHIMPANZEES Kris Krawczynski, Saleem Kamili, Centers for Disease Control and Prevention, Atlanta, GA; Stephen A Locarnini, Victorian Infectious Disease Reference Laboratory, Fairfield, Australia; John E Spelbring, Dorrie A Carson, Centers for Disease Control and Prevention, Atlanta, GA


5:OOpm # 200 NATURALLY OCCURING HBV VARIANTS WITHIN THE NUCLEOCAPSID PROTEIN CREATE NULL LIGAND PEPTIDES UNABLE TO ACTIVATE HBV-SPECIFIC CD4+ T- LYMPHOCYTES Norbert H Gruener, Tilman J Gerlach, Axel Ulsenheimer, Helmut Diepolder, Klinikum Groghadem, Medizinische Klinik 11, Munich, Germany; Eddy Wierenga, Laboratory of Cell Biology and Histology, University of Amsterdam, Amsterdam, Netherlands; Reinhart Zachoval, Albrecht Schirren, Gerd Pape, Maria-Christina Jung, Klinikum Groghadern, Medizinische Klinik 11, Munich, Germany

5:lSpm # 201 HEPATITIS B ASSOCIATED VASCULITIS IN ALASKA NATIVES: VIRAL GENOTYPE, CLINICAL AND SEROLOGIC OUTCOME AND INCIDENCE OF NEW CASES OVER TIME AFTER INITIATION OF HEPATITIS B VACCINATION PROGRAM Kathy Hurlburt, Alaska Native Tribal Health Consortium, Anchorage, AK; Brian McMahon, Alaska Native Tribal Health Consortium; Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK; Josephine Sirnonetti, Alaska Native Tribal Health Consortium, Anchorage, AK; Lisa Bulkow, Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK; Mary Snowball, Alaska Native Tribal Health Consortium, Anchorage, A K Vladimir Chulanov, Omana Nainan, Harold Margolis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA; James Williams, Alaska Native Tribal Health Consortium, Anchorage, AK

5:30~m

# 202 HEPATITIS B VIRUS GENOTYPES IN ALASKA NATIVES WITH HEPATOCELLULAR CARCINOMA. PREPONDERANCE OF GENOTYPE F Steve Livingston, Josephine Simonetti, Alaska Native Tribal Health Consortium, Anchorage, AK; Brian McMahon, Alaska Native Tribal Health Consortium; Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK; Lisa Bulkow, Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK; Kathy Hurlburt, Chriss Homan, Mary Snowball, Alaska Native Tribal Health Consortium, Anchorage, A K Vladimir Chulanov, Omana Nainan, Harold Margolis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA; James Williams, Alaska Native Tribal Health Consortium, Anchorage, AK

5:45prn # 203 COMBINED CYTOLYTIC AND NONCYTOLYTIC

IMPORTANT FOR RESPONSE TO ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B PATIENTS Thjon J Tang, Jaap Kwekkeboom, Shanta Mancham, Rekha S Binda, Johannes G Kusters, Solko W Schalm, Harry L A Janssen, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

INTRAHEPATIC CD8 T-LYMPHOCYTE REACTIVITY IS

600prn # 204

CHRONIC HEPATITIS B Kumar Visvanathan, Narelle Skinner, Murdoch Children’s Research Institute, Parkville, Australia; Stephen Locamini, Victorian Infectious Diseases Reference Laboratory and University of Melbourne, North Melbourne, Vic, Australia; Roger Williams, Institute of Hepatology, UCL, London, UK; Stephen Riordan, The Prince of Wales Hospital and University of New South Wales, Sydney, Australia

IMPAIRED TOLL-LIKE RECEPTOR EXPRESSION IN

Parallel Session 31: Liver Transplantation

Monday, October 27 4:45pm - 6:15pm Hynes Convention Center Ballrooni A Moderators: SANDY FENG and PAUL MARTlN

4:45pm # 205 LIVING DONOR LIVER TRANSPLANTATION DONOR SATISFACTION SURVEY Fred Poordad, Tram T Tran, Frank Yeh, Sh-Hui Pan, Nicholas Nissen, John M Vierling, Paul Martin, Steven Colquhoun, Christopher Shackleton, Cedars-Sinai Medical Center, Los Angeles, CA

5:OOprn # 206 MEASUREMENT OF HEPATIC PERFUSION USING THERMODIFFUSION AFTER LIVING DONOR ADULT LIVER TRANSPLANTATION (LDALT) USING RIGHT LOBE GRAFTS James J Pomposelli, Elizabeth A Pomfret, W David Lewis, Fredric D Gordon, Mohammed Akoad, Edward Kreske, JoAnne Pratt, Mary Ann Simpson, Lahey Clinic Medical Center, Burlington, MA; Gregory T Martin, H Frederick Bowman, Hemedex, Cambridge, MA; Roger L Jenkins, Lahey Clinic Medical Center, Burlington, MA

5 1 5Drn ~ ~~

# 207

MALIGNANCIES AFTER LIVER TRANSPLANTATION Ivo W Graziadei, Karin Nachbaur, Alfred Koenigsrainer, Raimund Margreiter, Wolfgang Vogel, University of Innsbruck, Innsbruck. Austria

INCIDENCE AND PROGNOSIS OF DE-NOVO

5:30prn # 208 INCREASED DONOR AGE IS ASSOCIATED WITH INCREASED RISK OF RECURRENT PRIMARY BILIARY CIRRHOSIS FOLLOWING LIVER TRANSPLANTATION Silvania P Cauduro, Russell H Wiesner, Daivd J Brandhagen, Lawrence J Bugart, Ruud A F Krom, Walter K Kremers, Mayo Clinic, Rochester, MN

70A AASLD PROGRAM HEPATOLOCY, October 2003

5:45prn # 209 LIVER TRANSPLANTATION IN CHILDREN WITH BILIARY

OSTOMY (NHPE) Benjamin L Shneider, Sukru Emre, Mount Sinai School of Medicine, New York, NY; Ravinder Anand, The EMMES Corporation, Rockville, MD

6:OOprn

ATRESIA (BA) AND N O PRIOR HEPATOPORTOENTER-

#210 ZOLEDRONIC ACID PREVENTS BONE LOSS AT 3 MONTHS IN LIVER TRANSPLANT PATIENTS: AN INTERIM ANALYSIS Bronwyn A L Crawford, Royal Prince Alfred Hospital and the University of Sydney, Sydney, Australia; Cherie Kam, Royal Prince Alfred Hospital, Sydney, Australia; Julie Pavlovic, The Austin Repatriation Medical Centre, Melbourne, Australia; Anthony J Donaghy, Royal Prince Alfred Hospital, Sydney, Australia; Peter Angus, The Austin Repatriation Medical Centre, Melbourne, Australia; Geoffrey McCaughan, Royal Prince Alfred Hospital and the University of Sydney, Sydney, Australia

Parallel Session 32: Stellate Cell Biology

Monday, October 27 4:45pm - 6:15pm Hyws C ~ J ~ Z ~ ~ ~ ~ I O I I G w t c r Room 372 Modrmtors. SANIEEV GLiPTA mid MASSIMO PlNZANl

4:45prn # 211 ADIPOGENIC REGULATION OF HEPATIC STELLATE CELL TRANSDIFFERENTIATION Hongyun She, Saswati Hazra, Shigang Xiong, Jiaohong Wang, Chin K Sung, Hidekazu Tsukamoto, Keck School of Medicine of the University of Southern California, Los Angeles, CA

5:OOprn #212 LEPTIN STIMULATES TISSUE INHIBITOR OF METALLOPROTEINASE-(TIMPbl IN HUMAN HEPATIC STELLATE CELLS: RESPECTIVE ROLES OF THE JAK-STAT

PATH WAYS Q Cao, K M Mak, C Ren, C S Lieber, Alcohol Research Center, Bronx VA Medical Center and Mount Sinai School of Medicine, Bronx, NY

AND MITOGEN-ACTIVATED PROTEIN KINASE(MAPK)

5:lSpt-n # 213 LEPTIN PROTECTS STELLATE CELLS, BUT NOT HEPATOCYTES, FROM CD95 MEDIATED APOPTOSIS Amir A Qamar, Shehzad Z Sheikh, Irteza B Inapt , Wajahat Z Mehal, Yale University, New Haven, CT Travel Award Recipient

5:30~rn # 214 INTRASPLENICALLY TRANSPLANTED HUMAN HEPATIC STELLATE CELLS (HSC) ENGRAFT AND SURVIVE IN THE LIVER OF IMMUNODEFICIENT MICE FOR PROLONGED PERIODS Daniel Benten, Vinay Kumaran, Brigid Joseph, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY; David A Brenner, College of Physicians and Surgeons, Columbia University, New York, NY; Sanjeev Gupta, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY

5:45pm # 215 HEPATIC STELLATE CELLS REGULATE IMMUNE RESPONSES BY INDUCTION OF ACTIVATED T CELLS APOPTOSIS Cheng-Hsu Chen, Ming-Chin Yu, Lina Lu, Lianfu Wang, Shekhar Gandhi, John F Fung, Shiguang Qian, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA

600om

# 216 TARGETED AND REGULABLE EXPRESSION OF TRANSGENES IN HEPATIC STELLATE CELLS USING AN

Kohji Kinoshita, Yuji Iimuro, Jiro Fujimoto, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Yutaka Inagaki, Tokai University School of Medicine, Isehara, Japan; Scott L Friedman, Mount Sinai School of Medicine, New York, NY; Kazuhiko Namikawa, Hiroshi Kiyama, Yuji Nakajima, Norifumi Kawada, Kazuo Ikeda, Graduate School of Medicine, Osaka City University, Osaka City, Japan

ADENOVIRAL CRE-LOXP SYSTEM


Monday, October 27

700 - 1O:OO pm Sheratoiz T B A (Limited to 50 Attendees) Primary Biliary Cirrhosis (PBC) Course Directors: Nora V. Bergasa, M D

Howard J. Worman, M D

Goals and Objectives: Disseminate current concepts on PBC. Identify areas that require research attention. Establish research collaborations.

This focused study will unite a group of investigators in the area of PBC to present their current work and to identify areas that need research attention. Everyone is welcome to attend this complimentary event, but note space will be limited.

Pathogenesis of PBC

700 - 705 pm

705 - 720 pm

720 - 7:35 pm

735 - 750 pm

Opening Remarks Nora K Bergasa, M D PBC: From Induction to Destruction Eric M. Gerswhin, M D Immunogenetics of PBC Aiinarosa Floreani, M D Potential Role of Human Betaretrovirus in the Pathogenesis of PBC A n d r e w L. Mason, M B B S

7:50 - 8:lO pm Discussion

The Problem of Fatigue in PBC

890 - 8:25 pm

825 - 8:40 pm

Fatigue in PBC: Is it All in the Head? Mark Gordon Swain, M D Tools to Study Fatigue: Are They Objective? David Jones, MD, PhD

8:40 - 9:00 pm Discussion

TheraDeutic Interventions

9:OO - 995 pm Mycophenolic Mofetil in Combination with UDCA and Other Upcoming Therapies for PBC Keith D. Lindor, M D Novel Ideas for the Treatment of PBC Margaret Bassendine, MD

Howard J . Worman, M D

9:15 - 9:30 pm

9:30 - 1000 pm Summary

Focused Studv Grouu Facultv Disclosure


Speakers have provided the following disclosure information:

Margaret Bassendine No relationship to disclose Content of presentation does include discussion qfofl-

label/inuestigative use of nzedicids) , inedical devices or procedure(s)

Nora V. Bergasa Speakers' Bureau: Axcan Scandipliarin Content ofpresentation does not incltidc discussion o f o f -

label/inaestigative use of nzedicine(s), tnedicnl devices or procedurek)

Eric M. Gershwin No relationship to disclose Content ofpresentation does riot include disctrssioii of ofl-

Inbel/iriaesfigati~~e use ofniedicirids), medical dcvices or procedure(s)

Annarosa Floreani No relationship to disclose Content of presentation does not include discussion of off-

/nbel/investigatiz~e nse of niedicinds), medical devices or procedure(s)

David Jones No relationship to disclose Content of presentation does inc l i~de discnssion of of -

label/investigafive use of mediciiids), medical devices or procedure(s)

Keith D. Lindor Did not provide disclosure a t time ofprinting

Andrew L. Mason No relationship to disclose Content ofpresentation does not include discussion of off-

labellinvestigative use of medicinds), medical devices or procedu re(s)

Mark G. Swain No relationship to disclose Content of presentation does tiat include discussion of off:

label/inuestigatiue use of medicine(s), medical devices or procedure(s)

Howard J. Worman Did not p Y O v i d e disclosure at time ofpnnting


Tuesday, October 28 700 - 750 am Please, refer to yoiiv E M W ticket for nreetirq room location.

Basic Research Workshops

501.

502.

503.

504.

505.

506.

507.

Cell Biology of Vesicle Trafficking in Hepatocytes Allan W Wolkoff, M D a n d Mark A McNiven, PhD

Molecular Defects in Cholestasis Lniiin Bul l , PhD a i d Ben~aniiii L Shneider, M D

Liver Stem Cells S t m a i t Sell, M D and Ned D Theist, M D

Oxidative Injury in Liver Disease Doriiinique Pcssnyre, M D and John ] Ltinasters, M D , PhD

Maintenance Therapy in Patients with Chronic Hepatitis C and Fibrosis Mitc hell L Shiflnnri, M D niid Joli~i G McHutchisorl, M D

Organic Anion and Bile Acid Transport Jnnie. L B o ~ ~ Y , M D ~ t i d Michael H TtnirrlPI, M D

Pathogenesis of Gallstones Dniiid E Coheir, M D PhD and Ma1 t in C Caiciy, M D , DSc

Clinical Management Workshous

508.

509.

510.

511.

512.

513.

514.

Treatment of NASH Brent A. Tetri, M D and Craig McClain, M D

Treatment of Hepatitis C Riclznrd K. Sterling, M D and Michael W . Fried, M D

Treatment of Hepatitis C in Children Mairreeii Jonas, M D and Katlzleen B. Schwarz, M D

Treatment of Autoimmune Hepatitis Albert I. Czaja, M D and Michael I? Marzns, M D

Management of Sinusoidal Obstruction Syndrome (VOD) and Budd-Chiari Syndrome George B. McDonald, M D and Laurie D. DeLezit,, M D , PhD

Role of TIPS in Management of Portal Hypertension Nathan M. Bass, M D , PhD and Tlionm D. Boycr, M D

Hepatorenal Syndrome Vincente Arroyo, M D arid Didier Lebrec, M D

Please see pages 40 - 41 for all of the Early Morning Workshop faculty disclosures.

Tuesday, October 28 8:00am - 930am Hynei Con~ierztioii Center Veterans Memorial Auditoriunz Moderators: PATRICIA S . LATHAM and T H O M A S D. BOYER

800am #217

TO SPONTANEOUS AND PERSISTENT HEPATOCYTE APOPTOSIS AND LIVER FIBROGENIC RESPONSE

AND FIBROSIS Tetsuo Takehara, Takahiro Suzuki, Chihiro Ohnishi, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Edmund B Rucker 111, University of Missouri, Columbia, MO; Masahisa Jinushi, Takuya Miyagi, Naolu Hiramatsu, Norio Hayashi, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

8:15am

HEPATOCYTE-SPECIFIC DISRUPTION OF BCL-XL LEADS

riv vlvo EVIDENCE FOR THE LINK BETWEEN APOPTOSIS

~ ~~

ti 218

INCORPORATION INTO CERULOPLASMIN Ting Wang, Steven A Weinmnn, University of Texas Medical Branch, Calveston, TX

THE CLC-4 CHLORIDE CHANNEL PROMOTES COPPER

8:30am # 219

COMPARATIVE TRIAL OF TELBIVUDINE, LAMIVUDINE, AND THE COMBINATION, IN PATIENTS WITH CHRONIC HEPATITIS B Ching-Lung Lai, University of Hong Kong, Hong Kong, China; Nancy W Y Leung, Chinese University of Hong Kong, Hong Kong, China; Eng-Gong Teo, Changi General Hospital, Singapore, Singapore; Myron Tong, Huntington Memorial Hospital, Pasadena, CA; Florence Wong, Toronto General Hospital, Toronto, ON, Canada; Hie-Wan Hann, Jefferson Medical College, Philadelphia, PA; Steven Han, UCLA School of Medicine, Los h g e l e s , CA; Thierry Poynard, Hospital Pitie- Salpetriere, Paris, France; Maureen Myers, George Chao, Deborah Lloyd, Nathaniel Brown, Idenix Pharmaceuticals, Cambridge, MA

8:45am # 220 EFFECTS OF LAMIVUDINE ON DISEASE PROGRESSION AND DEVELOPMENT OF LIVER CANCER IN ADVANCED

RESULTS OF A ONE-YEAR INTERNATIONAL PHASE IIB

CHRONIC HEPATITIS B: A PROSPECTIVE DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL Yun-Fan Liaw, Chang Gung University, Taipei, Taiwan; Joseph J Y Sung, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Wan Cheng Chow, Singapore General Hospital, Singapore, Singapore; Kelly Shue, GlaxoSmithKline Asia Pacific, Singapore, Singapore; Oliver Keene, GlaxoSmithKline R&D, Greenford, UK; Geoff Farrell, The Storr Liver Unit, Sydney, Australia


9:OOam 915am # 221 # 222 HCV-SPECIFIC IMMUNE RESPONSES AT BASELINE DO NOT PREDICT VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY

Chihiro Morishuna, University of Washington, Seattle, WA; Ranjit Ray, Saint Louis University, St. Louis, MO; Stephen J Polyak, Daniel G Sullivan, Ming Chang, University of Washngton, Seattle, WA; Adrian Di Bisceglie, Saint Louis University, St. Louis, MO; William M Lee, University of Texas Southwest Medical Center, Dallas, TX; Herbert L Bonkovsky, University of Connecticut, Farmington, CT; David R Gretch, University of Washington, Seattle, WA; Elizabeth C Wright, New England Research Institute, Watertown, MA; Alan L Rothman, University of Massachusetts, Worcester, MA; Margaret J Koziel, Harvard University, Boston, MA; Karen L Lindsay, University of Southern California, Los Angeles, CA

INTER-ORGAN TRAFFICKING OF AMMONIA AND ITS METABOLITES IN ACUTE LIVER FAILURE: RESULTS OF A

Claudia Zwingmann, Nicolas Chatauret, Roger F Butterworth, CHUM-H6pital Saint-Luc, Montreal, PQ, Canada

IN ADVANCED HEPATITIS C 13C-NUCLEAR MAGNETIC RESONANCE STUDY

Poster Session 4

Tuesday, October 28 800am - 12:3Oum Hynes Convention Center, Exhibit Hall C See page 238 for Poster Presentations

Tuesday, October 28 9:30 - 10:OOam Hunes Conuen tion Center Veternns Metnorial Auditorium

the participant any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.

Hepatocellular Carcinoma: Challenges and Opportunities Speaker: Adrian M . Di Bisceglie, M D Moderator: Thomas D. Boyer, M D

Facultv Disclosure All faculty participating in continuing medical education programs sponsored by the AASLD are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters are asked to make a reasonable effort to identify for

Adrian M. Di Bisceglie provided the following disclosure information:

Gran tlliesearch Support: Schering-Plough, Roche, Gilead Sciences,

ConsultantlAdvisor: Roche, Gilead Sciences, Idenix, SciClone

Speakers’ Bureau: Schering-Plough Other: DSMB member (Schering Plough) The content of the presentation does include discussion ofoff-

label/investigative use oJmedicine(s), medical devices, or procedure(s).

In terMune

Pharmaceuticals, MDS Nordion, ZnterMune, Chiron, Novartis

Tuesday, October 29 1000 - 1l:ooam Hynes Convention Center Veterans Memorial Auditorium Frederick 1. Suchy, MD, presiding

7414 AASLD PROGRAM HEPATOLOGY, October 2003

Parallel Session 33: Alcoholic Liver Disease

Tuesday, October 29

11 15am - 1245p11-1 Hilizes Corzs~eiitror? Ceiitei Rooin 311 Modeintors VlIAY SHAH m i d T l M O T H Y R MORGAN

1l:lSam k 223 THE ACUTE ALCOHOLIC HEPATITIS SCORING SYSTEM (GLASGOW) IMPROVES THE PREDICTION OF SHORT AND

Ewan H Forrest, Victoria Infirmary, Glasgow, UK; Chris J Evans, Glasgow Royal Infirmary, Glasgow, UK; Lilian Murray, University of Glasgow, Glasgow, UK; John Morris, Glasgow Royal Infirmary, Glasgow, UK

11:30am

MEDIUM-TERM MORTALITY

# 224 SAFETY AND POTENTIAL EFFICACY OF ETANERCEPT IN PATIENTS WITH ALCOHOLIC HEPATITIS: ANALYSIS OF A RECENTLY COMPLETED PILOT STUDY K Naiayanan Menon, Lath Jamil, Linda Stadhelm, Patrick S Kamath, Russell H Wiesner, Gregory J Gores, Mayo Clinic, Rochester, MN, Craig J Peine, Hennepin County Medical Center, Minneapolis, MN, Vijay Shah, Ma yo Clinic, Rochester, MN

11:45am k 225 A RANDOMIZED PLACEBO CONTROLLED TRIAL OF VITAMIN E IN ALCOHOLIC HEPATITIS Esteban Mezey, James J Potter, Lynda Rennie-Tankersley, Johns Hopkins University School of Medicine, Baltimore, MD; Juan Caballeria, Albert Pares, Hospital Clinic I Provincial, Universitat de Barcelona, Barcelona, Spain

12:OOpm tt 226 SPHINGOSIN 1-PHOSPHATE (SIP) INDUCES INCREASE IN INTRACELLULAR CA2+ AND NITRIC OXIDE (NO) FORMATION, BUT NOT PROTEIN KINASE B (PKB)/AKT ACTIVATION IN RAT LIVER SINUSOIDAL ENDOTHELIAL CELLS: POSSIBLE MECHANISMS OF S1P FOR SINUSOIDAL

Dongmei Zheng, Tsuneo Kitamura, Kenichi Ikejima, Nobuyuki Enomoto, Shunhci Yamashina, Shigeki Tsukada, Kazuyoshi Kon, Yoshiyuki Takei, Nobuhiro Sato, Juntendo University School of Medicine, Tokyo, Japan

12:lSom

PROTECTION AGAINST ETHANOL-INDUCED INJURY

k 227 INCREASED LIVER DAMAGE IN CYTOCHROME P450 2E1 TRANSGENIC MICE FED ETHANOL INTRAGASTRICALLY FOR 4 WEEKS Kengathevy Morgan, Lin Mao, Rene Qumtanilla, Erika Handoko, \‘A Medical Center, Long Beach, CA, Qinggao Deng, Hide Twkamoto, U5C Medical Center, L o 5 Angeles, CA, Samuel W Fiench, Harbor UCLA Medical Center REI, Torrance, CA, Tiniothv R Moigan, VA Medical Centei, Long Beach, CA

12:30pm # 228 OSTEOPONTIN INDUCTION: POSSIBLE MECHANISM BEHIND HEPATIC NEUTROPHIL INFILTRATION DURING ALCOHOLIC STEATOHEPATITIS Udayan M Apte, Rachel McRee, Shashi K Ramaiah, Texas A & M University, College Station, TX

Parallel Session 34: Clinical and Epidemiologic Advances in

Chronic Liver Disease

Tuesday, October 28

11:15am - 12:45pm Hyries Coiizwi tion Center Rooin 304, 306 Moilcrntors: HASHEM B. EL-SERAG niid DAVlD L T H O M A S

1l:lSam tr 229 HEPATITIS C VIRUS REINFECTION WITHIN A COHORT OF INJECTING DRUG USERS Joanne M Micallef, National Centre in HIV Epidemiology and Clinical Research, Darlinghurst NSW, Australia; Marianne Jauncey, Centre for Epidemiology and Research, NSW Health Department, Sydney NSW, Australia; Janaki Amin, National Centre in HIV Epidemiology and Clinical Research, Darlinghurst NSW, Australia; William Rawlinson, Prince of Wales Hospital, Sydney NSW, Australia; Stuart Gilmour, Ingrid van Beek, Kirketon Road Centre, Sydney Hospital, Sydney NSW, Australia; John M Kaldor, National Centre in HIV Epidemiology and Clinical Research, Darlinghurst NSW, Australia; Peter A White, Prince of Wales Hospital, Sydney NSW, Australia; Gregory J Dore, National Centre in HIV Epidemiology and Clinical Research, Darlinghurst NSW, Australia

11:30arn f 230 DIABETIC HEPATOSCLEROSIS: PERISINUSOIDAL HEPATIC FIBROSIS WITHOUT STEATOHEPATITIS AMONG DIABETICS Stephen A Harrison, Elizabeth M Brunt, Saint Louis University, St. Louis, MO; Zach D Goodman, Armed Forces Institute of Pathology, Washington, DC; Adrian M Di Bisceglie, Saint Louis University, St. Louis, MO

11:45arn # 231 A COMPREHENSIVE STUDY OF HEPATITIS C VIRUS PREVALENCE AND RISK FACTORS IN THE INCARCERATED SETTING: INMATES, PAROLEES AND PRISON WORKERS IN CALIFORNIA STATE CORRECTIONS Rena K Fox, Sue Currie, Jennifer Evans, University of California San Francisco, San Francisco, CA; Leslie Tobler, Michael Busch, Blood Centers of the Pacific, San Francisco, CA; Teresa L Wright, Kimberly Page-Shafer, University of California San Francisco, San Francisco, CA


12:OOam 11:45am ~~~

# 232 ADVANCES IN DIGITAL QUANTIFICATION TECHNIQUE ENHANCES THE DISCRIMINATION BETWEEN MILD AND ADVANCED LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) Amy L Lazzarini, Robert A Levine, Schuyler 0 Sanderson, Robert Ploutz-Snyder, SUNY Upstate Medical University, Syracuse, NY

12:lSpm # 233 STEATOSIS IN CHRONIC HEPATITIS B AND C: PREDICTORS, DISTRIBUTION AND EFFECT ON FIBROSIS Adam Gordon, Catriona A McLean, John S Pedersen, The Alfred Hospital, Melbourne, Australia; Michael J Bailey, Monash University, Melbourne, Australia; Stuart K Roberts, The Alfred Hospital, Melbourne, Australia

1230pm # 234 WHY AFRICAN AMERICANS CONTINUE TO HAVE REDUCED SURVIVAL AFTER LIVER TRANSPLANTATION W Ray Kim, Mayo Clinic, Rochester, MN; Richard Sterling, Medical College of Virginia, Richmond, VA

Parallel Session 35: Drug Metabolism and Toxicity

Tuesdav. October 28

ll:15am - 12:45pm Hynes Convention Center Room 320 Moderators: PAUL B. W A T K I N S and GYONGYZ S Z A B O

11:lSam # 235 OXYGEN MODULATION OF CYTOCHROME P450 PATHWAYS:

HEPATOCYTES IN VITRO Jared W Allen, Randall S Johnson, Sangeeta N Bhatia, University of California San Diego, La Jolla, CA

11:30am

ROLE OF OXYGEN GRADIENTS AND HIF-1ALPHA IN

8 236 MONOCROTALINE PERTURBS HEPATIC ENDOTHELIAL CELLS AND HEPATOCYTES BUT NOT KUPFFER CELLS TO PROMOTE TRANSPLANTED CELL ENGRAFTMENT AND PROLIFERATION Brigid Joseph, Vinay Kumaran, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY; Kuldeep Bhargava, Christopher Palestro, Long Island Jewish Hospital, New Hyde Park, NY; Sanjeev Gupta, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY

# 237 ROLE OF THE MITOCHONDRIAL PERMEABILITY

AND APOPTOTIC CELL DEATH TO CULTURED MOUSE HEPATOCYTES Kazuyoshi Kon, Jae-Sung Kim, Elizabeth Doyal, University of North Carolina at Chapel Hill, Chapel Hill, NC; Hartmut Jaeschke, University of Arizona, Tucson, AZ; John J LeMasters, University of North Carolina at Chapel Hill, Chapel Hill, NC

12:OO~m

TRANSITION IN ACETAMINOPHEN-INDUCED NECROTIC

# 238

MORPHISMS (SNPS) AT THE HUMAN UGTlA GENE LOCUS: DIFFERENTIAL ALTERATIONS OF GLUCURONIDATION OF TWO NOVEL SNPS OF THE HEPATIC UGTlA4 GENE Ursula Ehmer, Arndt Vogel, Ayse Barut, Britta Bleidistel, Michael P Manns, Christian P Strassburg, Hannover Medical School, Hannover, Germany

1 2: 1 5 ~ m

HIGH FREQUENCY OF SINGLE NUCLEOTIDE POLY-

# 239 INTERINDIVIDUAL VARIABILITY OF CANALICULAR ATP- BINDING-CASSETTE (ABC)-TRANSPORTER EXPRESSION IN HUMAN LIVER Yvonne Meier, Bruno Stieger, Karin Fattinger, Ulrich Zanger, University Hospital Zurich, Zurich, Switzerland; Ulrich Zanger, Dr. Margarete Fischer-Bosch Institut f i r Klinische Pharmakologie, Stuttgart, Germany; Peter J Meier, Christiane Pauli-Magnus, University Hospital Zurich, Zurich, Switzerland

12:30pm # 240 INHIBITION OF CJUN AND FADD PROTECTS

NECROSIS Brett E Jones, Wan M Wu, Michael J Tapner, Geoffrey C Farrell, Westmead Millennium Institute, Westmead, Australia

HEPATOCYTES AGAINST AZATHIOPRINE-INDUCED

AASLD PROGRAM HEPATOLOGY, October 2003 76A

Parallel Session 36: Hepatitis B Therapies: Current and Future

Tuesday, October 28 ll:15am - 12:45pm H!/nes Cowention Center Ballrooni B, C Moderators: MARION G. PETERS iznd STEPHEN A . LOCARNlNl

11:lSam # 241 LONG-TERM (96 WEEKS) ADEFOVIR DIPIVOXIL IN HBEAG NEGATIVE CHRONIC HEPATITIS RESULTS IN SIGNIFICANT VIROLOGICAL, BIOCHEMICAL AND HISTOLOGICAL IMPROVEMENT Stefanos Hadziyannis, Henry Dunant Hospital, Athens, Greece; Nickolas Tassopoulos, Western Attica Hospital, Athens, Greece; Elizabeth Heathcote, Toronto Western Hospital, Toronto, ON, Canada; Ting-Tsung Chang, National Cheng Kung Hospital, Taiwan, Taiwan; George Kitis, Georgios Papanikolaou Hospital, Thessaloniki, Greece; Mario Rizzetto, Azienda Ospedaliera San Giovanni Battista, Torino, Italy; Patrick Marcellin, HBpital Beaujon, Clichy, France; Seng-Gee Lim, National University of Singapore, Singapore, Singapore; Shan-Shan Chen, Michael Wulfsohn, Shelly Xiong, Craig James, Graeme Cume, Carol Brosgart, Gilead Sciences, Inc., Foster City, CA

11:30am # 242 MOLECULAR MODELLING AND FUNCTIONAL STUDIES OF ADEFOVIR RESISTANT MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE SELECTED DURING THERAPY Angeline Bartholonieusz, Stephen Locarnini, Anna Ayres, Geoff Thompson, Ros Edwards, Danni Colledge, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia; Peter Angus, ARMC, Heidelberg, Vic, Australia; William Sievert, Monash Medical Centre, Clayton, Australia; Hans Tillmaiui, Medizinische Hochschule, Hannover, Germany; Ben Tehan, Victorian College of Pharmacy, Parkville, Australia; Da\,id Chalniers, Victorian College of Pharmacy, Parkville, Vic, Australia

1 1 :45am # 243 HBV REPLICATION IS REGULATED IN VIVO THROUGH THE ACETYLATION STATUS OF CCCDNA-BOUND H3 AND H4 HISTONES AND IS MODULATED BY CLASS I DEACETYLASES INHIBITORS Teresa Pollicino, Natalia Pediconi, Fondazione Andrea Cesalpino, Rome, Italy; Giuseppina Raffa, Giovanni Squadrito, Giovanni Rairnondo, University of Messina, Messina, Italy; Massimo Levrero, Fondazione Andrea Cesalpino, Rome, Italy

# 244 INCREASED THERAPEUTIC POTENTIAL AND FEWER SIDE EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS B RECEIVING A COMBINATION OF LAMIVUDINE AND

DENDRITIC CELLS Sk Md Fazle Akbar, Norio Horiike, Kojiro Michitaka, Ehime University School of Medicine, Ehime, Japan; Kouji Joko, Red Cross Hospital, Matsuyama, Japan; Kazuhisa Yamamoto, Matsuyama Shimin Hospital, Matsuyama, Japan; Naohiko Kojima, Ohzu Hospital, Ohzu, Japan; Masanori Abe, Yoichi Hiasa, Morikazu Onji, Ehime University School of Medicine, Ehime, Japan

12:lSpm # 245 INHIBITION OF HBV REPLICATION BY SIRNA IN STABLE

Masayoshi H Konishi, Catherine H Wu, George Y Wu, University of Connecticut Health Center, Farmington, CT

12:30pm # 246 A COMPARISON OF ADEFOVIR AND TENOFOVIR IN THE TREATMENT OF LAMIVUDINE-RESISTANT HEPATITIS B VIRUS (HBV) INFECTION Florian van Bommel, Thomas Wiinsche, Dirk Schiirniaiui, Alexandra Bergk, Bertram Wiedenmann, Uwe Hopf, Thomas Berg, Charit@, Campus Virchow-Klinikum, Berlin, Germany

VACCINE THERAPY; ROLE OF ANTIGEN-PRESENTING

HBV-PRODUCING CELL LINES

Parallel Session 37: Hepatitis C: Pre-Clinical and Clinical Trials

Tuesday, October 28 ll:15am - 12:45pm Hynes Convention Center Ballrooni A Moderntors: NEZAM H. AFDHAL and MlCHAEL W. F R E D

11:lSam # 247 ACUTE RESOLVING INFECTION AFTER E l BUT NOT AFTER E2 PROPHYLACTIC VACCINATION AND HETEROLOGOUS CHALLENGE WITH 100 CID50 OF HCV SUBTYPE 18 STRAIN

Erik Depla, Gwenny Mares, Sofie Priem, Innogenetics NV, Gent, Belgium; Ernst Verschoor, Babs Verstrepen, Joost Drexhnge, Jonathan Heeney, Biomedical Primate Research Center, Rijswijk, Netherlands; Geert Maertens, Innogenetics NV, Gent, Belgium

11:30am # 248 RETREATMENT OF STANDARD INTERFERON/RIBAVIRIN NONRESPONDER PATIENTS WITH CHRONIC HEPATITIS C WITH DAILY CONSENSUS INTERFERON AND RIBAVIRIN YIELDS HIGH SUSTAINED RESPONSE RATES Stephan Kaiser, Holger G Hass, Michael Gregor, University of Tuebingen, Tuebingen, Germany

HC-J4


11:45am # 249 FCRN-MEDIATED PULMONARY DELIVERY OF INTERFERON ALPHA FC-FUSION PROTEIN IN NON-HUMAN PRIMATES Vito J Palombelia, Danielle Boudreau, h a Maria Garcia, Keith Kropp, Susan Low, Yichun Lu, Kelly Morris, Robert Peters, James Stattel, Jennifer Dumont, Alan Bitonti, Syntonix Pharmaceuticals, Waltham, MA

12:OoDm # 250 24 WEEKS OF MONOTHERAPY WITH PEGYLATED

HEPATITIS C Johannes Wiegand, Hannover Medical School, Hannover, Germany; WuIf Boecher, University of Mainz, Mainz, Germany; Peter Buggisch, Universitatsklinikum Eppendorf, Universitat Hamburg, Hamburg, Germany; Stefan Zeuzem, Medizinische Kliniken 11, Universitat des Saarlandes, Homburg, Germany; Cornelia M Gelbmann, Klinikum der Universitat Regensburg, Regensburg, Germany; Markus Cornberg, Elmar Jackel, Heiner Wedemeyer, Michael P Manns, Hannover Medical School, Hannover, Germany

1 2 1 5pm # 251

INTERFERON ALFA-2B IN PATIENTS WITH ACUTE

ESTABLISHING THE VALIDITY OF THE ALB-UPAISCID MOUSE MODEL OF HCV IN THE TESTING OF ANTI-VIRAL THERAPIES Belinda Hsi, Daniel Schiller, Karl Fischer, Tiejun Gao, David Bigam, Lome Tyrrell, Norman Kneteman, University of Alberta, Edmonton, AB, Canada

1230pm # 252 RANDOMIZED CONTROLLED TRIAL OF PEGINTERFERON ALFA-2A PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS-GENOTYPE 4 AMONG EGYPTIAN PATIENTS Fouad I A Thakeb, Cairo University, Cairo, Egypt; Mahmoud M Omar, Theodor Bilharz Research Institute, Cairo, Egypt; Mostafa M El Awady, Academy of Research and Science, Cairo, Egypt; Sherif Y Isshak, Cairo University, Cairo, Egypt

11:30am # 254 IMPACT OF OVERWEIGHT, DIABETES MELLITUS AND TOBACCO SMOKING ON THE INCIDENCE OF HCC IN PATIENTS WITH ALCOHOL AND VIRAL C CIRRHOSIS Gisgle N'Koncthou, Jean Verdier Hospital, Ile de France, France

11:45am # 255 CHARACTERISTICS AND OUTCOMES OF AFRICAN AMERICAN PATIENTS WITH PRIMARY HEPATOCELLULAR CARCINOMA IN THE USA THE NATIONWIDE INPATIENT SAMPLE Lei Yu, Chuanfa Guo, Charles D Howell, University of Maryland, Baltimore, MD

12:OO~m # 256 DENDRITIC CELL VACCINATION FOR HEPATOCELLULAR CARCINOMA Rachel Midgley, University of Oxford, Oxford, UK; Daniel Palmer, Noweeda Mirza, Jane Steele, Neil Steven, University of Birmingham, Birmingham, UK; David J Kerr, University of Oxford, Oxford, UK; Lawrence S Young, David H Adams, University of Birmingham, Birmingham, UK

121 5pm #257 LIVER TRANSPLANTATION (OLT), COMPARED TO PERCUTANEOUS ETHANOL INJECTION (PEI), ASSURES BETTER SURVIVAL IN PATIENTS WITH "EARLY HCC": A CONTROLLED, MULTICENTER STUDY Angelo Andriulli, CSS Hospital, IRCCS, San Giovanni Rotondo, Italy; Ilario de Sio, I1 University of Naples, Naples, Italy; Luigi Solmi, S. Orsola-Malpighi University Hospital, Bologna, Italy; Virginia Festa, Eugenio Caturelli, CSS Hospital, IRCCS, San Giovanni Rotondo, Italy; Alessandro Grasso, Adrian K Burroughs, Royal Free Hospital, London, UK; Roberto Troisi, Bernard De Hemptinne, Liver Transplant Unit, Gent, Belgium; Lucian0 De Cadis, Niguarda Hospital, Milan, Italy; Francesco Perri, CSS Hospital, IRCCS, San Giovanni Rotondo, Italy

12:30pm

Parallel Session 38: Hepatocellular Carcinoma and Cholangiocarcinoma: Clinical

Tuesday, October 28

ll:15am - 1245pm Hynes Convention Center Room 312 Moderators: A L E X B E F E L E R and MORRIS SHERMAN

ll:15am

tt 258

(WISPlV) IS A NOVEL ONCOGENIC MOLECULE THAT MEDIATES INVASION OF CHOLANGIOCARCINOMA CELLS Shinji Tanaka, Keishi Sugimachi, Shin-icho Maehara, Ken Shirabe, Mitsuo Shimada, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Jack R Wands, The Liver Research Center, Brown Medical School, Providence, RI; Yoshiluko Maehara, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

THE WNT-INDUCIBLE SIGNALING PATHWAY 1 VARIANT

~ ~

# 253 SMOKING, OBESITY AND ALCOHOL ARE IMPORTANT

CELLULAR CARCINOMA A CASE CONTROL STUDY Jorge A Marrero, Allen Banegura, Sherry Fu, Hari S Conjeevaram, Grace L Su, Robert J Fontana, Anna S Lok, University of Michigan, Ann Arbor, MI

RISK FACTORS IN AMERICAN PATIENTS WITH HEPATO-

Documents

AASLD Program (pp. 27A–77A)